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Malaria parasites of the species infecting humans and animal hosts exhibit genetic and 
phenotypic diversity. Some of this diversity, including the responses to anti-malarial 
drugs, growth rate and virulence and antigenic variability, is medically significant. This 
is because these phenotypes may determine the existence and survival of the parasites in 
the host and, in turn, contribute to the clinical outcome of infection. Understanding of 
the biological characteristics and the genetic basis underlying these complex phenotypes 
can thus lead to the development of effective control strategies against the disease, such 
as anti-malarial drugs and vaccines. Genetic studies in rodent malaria parasites have 
proved useful in providing insights into the genetic determinants of these complex traits 
and thus can be used to complement the study of human malaria.   
 
The present studies aim to investigate genetic determinants underlying two major 
medically important phenotypes, Strain Specific Protective Immunity (SSPI) and 
Growth rate, using the newly devised genetic method of Linkage Group Selection 
(LGS).  The results presented here relate to the accomplishment of these aims.  
 
LGS analysis of SSPI using a genetic cross between clones AJ and CB-pyr10 of 
Plasmodium chabaudi chabaudi has identified a single region on chromosome 8 
containing the gene for the Merozoite Surface Protein-1 as encoding a major target of 
SSPI. A similar finding was also obtained in a previous LGS study using a different 
genetic cross between clones AS-pyr1 and CB of P. c. chabaudi (Martinelli et al., 2005). 
Hence, the results of two independent studies strongly indicate that a single locus within 
the parasite genome contains a major target antigen, or antigens, of SSPI against P. c. 
chabaudi malaria. These results have particular relevance for research on SSPI in 
human malaria and the choice of candidate antigens for malaria vaccine development. 
 
LGS analysis of growth rate conducted upon a genetic cross between a fast-growing 
line, 17XYM, and a slow-growing line, 33XC, of Plasmodium yoelii yoelii has 
identified a ~ 1 megabase pair region on P. y. yoelii chromosome 13 as containing a 
major genetic determinant(s) of growth rate in these malaria parasites. This is consistent 
with the finding of the classical linkage analysis by Walliker et al., (1976), that growth 
rate in P. y. yoelii is mainly determined at a single genetic locus. Because the fast-
growing line 17XYM arose spontaneously during infection with a mild strain of P. y. 
yoelii 17X, identification of parasites with a slow growth rate phenotype derived from 
the same genetic stock as 17XYM can be useful in determining genes underlying 
growth rate in these malaria parasites. It has been shown here that parasites of the P. y. 
yoelii lines 17X consist of two completely distinct genotypes. One is represented by the 
fast-growing line, 17XYM, and a slow-growing line of P. y. yoelii, 17XNIMR. The 
other is represented by another slow-growing line 17XA. Comparing the region of P. y. 
yoelii chromosome 13 under strong growth selection between the two congenic lines, 
17XYM and 17XNIMR, could lead to the identification of the gene(s) controlling 
growth rate differences in these two parasite lines. Such findings could be relevant to 
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CHAPTER 1: Introduction 
 
 
1.1 General Overview 
 
The purpose of this chapter is firstly to provide a short introduction to the life cycle 
of a malaria parasite. This is followed by a brief account of the current situation of 
the human malaria disease, including the global distribution of the disease, the socio-
economic impact of malaria and its consequences, and the problems related to 
malaria control. Then, the genetics and genomics of the human and rodent malaria 
parasites is reviewed. Finally, there is an introduction to the principle of Linkage 
Group Selection (LGS), a method that enables the identification of regions in the 
Plasmodium genomes containing genes controlling medically important phenotypes, 
including antigens controlling Strain Specific Protective Immunity (SSPI) and blood 
stage growth Rate.  
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1.2 Life Cycle of Malaria 
 
Malaria is a disease that is caused by parasitic protozoa that belong to the genus 
Plasmodium, members of a large phylum Apicomplexa. There are at least 172 
described species of Plasmodium infecting a range of vertebrate host species, 
including 89 species infecting reptiles (Telford, 1994), 32 species infecting birds 
(van Riper et al., 1994) and 51 species infecting mammals. The latter group includes 
11 species infecting rodents (Cox, 1988; Cox, 1993), 25 species infecting non-human 
primates (Collins et al., 1993), and 4 species infecting humans. The four species of 
human malaria parasite are Plasmodium falciparum, Plasmodium malariae, 
Plasmodium ovale and Plasmodium vivax. Their only reservoir is humans, except for 
P. malariae, which is common to man, the African apes and probably some South-
American monkeys (Fandeur et al., 2000). It is also known that non-human primate 
malaria parasite species, such as Plasmodium knowlesi, do occasionally infect 
humans under natural conditions (Jongwutiwes et al., 2004; Singh et al., 2004). 
 
All species of Plasmodium infecting mammals have a complex life cycle that 
involves both an invertebrate vector and a mammalian host. A typical life cycle of a 
malaria parasite is illustrated in Figure 1.1. 
 
Malaria transmission from a mammalian host to a mosquito can only be initiated by 
intra-erythrocytic sexual blood stages of the life cycle – the gametocytes. During a 
mosquito blood meal the mosquito ingests male and female gametocytes from an 
individual who is infected with malaria. Inside the mosquito’s midgut, the 
gametocytes of both sexes undergo gametocytogenesis. The female gametocyte 
escapes from the erythrocyte membrane and matures into a single macrogamete. 
Male gametocytes undergo three rounds of DNA replication resulting in eight motile 
microgametes, and they are released from the erythrocyte by a process called 
exflagellation. The macrogamete and microgamete combine to form a zygote. By 12 
to 24 hours after the blood meal, the zygote has transformed into a motile ookinete 
that penetrates the midgut wall of the vector and becomes an oocyst. Then, the 
oocyst matures, with the formation of thousands of sporozoites. Sporozoite 
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development in the oocysts takes between 10 and 25 days depending on the species 
of Plasmodium and environmental factors such as temperature. When the mature 
oocyst ruptures, the sporozoites are released into the haemocoel of the mosquito. 
Sporozoites that make their way into the salivary glands are in position to be injected 
into a new host when the mosquito takes a blood meal [reviewed by Vlachou et al., 
2006].  
 
Following the bite of an infected female mosquito, the phase of development of the 
malaria parasite in a mammalian host starts. During the blood meal, sporozoites from 
the salivary glands of the mosquito are injected into the skin or directly into the 
bloodstream (Amino et al., 2006). Despite the fact that the salivary glands of an 
infected mosquito may contain thousands of sporozoites (Sinden, 1997), less than 
100 of these are believed to be transmitted in any one bite (Rosenberg et al., 1990). 
The sporozoites that enter the bloodstream localise in liver sinusoid and there they 
invade hepatocytes, where they develop into liver schizonts and replicate asexually, 
thus producing 30,000 to 50,000 merozoites per sporozoite (Sinden et al., 2002). 
This period is known as the pre-erythryocytic stage [reviewed by Prudêncio et al., 
2006]. It normally takes between 1 to 2 weeks in human malaria parasites (Garnham, 
1966). In P. vivax and P. ovale, dormant stages (hypnozoites) can persist in the liver 
and cause relapses by invading erythrocytes months, or even years later (Mangoni et 
al., 2003).  
 
Then, the liver-stage schizonts rupture and release the merozoites into bloodstream. 
The merozoites continue to invade circulating erythrocytes where they mature and 
multiply by shizogony over a period of a few days. The merozoite then differentiates 
into a ring-form, then a trophozoite and then a schizont. The schizont eventually 
bursts, lysing the erythrocyte and releasing newly matured merozoites that 
immediately proceed to invade new erythrocytes to repeat the cycle. This is the 
erythrocytic stage of the parasite’s life cycle. The molecular basis of the malaria 
parasite’s maturation and muliplication in the erythrocytes has been described 
elsewhere (Galinski et al., 2005; Topolska et al., 2005). 
 3
 4
Some of the merozoites do not form the erythrocytic-stage schizonts, but eventually 
differentiate into gametocytes. The cellular events of gametocytogenesis have been 
described in detail previously (Khan et al., 2004; Janse et al., 2005; Kooij et al., 
2007). After being taken up by an anopheline mosquito during a blood meal, the 
gametocytes of both sexes mature and sexually combine in the insect host to generate 
a zygote. The latter develops into an oocyst, from which new sporozoites are 
generated and migrate into the salivary glands of the mosquito, ready to reinitiate the 





























Figure 1.1. A schematic representation of the life cycle of human malaria.  The malaria 
parasite life cycle involves two hosts: a man (blue arrows) and a female Anopheline mosquito 
(red arrows). The letter‘i’ in the blue triangle represents the infective phase (sporozoite stage) of 
the parasite. The letter‘d’ in the blue triangle represents the diagnostic phase (asexual 
erythrocytic stages) of the parasite in human. This figure was prepared with the help of artwork 
from the website of Centres for Disease Control and Prevention, Division of Parasitic Disease, 




All the clinical symptoms associated with malaria are commonly attributed to the 
erythrocytic stages of the parasite’s life cycle. In human malaria infections, 
symptoms associated with malaria include chills and high fever (paroxysms) that 
recur every 48 hours in tertian malaria (P. falciparum, P. ovale and P. vivax) or every 
72 hours in quartian malaria (P. malariae) (Garnham, 1966; Warrell, 2002), in 
synchrony with the release of malaria parasites (merozoites) from ruptured 
erythrocytes. A paroxysm lasts for 4 to 12 hours, after which time there is typically a 
cessation of symptoms for a period, before another wave of paroxysm.  
 
Without correct diagnosis and treatment with effective anti-malarial drugs, malaria 
can cause severe disease, which occurs most frequently with P. falciparum. Severe 
malaria is characterised by symptoms, such as severe anaemia, organ dysfunction 
and cerebral malaria, all of which are frequently fatal. These are most commonly 
found in individuals who have not acquired immunity to malaria, such as young 
children, pregnant women and travellers, and generally in areas of low endemicity 
(Chen et al., 2000; Casals-Pascual et al., 2006). The vast majority of malaria 
morbidity and mortality is caused by P. falciparum. P. vivax almost always causes 
mild disease, although it can cause severe clinical symptoms and mortality in humans 
(Choi et al., 2004). P. malariae and P. ovale are relatively infrequent causes of 
morbidity and are responsible for a small percentage of the total cases worldwide.  
 













1.3 Malaria Burden: The Current Situation   
 
1.3.1 Geographical Distribution and Burden of Malaria  
 
As recently as the early 1900s, human malaria was endemic on every continent 
except Antarctica. In the 1950s, the World Health Organisation (WHO) launched a 
global malaria control/eradication programme based on the use of insecticides. 
Despite the success of the eradication of malaria from North America, Europe and 
Australia, malaria remains endemic in a number of tropical and subtropical countries 
worldwide (Figure 1.2). The numbers of countries and territories with malaria 
transmission for 2004 is 107 (WHO, 2005). Nowadays, around three billion people 
living in these countries, which are about half of the world’s population, are at risk of 













Figure 1.2. The global distribution of malaria transmission from 1946 to 1994. The changing 
global distribution of malaria risk shows a disease burden that is being limited to tropical and 
subtropical countries in five continents. (Figure reproduced from Sachs et al., 2002).  
 
Malaria causes an estimated annual death toll of over 1 million (WHO, 2005), mainly 
caused by infections with P. falciparum. Approximately 800,000 deaths occur among 
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children younger than 5 years of age, especially in remote rural areas in Africa with 
poor access to health care. Globally, 8% of all deaths in children are attributed to 
malaria, this proportion increasing to 18% in sub-Saharan African countries (Black et 
al., 2003; Bryce et al., 2005; Rowe et al., 2006). This is due in part to the fact that 
severe anaemia and cerebral malaria are most frequent in African children and are 
responsible for 4 and 1 million cases annually, respectively (Greenwood et al., 
2005). 
 
The WHO estimates for 2004 that there are 350 to 500 million actual illnesses from 
malaria every year worldwide (WHO, 2005). 70 to 80 million cases are caused by P. 
vivax (Mendis et al., 2001) and 270 to 400 million are attributed to P. falciparum 
(Nahlen et al., 2005). However, a recent publication increased the estimate of global 
P. falciparum malaria episodes for 2002 to 515 million (range 300 to 600 million) 
(Snow et al., 2005).  Around 70% of the cases of clinical malaria caused by P. 
falciparum occur in Africa and most of the other 30% occur in Asia (Snow et al., 
2005). By contrast, the small number of malaria cases still found in Europe (about 
50,000 cases in 1999; Sabatinelli et al., 2001) and an even smaller number in the 
USA (about 1,300 cases in 2004; Skarbinski et al., 2006) are essentially all imported 
cases in travellers or military personnel.  With a rapidly growing human population 
in regions with high malaria transmission, it has been estimated that, in the absence 
of effective intervention strategies, the number of malaria cases will double by 2021 
(Bremen et al., 2001).   
 
1.3.2 Social and Economic Impacts of Malaria 
 
Malaria impairs the activity of infected individuals and the social development of the 
endemic community (Gallup et al., 2001; Sachs et al., 2002). Malaria causes sickness 
in adults, resulting in loss of working days and lost incomes. Malaria not only causes 
morbidity in pre-school children (i.e. those less than 5 years of age) but also affects a 
large number of school-aged children, resulting in school-absenteeism. A study in 
Kenya attributed 13 to 50% of medically related school absences to malaria (Brooker 
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et al., 2000). Consistent with the above, a study in Sri Lanka showed that malaria had 
an adverse effect on the school performance of children (Fernando et al., 2003). 
They found a strong negative correlation between the number of uncomplicated 
malaria attacks and both language and mathematical scores (Fernando et al., 2003). 
Thus, the burden of malaria extends beyond affecting human health and activity to 
impairing the economic development of countries.     
 
High levels of the malaria burden are also commonly considered a cause of poverty 
and depressed economy in many countries where malaria is endemic (Gallup et al., 
2001; Sachs et al., 2002). This is partly because malaria incidence appears to 
coincide with the world’s poorest countries, mainly in Africa south of the Sahara-
desert (Figure 1.2). Malaria has a deleterious effect on the wealth of individuals and 
the economic development of nations. Microeconomic costs include the price of 
household-level malaria prevention, such as insecticides and bed nets (Gallup et al., 
2001; Sachs et al., 2002). It also includes individual spending on diagnosis and 
treatment (Gallup et al., 2001; Sachs et al., 2002). The disease also reduces 
productivity and economic effectiveness of affected populations, which can represent 
about a 20% of an annual household income (Malaney et al., 2004). Macroeconomic 
costs include the large proportion of government public expenditure for maintaining 
public health facilities as well as continuing malaria vector control programs. The 
estimated costs of malaria, in terms of the strain on health services, are enormous. In 
malaria endemic countries, as many as 3 out of 10 hospital beds are occupied by 
malaria infected patients (WHO, 2005). Apart from the above examples, foreign 
trade and investment, tourism, job-seeking migrations and agricultural practices are 
all transformed by the existence of malaria, having a deleterious effect on the 
macroeconomy (Guinovart et al., 2006). The combined micro and macroeconomic 
cost of malaria in sub-Saharan Africa is estimated to be 1 to 5% pre-capita gross 
domestic product, a cost of US$12 billion a year (Sachs et al., 2002).  
 
There is no doubt that effectively reducing the burden of malaria will improve the 
quality of life for people and, therefore, increase the economic development of the 
countries affected.   
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1.4 Malaria control: Strategies and Problems  
 
Traditional strategies for the control of malaria depend upon the reduction of vector 
breeding sites and vector density, reducing human-mosquito contact, the effective 
use of the anti-malarial drugs delivered to malaria-infected individuals, or vaccines.  
 
1.4.1 The Vector Control  
 
Malaria is primarily a rural disease and is transmitted by the female infected 
anopheline mosquito. The use of mosquito nets and repellent as a protection from 
mosquito bites during the night has been practised from very early times. 
Environmental modification and manipulation, such as drainage of swamps and the 
use of larvalicides and insecticides, have also been among the main approaches to 
reducing the number of vectors. However, in many endemic areas drainage and 
general environmental planning were not feasible (Beales et al., 2002). It was also 
discovered that mosquitoes were able to become resistant to the cheap insecticides 
directed against them such as DDT, and thus DDT spraying has now been abandoned 
in many countries (Najera, 1989; Georghiou, 1990).  
 
Currently, insecticide-treated bed nets (ITN) have been increasingly used in many 
malaria endemic countries to replace indoor house spraying with insecticides (WHO, 
2005). It has recently shown the efficacy of 17 and 43% in reducing all causes of 
malaria mortality and morbidity in children younger than 5 years and also provides 
protection to pregnant women (Binka et al., 2006). However, the ITN in malaria 
endemic areas, particularly in Africa, is currently in a limited supply. It has been 
estimated that between 130 to 264 million ITNs are required in 2007 (Miller et al., 
2007). These numbers will reach the 80% coverage target for about 133 million 
children younger than 5 years and pregnant women living in 123 million households 
at high risk from malaria (Miller et al., 2007).  
 
In addition, where the uses of ITNs are in practice, a sufficient coverage of ITN in 
malaria-transmission areas and good community participation at a sustained level are 
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needed. Furthermore, malaria surveillance must be conducted to identify episodes of 
local transmission and to monitor emergence of vectors resistant to the particular 
insecticides and densities of malaria-infected mosquitoes throughout areas. Without 
such data, the long-term success of the ITN-based malaria control programs would 




A malarial infection in humans is currently treated with a variety of anti-malarial 
drugs. Many anti-malarial drugs, including quinine, chloroquine, sulfadoxine-
pyrimethamine, mefloquine and atovaquone, interfere with the replicating cycles of 
the erythrocytic stage malaria parasites (see Figure 1.1, section 1.2), thus reducing 
the parasite numbers in the blood and terminating the clinical attack (Wernsdorfer et 
al., 1991; White, 1999; Wongsrichanalai et al., 2002). Some are also gametocytocial 
drugs, such as tafenoquine, artemisinine and artesunate (Colman et al., 1992; Kumar 
et al., 1990; Chen et al., 1994, Chotivanich et al., 2006), which are active against the 
sexual forms of the parasite in the blood, thus having the potential to reduce 
transmission of malaria.  
 
However, emergence of parasites that are resistant to antimalarial-drugs, however, 
commonly develops within 1 year to 15 years after the introduction of a drug (Table 
1.1). The high prevalence of strains of P. falciparum and P. vivax resistant to 
chloroquine and sulfadoxine-pyrimethamine has been rising in Africa, South-East 
Asia and South-America over the past decades, and it has now become the major 
challenge that most malaria control programmes are facing.  
 
Nevertheless, so far there has not been any solid evidence of resistance to 
artemisininand its derivatives (e.g. artemether, artesunate, dihydroartemisinin) in 
human malaria. These compounds produce a very rapid therapeutic response (i.e. 
reduction of the parasite number and resolution of clinical symptoms) against 
multidrug resistant P. falciparum, and they reduce gametocyte carriage (Kumar et 
al., 1990; Chen et al., 1994; Chotivanich et al., 2006). Consequently, many countries 
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have now adopted artemisinine derivatives as their first line therapies, in 
combination with other drugs (such as benflumetol plus artemether, amodiaquine 
plus artesunate, and sulfadoxine-pyrimethamine plus artesunate) (WHO, 2006). 
These artemisinin combination therapies (ACTs) present favourable 
pharmacokinetics (i.e. the process by which a drug is absorbed, distributed, 
metabolized, and eliminated by the body) and are thought to reduce the probability of 
mutations that underlie resistance and treatment failure emerging in parasite 
populations (Yeung et al., 2004; WHO, 2006). However, the main problem with 
these drugs is that they are still in limited supply and are often too expensive to be 
afforded by poor countries (Enserink, 2005). Therefore, a safe, effective and 
affordable malaria vaccine is an urgently needed tool for reducing the global burden 
of the disease and is considered as a critical global public health priority (Malkin et 








Table 1.1 Year of introduction and first reports of anti-malarial resistance in




1.5 Human malaria vaccines 
 
Human malaria vaccine-based intervention could be used to supplement strategies of 
vector control and medical treatment for reducing rates of morbidity and mortality. 
The complexity of the life cycle of the malaria parasite leads to the development of 
an array of diverse strategies for malaria vaccines. The approaches to the generation 
of malaria vaccines have focused on the targeting of one of the three main stages of 
the life cycle of malaria parasites (see Figure 1.1, section 1.2): the sexual stage, the 
pre-erythrocytic stage and the erythrocytic stage.  
 
Sexual stage vaccine strategies aim to raise antibodies that target the sexual stages of 
malaria parasites in the anopheline mosquito gut [reviewed by Saul, 2007]. During a 
blood meal such antibodies are taken up by the mosquitoes and can block further 
parasite development. Although this type of vaccine would not directly prevent 
infection in the vaccinated individuals (vaccinees), the community where the 
vaccinees live would experience a decrease in transmission of the parasite to new 
hosts. Hence, this type of vaccine is known as a transmission-blocking vaccine.  
 
Pre-erythrocytic stage vaccine strategies aim to generate protective immunity 
directed against sporozoites via antibody responses and to destroy intra-hepatic 
parasitic stages via cell-mediated immunity [reviewed by Mikolajczak et al., 2007]. 
This would stop the parasites from reaching the erythrocytic stage and thus prevent 
any clinical manifestation. This type of vaccine would benefit individuals from areas 
with no exposure to malaria who travel to a region of high malaria endemicity. 
Among key target antigens at this stage are the circumsporozoite protein (CSP) and 
the thrombospondin-related adhesive protein (TRAP), which are expressed 
abundantly on the surface of sporozoites, and the liver stage antigen-1 (LSA-1), 
which are expressed on the surface of infected hepatocytes.  
 
Erythrocytic stage vaccine strategies aim to elicit protective immunity directed 
against the blood stages of the parasites, mainly the merozoite [reviewed by Genton 
et al., 2007]. They should, therefore, prevent the invasion of the merozoites into 
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erythrocytes, inhibiting the development of the parasites in erythrocytes and speeding 
the clearance of parasitised erythrocytes. This type of vaccine should reduce the 
blood parasite density, thereby reducing the incidence of severe malaria and malaria-
associated mortality in infants and young children with heavy exposure to malaria 
infections, such as those living in sub-Saharan Africa. A number of malarial surface 
antigens, including the merozoite surface proteins (MSP-1, MSP-2 and MSP-3) and 
the apical membrane antigen-1 (AMA-1), have been widely used as components of 
this type of vaccine. 
  
In addition to the above-mentioned conventional approach, the multistage or 
multivalent vaccine strategy has been developed. Although the incorporation of 
combined malarial antigens from different stages (multistage), or different antigens 
from the same stages (multivalent) may help trigger an intense and sequential 
immune response and increase vaccine efficacy, it should be noted that the inclusion 
of non-protective vaccine components could yield the unnecessarily high cost and 
may lead to any undesired effects. The most well-known multiple component 
vaccine is Combination B, comprising three blood-stage antigens MSP-1, MSP-2 and 
the ring-stage infected-erythrocyte surface antigen (RESA) (Lawrence et al., 2000; 
Genton et al., 2002) (see below for details).  
 
Currently, 75 candidate vaccines are being developed, most of which are still being 
assessed in humans in pre-clinical phases (Aide et al., 2007; Girard et al., 2007) [see 
also the portfolio of candidate malaria vaccines at the WHO website 
http://www.who.int/vaccine_research/documents/en/malaria_table.pdf]. The majority of the 
vaccines in active development today are the pre-erythrocytic stage and the 
erythrocytic stage vaccines. Since P. falciparum is responsible for most malaria 
mortality among the four species of human malaria parasites, this malaria species 
receives most attention in vaccine research. In the following section, I will describe 
progress in the vaccine development against the pre-erythrocytic stages and the 




1.5.1 Pre-erythrocytic vaccines 
 
Three main approaches are currently being undertaken to produce P. falciparum pre-
erythrocytic vaccines [reviewed by Mikolajczak et al., 2007]: (1) whole parasite 
vaccine approach, (2) heterologous prime-boost approach and (3) subunit protein 
vaccine approach.     
 
The whole parasite vaccine approach involves immunisation of individuals with 
large numbers of live irradiation-attenuated sporozoites or genetically attenuated 
sporozoites. It had already been shown in experimental animals (Nussenzweig et al., 
1976) and in humans that immunisation with irradiated sporozoites could confer a 
solid and sterile protection from laboratory-induced challenge infection (Hoffman et 
al., 2002). However, there are several obstacles associated with the whole parasite 
vaccine approach (Todryk et al., 2007). For instance, the irradiated sporozoites must 
be delivered though irradiated, infected mosquitoes. In addition, there are problems 
associated with mass production and cryopreservation of sufficient sporozoites. 
Nevertheless, the applications of reverse genetics and bioengineering in production 
process development of live attenuated vaccines are in progress and this would 
overcome problems that currently prevent their large-scale application (Kanoi et al., 
2007). 
 
The heterologous prime-boost approach is another vaccination approach that uses a 
regime of priming the immune response with antigens expressed as plasmid DNA or 
in T-cell inducing attenuated viral vectors, such as the fowlpox strain FP9 (FP9) or 
adenovirus, followed by boosting with another antigen-coding viral vector, such as 
the modified vaccinia virus Ankara (MVA) (Dunachie et al., 2003; Hill, 2006). This 
approach has involved the use of complex antigens. For example, the sporozoite 
surface antigen TRAP has been fused to a string of liver stage antigen T-cell epitopes 
to enhance the breadth of the T-cell response. Although immunisation of malaria-
naïve volunteers with TRAP-MVA vaccination has provided significant T-cell 
responses and protection from sporozoite challenge infection (Webster et al., 2005), 
trials in the Gambia following the same regimens showed no protection against 
occurrence of the disease in human volunteers (Dunachie et al., 2006) and showed 
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much lower immunogenicity in adults and children in Kenya (Bejon et al., 2006). 
Nevertheless, a new efficacy trail with FP9-TRAP vaccination is currently ongoing 
in Kenya [quoted from Girarad et al., 2007].   
 
The third approach to the development of pre-erythrocytic vaccines is based on the 
use of recombinant proteins or peptides derived from the surface antigen(s) of the 
sporozoites. The subunit vaccine development aims to reproduce or enhance the level 
of immunity achieved with the whole attenuated parasite. The vaccine of this type 
that is currently most advanced in development is the RTS,S vaccine in a potent 
proprietary AS02 adjuvant, developed by GlaxoSimthKine Biologicals (GSK). The 
RTS,S/AS02A vaccine is a fusion protein of the central repeat sequence (R) and 
major T-cell epitopes (T) of the CSP of P. falciparum (strain NF54, laboratory clone 
3D7), fused to the entire surface antigen (S) of the hepatitis B virus, and expressed in 
the form of virus-like particles with nonrecombinant S antigen in yeast 
Saccharomyces cerevisiae (Bojang, 2006). Initial Phase I clinical trials of RTS,S 
formulated with the AS02 adjuvant, containing an oil-in water emulsion plus the 
immune stimulant monophosphoryl lipid A and QS21, showed protection against a 
laboratory-based homologous sporozoite challenge in six out of seven volunteers, 
although the duration of protection appeared to be short-lived (Stoute et al., 1997; 
Stoute et al., 1998). Subsequent evaluations of RTS,S/AS02A have confirmed 
tolerability and immunogenicity in malaria-naïve and malaria-experienced adult 
populations. A dose-range Phase I/II study has demonstrated levels of efficacy from 
30% (single-dose vaccination schedules) to 55% (three-dose vaccination schedules), 
with an overall protective efficacy of 40% in non-immune vaccines against 
sporozoite challenge (Kester et al., 2001).  
 
The first field trials of the RTS,S/AS02A vaccine were conducted in an area of low 
seasonal malaria transmission in the coastal region of The Gambia and in a 
hyperendemic region of western Kenya. The trials in The Gambia demonstrated a 
protective efficacy of 71% against naturally acquired malarial infection for the first 9 
weeks of follow-up (Bojang et al., 2001). However, protection appeared to wane, 
declining to 0% in the last 6 weeks of follow-up (Bojang et al., 2001). In a phase IIb 
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clinical carried out in children 1 to 4 years of age in Mozambique, this vaccine 
reduced the risk of P. falciparum infection, uncomplicated malaria and severe 
disease, and this protection lasted for at least 18 months (Alonso et al., 2004; Alonso 
et al., 2005). More recently, the safety, immunogenicity and initial efficacy of the 
RTS,S vaccine has been assessed in Mozambican young infants (e.g. children 
younger than one year). This vaccine was found to be safe, well-tolerated and 
immunogenic in young infants, with an overall protective efficacy of 66% (Aponte et 
al., 2007) against natural malaria infections. The results obtained from these trails are 
encouraging and these findings set the stage for large-scale, multi-centre phase III 
efficacy studies.  
 
 
1.5.2 Erythrocytic vaccines 
 
The goal of the asexual erythrocytic malaria vaccines is to induce immune responses 
against merozoites in order to reduce parasite burden and, hence, protect against 
pathological severity of disease. Currently, eighteen clinical trails with erythrocytic 
vaccines have been registered in the main clinical trials registries [quoted from 
Genton et al., 2007; see also the World Health Organisation website at 
http://www.who.int/trialresearch]. The majority of erythrocytic vaccines are based on 
the use of the proteins expressed at the merozoite surface, e.g. MSP-1, MSP-2 and 
MSP-3 and the proteins present at the apical organelles of the malaria parasites, e.g. 
AMA-1. A number of these vaccines being developed are based on the use of single 
malaria antigens and, hence, registered as single-type antigen vaccines. There are 
only a small number of erythrocytic vaccines being developed through a 
multicomponent approach by combining more than one blood-stage antigen in a 
vaccine formulation.  
 
In the following section, I will give a brief account of candidates of erythrocytic 




1.5.2.1 MSP-1 based vaccines 
MSP-1 is the most abundant complex protein on the merozoite surface. P falciparum 
MSP-1 is initially synthesized as a polypeptide of ~200 kDa which undergoes 
proteolytic cleavage before schizont rupture into fragments of 83kDa (N-terminus), 
28kDa, 38kDa (Central portions) and 42kDa (C-terminus) (Holder, 1988; Stafford et 
al., 1994; Stafford et al., 1996). The latter fragment called MSP-142 remains 
membrane-bound by means of a GPI anchor and undergoes secondary processing 
into 33kDa and 19kDa fragments during red cell invasion. While the other fragments 
are shed from the parasite surface, forming a complex by non-covalent bonds, the 19 
kDa fragment, known as MSP-119, composed of two epidermal growth factor-like 
domains, remains membrane-bound and is carried inside the erythrocyte.  
 
The gene for MSP-1 is located on chromosome 9 in P. falciparum. According to the 
nucleotide sequence comparison from a number of P. falciparum isolates, the gene is 
divided into 17 blocks of variable and conserved regions (Tanabe et al., 1987; Miller 
et al., 1993). With the exception of the highly polymorphic block 2, the genes are 
dimorphic and can be classified into the MAD-20 and Wellcome families with 
additional variance being produced by limited intragenic recombination between the 
families. Block 2 of MSP-1 can be classified into three families, MAD-20, Wellcome 
and RO33 (Miller et al., 1993). Block 17 at the extreme C-terminus, which 
corresponds to MSP-119, is highly conserved, although there are limited 
polymorphisms identified at specific residues in this region (Kang et al., 1995; Tolle 
et al., 1995).   
 
The protective role of the C-terminal regions of MSP-1 has been assessed in a 
number of studies that use recombinant MSP-142 and MSP-119 (reviewed by Holder 
et al., 1996). It has been shown that the presence of antibodies against the MSP-142 
(Riley et al., 1992) and MSP-119 (Egan et al., 1996; Branch et al., 1998; Perraut et 
al., 2005) are associated with protection from clinical P. falciparum infection. In 
addition, a longitudinal survey conducted with infants in Liberia indicated that the 
high levels of maternally derived antibodies against MSP-119 in the first year of life 
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were associated with protection from clinical malaria (Hogh et al., 1995). Another 
study conducted with children and adults in the Gambia demonstrated a correlation 
between protection from clinical malaria and the ability of sera to block binding of 
two monoclonal antibodies against different epitopes on MSP-119 by ELISA (Shai et 
al., 1995). Moreover, immunisation with a recombinant baculovirus P. falciparum 
MSP-142 (strain FUP) in complete Freund's adjuvant provides protection in Aotus 
monkeys against lethal parasite challenge (Chang et al., 1996). All vaccinated, 
protected Aotus monkeys produced antibodies which inhibited in vitro parasite 
growth, indicating that the immunity induced by MSP-142 immunization is mediated, 
at least in part, by a direct effect of antibodies against the MSP-1 C-terminal region. 
Likewise, vaccination with a recombinant MSP142 from P. falciparum strain FVO 
expressed in Escherichia coli protected monkey against the blood challenge infection 
with homologous strain (Darko et al., 2005). Protective immunity in these monkeys 
was found to be correlated with antibodies against the epidermal growth factor 
(EGF)-like domain 2 fragment of MSP142 (Darko et al., 2005). Therefore, these lines 
of evidence support further development of MSP-142 and MSP-119 as a candidate 
malaria vaccine. 
 
The most advanced MSP-1 based vaccine is FMP1/AS02. This vaccine consists of a 
MSP-142 fragment from P. falciparum clone 3D7 expressed in E. coli, and 
formulated in the AS02 adjuvant. Preclinical evaluation of FMP1 in the rhesus 
monkey safety and immunogenicity model identified AS02A as a safe, well-
tolerated, and highly immunogenic adjuvant (Pichyangkul et al., 2004). FMP1/AS02 
have been subsequently assessed in clinical trials in human volunteers in the USA, 
Kenya and Mali (Ockenhouse et al., 2006; Stoute et al., 2007) and found to be safe 
and immunogenic. However, in a subsequent proof of concept efficacy phase IIb trail 
in Kenyan children, the vaccine showed no evidence of protection from natural 
malaria infections and no efficacy to reduce the number of episodes of clinical 




Another leading MSP-1 based erythrocytic vaccine candidate is MSP-1 C1, based on 
the use of the 42kDa fragment from P. falciparum clones 3D7 and FVO, formulated 
in Alhydrogel. The msp-1 alleles of the 3D7 and FVO parasites lines represent the 
two major allelelic types, MAD20 and K1, of this molecule. In a phase I trial in 
malaria-naive volunteers in the USA, MSP1(42)-FVO/Alhydrogel and MSP1(42)-
3D7/Alhydrogel was found to be safe, but not sufficiently immunogenic (Malkin et 
al., 2007). Vaccine development is currently in progress to improve immunogenicity 
of the Alhydrogel formulation in humans. A vaccine candidate based upon the 19 
kDa C-terminal fragment of MSP-1 has also been produced at Baylor University, but 
a Phase I trial carried out demonstrated that this vaccine had unacceptable side 
effects and was poorly immunogenic (Girard et al., 2007).    
 
Though the conserved MSP-142 and MSP-119 fragments have been the focus of 
vaccine development efforts, there is evidence from epidemiological and 
immunological studies that the polymorphic N-terminal block 2 region of MSP-1 
may be a target of protective immunity and of stain-specific protective immunity 
against P. falciparum infection (Conway et al., 2000; Polley et al., 2003a; see section 
1.6.1 for discussion). Currently, block 2 of P. falciparum MSP-1 has been selected 
for inclusion in a subunit vaccine against malaria that is under development at 
Edinburgh University (D. Cavanagh, personal communication).  
 
1.5.2.2 MSP-2 based vaccines 
 
P. falciparum MSP-2 is a protein on the merozoite surface, encoded by a single-copy 
gene on chromosome 2, with a predict molecular weight between 46 and 53 kDa 
(Smythe et al., 1988). The gene for MSP-2 is located on P. falciparum chromosome 
2 (Marshall et al., 1998) and is divided into five blocks. Blocks 1 and 5 encode 
highly conserved N- and C-termini, respectively. The central variable region, block 
3, consists of centrally located repeats, which are flanked by non-repetitive 
sequences. MSP-2 sequences are assigned into one of the two families, FC27 and IC-
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1/3D7, on the basis of the non-repetitive sequences (Smythe et al., 1990; Smythe et 
al., 1991; Marshall et al., 1992; Felger et al., 1997).  
 
Evidence for involvement of MSP-2 in protective immunity derives from several 
studies. The presence of IgG antibodies to the 3D7 allele of MSP-2 has been found to 
be associated with protection from clinical malaria in Papua New Guinea (Al-Yeman 
et al., 1994), in the Gambia (Taylor et al., 1998; Metzger et al., 2003) and, more 
recently, in Kenya (Polley et al., 2006). The extent of antibody reactivity to MSP-2 is 
sequence dependent, such that antibodies are inhibitory to parasites expressing on the 
same allelic type of MSP-2 but not parasites expressing a different allelic type 
(Ranford-Cartwright et al., 1996).  
 
A recombinant MSP-2 protein from P. falciparum clone 3D7 was included in the 
multivariant erythrocytic vaccine Combination B, which also contained the 
conserved blocks 3-4 of  MSP-1 from P. falciparum strain K1 and part of the ring-
infected erythrocytic surface antigen (RESA) in a Montaside 720 adjuvant 
formulation (Lawrence et al., 2000).  Though vaccination of naïve volunteers with 
Combination B vaccines followed by blood-stage challenge failed to provide any 
protection (Lawrence et al., 2000), the vaccine demonstrated a 62% reduction in 
parasite densities in the vaccine group in those not pretreated with sulfadoxine-
pyrimethamine when compared to those in the placebo group (Genton et al., 2002) in 
a phase IIb trial conducted in children, aged 5 to 9 years, in Papua New Guinea. 
Furthermore, it was found that the prevalence of parasites carrying alleles belong to 
the 3D7 family appeared to be lower in vaccinated children when compared to the 
placebo group. However, the prevalence of parasites carrying alleles of the other 
allelic type of MSP-2, FC-27, was not different between the vaccinee and placebo 
groups. These findings demonstrated that the activity of the Combination B vaccine 
is due, at least in part, to the MSP-2 component (Genton et al., 2002), which seems 
to confer protection in the vaccinees against blood stage infections with malaria 




Following the promising results of the phase IIb trial in Papua New Guinea (Genton 
et al., 2002), an MSP-2 based vaccine that comprise two major variants of MSP-2 
from P. falciparum clones 3D7 and FC27 is now developed. A phase I trial in 
malaria-naïve adults in Australia is underway with a Montanide ISA720 formulation 
(R. Anders, unpublished; quoted from Genton et al., 2007).  
 
1.5.2.3 MSP-3 based vaccines  
 
MSP-3 is a ~45-76 kDa polypeptide that is synthesised by mature stage parasites and 
secreted into the parasitophorous vacuole (McColl et al., 1994; Oeuvray et al., 
1994a). The MSP-3 protein was first detected using human hyperimmune serum and 
with antibodies that inhibit P. falciparum asexual blood stage growth in vitro by in-
corporation with monocytes in an antibody-dependent cellular inhibition (ACDI) 
assay (Oeuvray et al., 1994b). There is evidence to implicate MSP-3 as a potential 
target of protective immune responses against malaria infection. In a primate model, 
vaccination with recombinant P. falciparum MSP-3 can protect Aotus monkeys from 
a lethal blood stage challenge infection (Hisaeda et al., 2002). More recently, 
evidence from epidemiological and immunological studies showed that the levels of 
IgG3 antibodies against the allele-specific and conserved epitopes in MSP-3 were 
strongly associated with protection from clinical malaria (Osier et al., 2007; Polley et 
al., 2007; Roussolhon et al., 2007; Soe et al., 2007), suggesting the involvement of 
MSP-3 in protective immunity against malaria in humans. These observations 
support the further development of MSP-3 based vaccine formulations.  
 
Thus, the Pasteur institute and the Europian Malaria Vaccine Initiative have 
developed an erythrocytic vaccine based on MSP-3. It has been developed as a long 
synthetic peptide incorporating regions of MSP-3 and containing three human B cell 
epitopes and T cell epitopes. These epitopes were selected on the basis of the finding 
that they were targeted by cytophilic antibodies that participate in ACDI (Oeuvray et 
al., 1994b). In a phase Ia study in Burkina Faso, the MSP-3 vaccine, formulated in 
either alum or Montanide ISA720, induced sustained high levels of antibody 
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responses displaying ACDI activity (Audran et al., 2005). When passively 
transferred into P. falciparum–infected humanized SCID mice, the antibodies from 
the vaccinated volunteers could abrogate parasitaemia in mice (Druilhe et al., 2005). 
The encouraging safety and immunogenicity of this vaccine in adults allows its entry 
into a phase Ib trial in children. Such vaccine trials are currently underway in 
Burkina Faso and Tanzania (quoted from Genton et al., 2007). 
 
1.5.2.4 Erythrocytic vaccines based on other antigens  
 
Additional blood stage antigens of P. falciparum under development as vaccine 
candidates include AMA-1, the serine repeat antigen (SERA), the Glutamine-rich 
protein and other merozoite surface proteins (MSP-4 and MSP-5). Progress towards 
the development of erythrocytic vaccines based these antigens is described elsewhere 




Results obtained from clinical trials of human malaria vaccines have shown only 
moderate success. One of the major obstacles to the development of malaria vaccines 
is polymorphism of the vaccine candidates. For instance, following the clinical trials 
of the Combination B (Genton et al., 2002), P. falciparum identified in breakthrough 
infections from the vaccinated volunteers were found to carry alleles of MSP-2 that 
were not present in the vaccine formulation (Felger et al., 2003; Flück et al., 2007). 
This suggests that all allelic variants of MSP-2 need to be included in the vaccine in 
order to counteract the effect of polymorphism of the candidate antigen. Since 
merozoite surface antigens, such as MSP-1 and AMA-1, also have a substantial 
polymorphism, this may have an impact on immunogenicity and protective 
effectiveness (Tanabe et al., 1987; Miller et al., 1993; Marshall et al., 1996). Thus, 
there is an urgent need to obtain molecular epidemiological data of all the possible 
variants of the antigens present in a vaccine testing site prior to conducting clinical 
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vaccine trials. This information would enable measurement and interpretation of the 
host and parasite responses to vaccines, both during efficacy trials and after 
introduction of vaccines into the population (Genton et al., 2007; Sutherland, 2007). 
This data may provide invaluable insights into vaccine-induced selection pressure 
acting on antigen genes and the potential implications of allele-specific immunity. 
Such an investigation was already performed in a vaccine-testing site in Mali in 
which the population-level dynamics of 14 different haplotypes encoding MSP-119 
were analysed prior to conducting clinical trials (Takala et al., 2007). 
 
To improve malaria vaccine research and development we must also gain the 
definitive knowledge on the nature of host protective immunity to malaria and 
understand the mechanisms by which parasites escape immunity. This information 
would allow us to identify and prioritise appropriate antigens as vaccine candidates 
and, therefore, develop formulations that could elicit desired protective immune 
responses (Girard et al., 2007).  
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1.6 Rodent malaria parasites  
 
There are eleven species of malaria parasite that occur naturally in African rodents 
(Cox, 1988; Cox, 1993). Of these species, four from murine rodents have been grown 
in laboratory mice: Plasmodium berghei (Vincke and Lips, 1948), Plasmodium 
vinckei (Rodhain, 1952), Plasmodium chabaudi (Landau, 1965) and Plasmodium 
yoelii (Landau and Killick-Kendrick, 1966; Killick-Kendrick, 1974). The main 
features of the four rodent malaria species are described elsewhere (Garnham, 1966; 
Carter et al., 1977; Landau et al., 1978; Cox, 1988; Cox, 1993; Landau et al., 1994; 
Landau et al., 1998). The locations from which the four species of most commonly 















Figure 1.3. The origin of the four species of rodent malaria parasites in Africa. Two species of
rodent malaria, Plasmodium yoelii yoelii and Plasmodium chabaudi used in the present studies (blue
letters) originated from thicket rats, captured in the Central African Republic (see text). Red dots
represent foci from which murine hosts were collected. The distribution of the rodent malaria
parasites in Africa was previously described by Carter et al., (1977); Killick-Kendrick (1978) and
Landau et al., (1994).   
* Foci in the highlands of Katangain Democratic republic of Congo from which Plasmodium berghei 
was isolated included Kisanga and Kasapa near Elizabethville; Kanzenzi near Kolwezi; near 




The experiments described herein were carried out using two species of rodent 




P. chabaudi was originally isolated from blood of wild thicket rats, Thamnomys 
rutilans, captured in the Central African Republic (La Mobokè, near Bangui) in 1965 
(Landau, 1965) and in the Congo (Brazzaville) between 1970 and 1972 (Carter et al., 
1976) (see Figure 1.3). The parasites in each region were accorded subspecies status 
as Plasmodium chabaudi chabaudi (Landau, 1965) and Plasmodium chabaudi adami 
(Carter and Walliker, 1976), respectively. Many strains of P. c. chabaudi have been 
derived and used in many laboratories (Beale et al., 1978; Walliker, 1983). Two 
cloned strains denoted AJ and CB of P. c. chabaudi used in the present study were 
derived from isolates AJ and CB (Carter, 1978) (see Chapter 2). 
 
Parasites belonging to the P. chabaudi group show a predilection for mature 
erythrocytes (normocytes), which more closely resembles P. vinckei than P. berghei 
or P. yoelii. Blood infections of P. chabaudi are synchronous with a periodicity of 24 
hours. The main distinguishing features are the virtual absence of malaria pigment in 
the growing trophozoite stage, although the pigment is apparent in blood stage 
schizonts as a single large granule of black pigment at the centre or edge of the 
dividing parasite (Carter et al., 1975a; Carter et al., 1977). The number of merozoites 
per schizont is between 6 and 8 (Carter et al., 1975a). The two subspecies of P. c. 
chabaudi are identical morphologically; they are distinguishable only by the 




P. yoelii was isolated from blood of adult thicket rats, T. rutilans, captured in three 
geographically isolated localities: the Central African Republic (La Mobokè, near 
Bangui) in 1963, 1965, 1969 and 1970, Congo (Brazzaville) in 1966 and 1968, and 
Nigeria (Lagos) in 1970 (Carter, 1978; Beale et al., 1978) (see Figure 1.3). The 
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parasites in each region were given subspecies status: Plasmodium yoelii yoelii 
(Landau and Killick-Kendrick 1966), Plasmodium yoelii killicki (Landau, Michel and 
Adam, 1968), and Plasmodium yoelii nigeriensis (Killick-Kendrick, 1973). P. yoelii 
was initially classified as a subspecies of P. berghei under the name of P. berghei 
yoelii (Landau et al., 1966). This parasite was renamed P. y. yoelii by Killick-
Kendrick in 1974.  Numerous strains of P. y. yoelii have been derived (Beale et al., 
1978). One of the most commonly studied strains of this parasite is denoted 17X (see 
Chapter 3). 
  
In the morphology of their blood stages, the three subspecies of P. yoelii and, indeed, 
P. berghei are indistinguishable from each other. Blood infections of P. yoelii are 
asynchronous (Carter et al., 1977). The blood stages of both species preferentially 
invade immature erythrocytes (reticulocytes), although some strains of P. y. yoelii 
are able to invade normocytes extensively during the late phase of an infection (Yoeli 
et al., 1975; Finerty et al., 1976; Finerty et al., 1977; Burns et al., 1989) (see also 
Chapter 3 and 4). The number of merozoites per schizont is between 12 and 18 
(Landau et al., 1978). The main distinction between P. yoelii and P. berghei lies in 
the characteristics of the sporogonic stages and in the enzyme character of the blood 
stages. The sporogonic development of P. yoelii is completed between 24˚C and 
26˚C, but at this temperature P. berghei fails to develop. The optimum temperature 
for the sporogonic development of P. berghei is between 19˚C and 21˚C. All lines of 
P. yoelii so tested are resistant to chloroquine in the presence of para-aminobenzoic 
acid (PABA) in the host diet (Carter, 1972), whereas strains of P. berghei are 
normally susceptible to this drug with or without the presence of PABA 
supplemented in the diet. The distinctive enzyme characteristics of the three 

















      
Species and Subspecies   Characteristic enzyme forms 
of rodent malarias  GPI GDH LDH 6PGD 
          
Plasmodium berghei 3 3 1 1 
     
Plasmodium yoelii yoelii 1,2,10 4 1 4 
Plasmodium yoelii killicki 1 1 1 4 
Plasmodium yoelii nigeriensis 2 2 1 4 
     
Plasmodium vinckei 5,6,7,9,11 6 6,7,9 5,6 
     
Plasmodium chabaudi chabaudi 4 5 2,3,4,5 2,3,7 
Plasmodium chabaudi adami 8 5 8,10 2 
          






Table 1.2. Characteristic enzyme forms among species and subspecies of African rodent
malaria parasites (Carter, 1978). 
GPI, glucose phosphate isomerase;  
GDH, NADP-dependent glutamate dehydrogenase;  
LDH, Lactate dehydrogenase;  
6PGD, 6-phospho gluconate dehydrogenase.   27
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1.7 Medically important phenotypes of malaria parasites 
 
Malaria parasites exhibit wide variation in their phenotypes between species and 
between strains of the same species. Examples of phenotypes are antigenic 
polymorphisms (i.e. the presence of allelic forms) in genes encoding surface antigens 
of malaria parasites) and blood stage growth rate. This diversity is of medical 
importance since (1) the antigenic polymorphism may contribute to evasion of host 
immune response, probably due to allele specificity of host protective immunity 
(Mendis et al., 1991), and (2) growth rate can be positively correlated with 
pathological severity of an infection (Dondrop et al., 2005). Thus, these phenotypes 
can not only determine the survival of the parasites in the host but also influence the 
outcome of an infection. The genetic determinants that control some of the medically 
important phenotypes of malaria parasite, such as antigens determining strain 
specific protective immunity and proteins involved in blood stage growth rate, are, 
however, poorly understood. These two phenotypes are, therefore, the main subjects 
of the present studies. 
 
1.7.1 Strain Specific Protective Immunity 
 
Protective, but not sterilising, immunity against blood stages of malaria parasites, 
particularly human malaria parasites, can be induced in individuals after several 
years of exposure to endemic malaria (McGregor et al., 1956; McGregor, 1974; Day 
et al., 1991). This reflects the need to be infected with a large number of 
antigenically diverse parasite populations in order to become effectively immune 
(Mendis et al., 1991). By contrast, some studies showed that acquired protective 
immunity against the blood stages of human malaria parasites can be readily 
achieved after only one or a few infections (Ciuca et al., 1934; Boyd et al., 1936). A 
study reported by Jeffrey (1966) showed that immunity was most effective in 
individuals who had been previously infected with the homologous genotype (strain) 
of human malaria parasites, while it became less effective against a heterologous 
(genetically distinct) strain. This effect has led to the concept of ‘Strain Specific 




The first study on SSPI in rodent malaria was conducted using P. c. chabaudi lines 
AS and CB by Jarra and Brown (1985) in a protocol in which parasites of one or the 
other strain were used to induce an immunity in laboratory mice and subsequently 
used for challenge infection. The studies showed that mice infected with strain AS 
developed strong immunity against the challenge infection with blood stages of the 
homologous strain (AS), but developed much weaker immunity against those of a 
heterologous strain (CB). In a reciprocal experiment, mice infected with strain CB 
were protected from challenge infection with CB, but not AS. This experiment was 
recently repeated and extended in our laboratory, using other genetically distinct 
strains of P. c. chabaudi, including AJ, AS, AQ and CB (Martinelli et al., 2005a; 
Cheesman et al., 2006). These studies again confirmed the existence of SSPI of one 
degree or another to all strain combinations of P. c. chabaudi in laboratory mice 
(Martinelli et al., 2005a; Cheesman et al., 2006) as was also found in the previous 
study (Jarra et al., 1985).  
 
Several antigens of the blood stages of malaria parasites might be targets of SSPI. It 
would, however, be necessary that the antigens targeted by SSPI are antigenically 
and genetically different among different strains, or genetically distinct lines, of 
malaria parasite. There is a high degree of allelic polymorphism in genes encoding 
parasite surface-located antigens. This antigenic diversity means that among 
genetically distinct strains of the same species of malaria parasite, each candidate can 
be represented in more than one allelic form, each of which may be a target of host 
protective immunity. Prominent candidate antigens of SSPI are the merozoite surface 
protein-1 (MSP-1) and apical membrane antigen-1 (AMA-1). In the following 
section I will describe literature that demonstrates the possible involvement of MSP-
1 and AMA-1 in SSPI in rodents and humans. 
 
MSP-1 is considered a prime candidate target of protective immunity and of SSPI in 
humans (see section 1.5.2.1) and rodents, and is also the most extensively studied 
surface antigen of the merozoites. Data from several experimental studies in rodent 
malarias have demonstrated that MSP-1 exhibit extensive sequence polymorphism 
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among laboratory strains of the rodent malaria parasite P.  c. chabaudi and P. yoelii 
(Cheesman S., unpublished data). Immunisation with recombinant MSP-1 could 
induce antibody-mediated immune responses, which are highly effective in 
eliminating parasites and protecting hosts against a malarial infection in a strain 
specific manner. For instance, immunisation with the recombinant C-terminus MSP-
1 of P. y. yoelii 17XYM completely protected mice against sporozoite-induced 
infections with the same strain, but was not protective against challenge with 
sporozoites of a non-homologous strain, P. y. yoelii 265BY (Renia et al., 1997).  In 
addition, passive transfer of a monoclonal antibody raised against the C-terminus of 
MSP-1 of P. c. chabaudi AS protected mice specifically against challenge with the 
homologous strain (AS) (Boyle et al., 1982), but had no effect on challenge infection 
with a heterologous strain CB (Brown et al., 1985).  
 
Furthermore, there is evidence from epidemiological studies in human malarias to 
suggest the possible involvement of MSP-1 in SSPI in humans. Field studies on 
malaria in endemic human populations have used molecular population genetic 
approaches to test the involvement of antigens in protective immunity and to test the 
“strain” or allelic-type specificity of this immunity. The underlying hypothesis of 
these studies is that target loci encode products that induce allele specific protective 
immune responses. Conway and colleagues (2000) proposed that there should be 
frequency-dependent selection on a polymorphic target antigen of anti-parasitic 
immunity, so that a parasite with a more frequent allelic type is more likely to be 
eliminated by protective immunity than is a parasite with a rare allelic type (Conway 
et al., 2000). Thus, the high prevalence of a frequent antigenic type should lead to its 
reduction in prevalence, while prevalence of a rare antigenic type is increased under 
anti-parasitic allele specific immune selection. This leads to a concept of ‘balancing 
selection’ which perpetuates both polymorphisms in the population at stable 
equilibrium frequencies.  
 
Following this approach, Conway and colleagues measured the allele-frequencies on 
different blocks of the P. falciparum msp-1 gene in parasite populations in different 
geographical regions in Africa and Asia (Conway et al., 2000). Their results showed 
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that block 2 of MSP-1 had relatively conserved allele frequencies in parasite 
populations from different endemic regions, while the other blocks of MSP-1 
exhibited more divergent allele frequencies in populations from different 
geographical regions. These findings are consistent with block 2 of MSP-1 evolving 
under allele specific balancing selection as would be expected of a target of SSPI 
against a malarial infection.  
 
To test whether MSP-1 block 2 is the target of protective immunity, Conway and 
colleagues collected serum prior to malaria transmission season from a cohort of 
children (3 to 7 years old) in The Gambia and tested for antibody reactivity to 
recombinant proteins representing different allelic forms of full-length block 2 of 
MSP-1. They determined the ratios of individuals who experienced clinical malaria 
at any time during the transmission season, among those with or without detectable 
serum IgG levels against recombinant MSP-1 antigens at the start of the study. The 
results indicated that antibodies against either of the two most frequent allelic types 
of MSP-1 block 2 were strongly associated with a lower prospective risk of clinical 
malaria, whereas antibodies to the rarest block 2 type were not significantly 
associated with protection from P. falciparum malaria (Conway et al., 2000). 
Consistent with the above, Cavanagh and his co-workers (2004) found that 
antibodies to full-length antigens from the two common MSP-1 block 2 allelic types 
were strongly associated with protection against malaria in a cohort of children (3 to 
15 years old) in Ghana. The study also showed that while there were no significant 
association between antibodies to the MSP-1 block 2 flanking sequence antigens of 
either the K1 or the MAD20 block 2 types and a reduced risk of clinical malaria, 
antibodies to the MSP-1 block 2 repeat sequence antigens are strongly associated 
with protection from clinical malaria (Cavanagh et al., 2004). The above finding is 
consistent with results from another cohort from The Gambia (Polley et al., 2003a). 
Together, these studies provide evidence for the involvement of MSP-1 block 2 as a 
target of protective immunity against P. falciparum malaria in humans, and that this 




AMA-1 is also considered to be a possible target of SSPI against human and rodent 
malaria parasites. Mice immunised with the refolded ectodomain of the P. c. adami 
DS allele of AMA-1 were protected against challenge with blood stages of the 
homologous strain, DS, but were not protected against challenge with a non-
homologous strain, P. c. adami 556KA (Crewther et al., 1996). In a reciprocal 
experiment, immunisation of mice with the refolded ectodomain of the P. c. adami 
DK allele of AMA-1 induced protective immunity against challenge with DK strain 
but not DS strain (Barclay V. and Read A.F., personal communication). Furthermore, 
on passive transfer into non-immune mice, the IgG antibodies which had been raised 
against the refolded recombinant DS AMA-1, were able to confer protection against 
challenge with the homologous strain, but had no protective effects on challenge with 
a heterologous strain (Crewther et al., 1996). 
 
Furthermore, data from epidemiological studies in human malaria have indicated the 
possible association of AMA-1 with SSPI in humans. Using the molecular 
population genetic approaches of Conway et al. (2000), Polley and others analysed 
sequences of the gene for AMA-1 from natural populations of P. falciparum from 
Nigeria (Polley et al., 2001) and Thailand (Polley et al., 2003b). In both of these 
cases, Domains I and III of the ectodomain region (N-terminus) of AMA-1 were 
considered to be evolving under strong balancing selection. It was, therefore, 
predicted that naturally acquired protective immune responses exist against allele-
specific epitopes in the Domains I and III of AMA-1 protein (Polley et al., 2001; 
Polley et al., 2003b). Thus, Polley and colleagues (2004) collected serum from two 
cohorts (e.g. two villages) of children and adults (0 to 85 years old) in Kenya prior to 
a malaria transmission season, to determine the relationship between antibodies to 
the recombinant AMA-1 proteins representing the P. falciparum FVO or 3D7 full-
length ectodomain and subsequent incidence of malaria. The results showed that the 
presence of the antibodies to the recombinant proteins representing either the full-
length ectodomain of FVO or 3D7 AMA-1 reduced the risk of having a subsequent 
episode of malaria (Polley et al., 2004).  These findings have indicated, therefore, 
that AMA-1 appears to be a target of allele-specific protective immunity against P. 
falciparum malaria in human populations.  
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1.7.2 Growth rate 
 
In the context of the present subject, the following definitions of terms are used. 
 
‘Growth rate’ refers to the replication rate of malaria parasites in the blood. Lines of 
malaria parasites that are considered to have a ‘fast’ growth rate phenotype refers to 
those developing a high parasite density (high levels of parasitaemia), and causing a 
fulminating and lethal infection in their host. Lines of malaria parasites that are 
considered to have a ‘slow’ growth rate phenotype refers to those producing a low 
parasite density (low levels of parasitaemia) throughout infection, and normally 
causing a mild, self-limiting disease. The term ‘growth rate’ described herein has a 
different meaning from ‘parasite multiplication rate’, which is an indication of how 
many erythrocytes are newly infected when a schizont bursts (Chotivanich et al., 
2000; Deans et al., 2006).    
 
‘Virulence’ refers to the ability of malaria parasites to do harm to their host following 
infection, where harm is defined as disease severity (morbidity) and/or mortality 
(Mackinnon et al., 2002; Mackinnon et al., 2004).  
 
All Plasmodium species have an asexual haploid life stage that replicates in the blood 
of their vertebrate hosts, thereby causing destruction of infected erythrocytes leading 
to general pathology. The clinical outcome of a malarial infection can be highly 
variable and dependent upon the interactions of multiple factors from the hosts and 
parasites themselves (Miller et al., 2002). Environmental changes, such as the effects 
of PABA in the growth of P. berghei (Jacobs, 1964; Carter, 1972), or concurrent 
infections with other organisms (Cox, 1978; Cox, 2001), are well-known causes for 
alternation in the natural course of infection of Plasmodium. Host genetic factors 
determine the ability of parasites to grow in the host. For instance, while individuals 
that are homozygous for the allele of the β-globin gene for haemoglobin variant S 
(HbS) develop sickle cell anaemia, heterozygotes are healthy and strongly protected 
against severe P. falciparum malaria (Beet, 1946; Allison, 1954; Aidoo et al., 2002). 
HbS is caused by a single nucleotide substitution (A to T) of codon GAG, which 
results in an amino acid substitution from glutamic acid to valine at position 6 in the 
 33
 34
β-globin. The Duffy-negative (FYnullFYnull) erythrocyte genotype is also involved in 
resistance to P. vivax infection (Miller et al., 1976). Furthermore, different strains, or 
genotypes, of laboratory mice can influence the growth rate of a rodent malaria 
parasite. Some strains of mice, e.g. DBA/2, are resistant to a slow-growing strain of 
P. y. yoelii 17X, while being highly susceptible to a lethal strain of P. y. yoelii 
17XYM. In contrast, it has been reported that some mouse strains, e.g. C57BL/6, are 
resistant to P. y. yoelii strain 17XYM, but are sensitive to strain 17X (Sayles et al., 
1988). However, when C57BL/6 mice were infected with sporozoites, or inoculated 
intra-peritoneally with blood stages, of P. y. yoelii strain 17XYM in our laboratory, 
we found that no mice of this strain, C57BL/6, survived (Pattaradilokrat S. and 
Carter R., unpublished observation).  Our observation has been made several times 
and is in absolute contrast to that reported by Sayles and Wassom (1988). The reason 
for this discrepancy is not known, and this subject needs further investigation. 
However, mixing of the two parasite strains of 17X must be considered to be a 
possibility.  
 
In addition to environment and host factors, parasite-associated factors, as already 
mentioned above, appear to contribute to differences in the clinical outcome of a 
malarial infection (see a review by Miller et al., 2002). One factor positively 
associated with severe pathology is the rapid multiplication of the parasites in the 
host, or blood stage growth rate (Yoeli et al., 1975; Dondrop et al., 2005). 
Differences in growth rate of malaria parasites of humans and rodents are likely to be 
due to variation in multiplication ability of the blood stages and their selectivity for 
different classes, e.g. age, of erythrocyte. It is known that different strains of malaria 
parasites that vary in growth rate have different multiplication ability (Simpson et al., 
2002). In a clinical study of P. falciparum malaria in Thailand, isolates from patients 
with severe clinical symptoms were found to multiply three times as fast and to be 
less selective in their invasion of erythrocytes, than those from mild cases 
(Chotivanich et al., 2000). By contrast, this was not found to be the case with P. 
falciparum isolates from Mali and Kenya, in which there were no significant 
differences in selectivity or multiplication ability between parasites from severe or 




Differences in growth rate can be related to the ability of the blood stages of the 
parasite to invade erythrocytes of different ages. It has long been known that 
merozoites of certain malaria species infecting humans or other animals have a 
predilection for a minor sub-population of erythrocytes, the reticulocytes. These 
include the human malaria parasites, P. vivax (Craik, 1920) and P. ovale (Garnham, 
1966), a simian malaria parasite, P. cynomolgi (Garnham, 1966), and a rodent 
malaria parasite, P. berghei (Garnham, 1966) and P. yoelii (Carter et al., 1977; 
Landau et al., 1978). Since reticulocytes only make up a small proportion of the total 
erythrocyte content, usually below 2% in humans (Bessman, 1990), reticulocyte-
preferring Plasmodium species tend to have slow growth rate and low parasite 
density, with rare severe pathology and mortality. By contrast, the human malaria 
parasite, P. falciparum (Bruce-Chwatt, 1948), and the rodent malaria parasite, P. 
chabaudi (Carter et al., 1975a; Carter et al., 1976), generally invade erythrocytes of 
all ages, although they are mostly seen in mature erythrocytes (normocytes). 
Plasmodium species of this phenotype could lead to a much higher parasite density, a 
condition that frequently causes severe anaemia and other potentially life-threatening 
disease symptoms, compared to the vivax-type malaria parasites.  
 
Such variation in growth rate is also observed between genotypes, or ‘clones’, of the 
same species of the malaria parasite infecting rodents (see Chapter 3). Many P. y. 
yoelii lines derived from isolate 17X, such as 17XA and 17XNIMR, have a slow 
growth rate phenotype. Parasites of this phenotype show marked preference for 
reticulocytes (Figure 1.4, panel B), and undergo a mild course of infection in mice. 
In contrast, there are a few P. y. yoelii lines with fast growth rate, designated 17XYM 
(Yoeli et al., 1975) and 17XL (Finerty et al., 1976; Finerty et al., 1977). These 
strains emerged spontaneously during passage of the normally slow-growing P. y. 
yoelii strain 17X, and developed a dramatic increase in growth rate and virulence, 
compared to their original stock. Although retaining reticulocyte invasion preference 
in early infection, after four or five days these parasites switch to invade mainly 
normocytes (Figure 1.4, panel A). Parasites of this group are able to produce a high 
parasite density. As a result, infected animals normally die on the six or seventh day 
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of infection, with mean parasitaemia of 60 to 80% (Yoeli et al., 1975; Burns et al., 
1989).  
 
The first genetic study of growth rate in a rodent malaria parasite was conducted by 
Walliker and his co-workers (1976), by crossing two lines that differed in growth 
rate, isozyme type and pyrimethamine-sensitivity. The fast-growing line was P. y. 
yoelii 17XYM, and the slow-growing line was P. y. yoelii A/C. Analysis of the 
cloned progeny of the 17XYM x A/C genetic cross showed that the fast growth rate 
and slow growth rate characters segregated in the cloned progeny, implicating a 
single locus for genes conferring these growth characters. However, the genetic 
determinants of growth rate in this parasite are not known. This subject will be 

















Figure 1.4 Microscopic examination of blood stage-induced infections with (panel A) a fast-
and (panel B) slow-growing line of the rodent malaria parasite Plasmodium yoelii yoelii.
Parasites with fast growth rate were 17XYM. Parasites with slow growth rate were 17XA.
Laboratory mice were inoculated intra-peritoneally with 1 x 106 parasitised erythrocytes of either
17XYM or 17XA line. Infections were monitored by light microscopy of thin blood smears
stained with Giemsa’s stain on day 2, 4 and 5 post-inoculation. All photos were taken at 1000 x
magnification. Parasitised reticulocytes and normocytes are indicated by black and red arrows,
respectively.  Photos were kindly supplied by Dr Richard Culleton (Nagasaki University). 
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1.8 Genetics of malaria parasites 
1.8.1 Glossary 
 
In the context of this thesis, the following definitions of terms are used (Carter, 1973; 
Carter, 1978; Walliker, 2005). 
  
An ‘isolate’ refers to a single sample of parasite material that has been collected 
from a naturally infected host specimen on a single occasion. The parasite cells are 
not necessarily genetically identical and may contain representatives of several 
distinct species. 
   
A ‘line’ refers to the progeny of parasites derived by laboratory passage on a unique 
occasion. Like an isolate, a line of parasites may not be genetically homogeneous. 
 
 A ‘strain’ may be used to refer to lines of parasites presumed to represent a single 
species and having derived from the same isolate. For example, lines derived from 
isolate 17X and apparently containing only P. y. yoelii may be referred to 
collectively as P. y. yoelii strain 17X.  
  
A ‘clone’ refers to the asexually dividing progeny of a single cell. Assuming that no 
spontaneous mutations or mitotic recombination had taken place during parasite 
growth, all parasite cells of a single clone should have identical genetic constitutions.  
 
1.8.2 Genetic variation in malaria parasites 
 
Considerable phenotypic variation occurs in natural populations of human and rodent 
malaria parasites of the same species. Many studies in the past reported that some 
variation did occur between ‘strains’ of the human malaria parasites, P. falciparum 
and P. vivax, isolated from infected individuals from various geographical regions. 
Some of the variation is manifest as differences in virulence (see section 1.7.2 for 
definition) and in ability to escape the “strain specific” components of the host’s 
protective immune response. One of the earliest examples was found nearly 80 years 
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ago following the use of induced malaria for the therapy of neurosyphilis. It was 
found that “A striking difference can be observed between the clinical virulence of 
different geographical races or strains of the same morphological species of the 
parasite; the difference is particularly apparent between various races of P. 
falciparum” (quoted from James et al., 1932; page 1176). In P. vivax malaria, there is 
also natural variation that appears to exist between a number of different ‘strains’, as 
shown by the absence of cross protective immunity between them. Evidence to 
support this view came from a study by Boyd and co-workers that described, “an 
immunity derived from the local Floridan strain (McCoy) of P. vivax [from Florida, 
USA] was unable to protect against infection with four other strains (two of which 
were local and two exotic). There is an absence of cross immunity between the 
American St Elizabeth [from Washington, USA] and the New Guinea Chesson [from 
Papua New Guinea] strains; also between the Dutch [from Holland] and the 
Madagascar strains” (quoted from Garnham, 1966; page 143). Such absence of cross 
protective immunity in the host is considered a reflection of variant forms of antigens 
that induce protective immunity in the host.  
  
Over the past three decades the ‘true’ extent of genetic variation within natural 
populations of malaria parasites of the same species has become clear. The detection 
of variation depended initially upon the observation of protein variation, usually 
using starch gel electrophoresis (Carter, 1970). Since enzymes are proteins, which 
are the products of genes, protein variation is thus a direct reflection of genetic 
variation. The two species of rodent malaria parasite in which protein variation was 
most studied are P. yoelii and P. chabaudi. A large number of electrophoretic 
enzyme variants have been observed among natural isolates and clones of these 
organisms (Carter, 1973; Carter, 1978; Beale et al., 1978; Walliker, 1983). Protein 
variation was also detected in natural populations (isolates) of P. falciparum (Carter 
et al., 1973; Carter et al., 1975b). Subsequently, the extent of protein variation could 
be studied by 2-dimensional protein gel electrophoresis, in which variant forms of 
proteins among clones of P. falciparum were differentiated by iso-electric point and 
molecular size (Fenton et al., 1985), since blood stage malaria parasites were readily 
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cloned out from clinical isolates of the human malaria parasite, P. falciparum, 
(Rosario, 1981) using methods such as limiting dilution.  
 
In more recent times, genetic variation in natural populations of human and rodent 
malaria parasites has been detected with DNA-based methodology, such as the 
polymerase chain reaction (PCR). The identification and sequencing of Plasmodium 
genes can be used to detect polymorphism at the molecular level (nucleotide 
sequence level). By contrast, a range of advance molecular techniques, including 
Restriction Fragment Length Polymorphism (RFLP) (Walker-Jonah et al., 1992; 
Carlton et al., 1995) and microsatellites (Su et al., 1996; Li et al., 2007), has 
facilitated the assessment of genetic polymorphisms in malaria parasites at the 
genome scale. An additional technique - amplified fragment length polymorphism 
(AFLP) - is able to detect restriction site-associated polymorphisms without prior 
sequence knowledge using PCR (Vos et al., 1995; Rubio et al., 2001; Grech et al., 
2002). These molecular techniques have a number of advantages over isozyme 
electrophoresis, particularly in their requiring much smaller quantities of material to 
work with. The AFLP method has been used throughout the present work to detect 
genetic variation between strains of the rodent malaria parasites, P. c. chabaudi 
(Chapter 2) and P. y. yoelii (Chapter 3 and 4). 
1.8.3 Genetic recombination of malaria parasites  
 
 
All genetic variation arises by genetic mutation, while novel genotypes arise through 
genetic recombination (Walliker, 1983; Walliker et al., 1998). The existence of a 
sexual phase during the parasite’s life cycle in the Anopheline mosquito presents an 
opportunity for crossing between genetically variant clones of malaria parasites, with 
the subsequent generation of new genotypes through genetic recombination. 
  
How does genetic recombination occur in malaria parasites? Genetic recombination 
in eukaryotes occurs principally during chromosome pairing at meiosis. The process 
takes place during the early phase of development of the malaria parasite in the 
mosquito. Following the release of ‘haploid’ male and female gametes in the mid-gut 
of the mosquito, fertilisation takes immediately and a ‘diploid’ zygote is formed. The 
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fertilised zygote develops into a motile ookinete which traverses the wall of the 
mosquito stomach and emerges to be beneath the basal lamina of the midgut. There, 
it comes to rest and begins differentiation into an oocyst. Meiosis appears to occur in 
the zygote/ookinete, with the appearance of a synaptonemal complex within the 
nucleus (based on P. berghei) as described by Sinden et al., (1985). During meiotic 
cell division, the homologous chromosomes pair (synapsis) at the time when each 
chromosome already consists of two chromatids. If the zygote is derived through 
cross-fertilisation between gametes of the two genetically distinct parasites, genetic 
exchange can occur by means of ‘crossing-over’ between the non-sister chromatids 
of a pair of homologous chromosomes resulting in the recombination of genetic 
material at homologous loci. In addition to inter-chromosomal crossing events, 
genetic recombination during meiosis of heterozygotes can be produced by simple 
reassorment between members of chromosome pairs. Each zygote undergoes two 
successive nuclear divisions to obtain four ‘haploid’ nuclei. As a result, the 
maximum number of genetically distinct types of haploid daughter cells (progeny) 
produced by a single heterozygote is four. This event is all-important in determining 
the genetic fate of the progeny of the zygote. The production of recombinant forms at 
meiosis is summarised in Figure 1.5.  
 
The earliest attempt to carry out a genetic cross on malaria parasites made use of the 
avian species, Plasmodium gallinaceum (Greenberg et al., 1954). The approach 
involved (1) mixing blood forms of P. gallinaceum strains M and BI that differed in 
patterns of pre-erythrocytic schizogony and responses to pyrimethamine, (2) 
transmitting the mixture through mosquitoes to allow cross-fertilisation between 
gametes of the two parental genotypes and (3) examining for evidence of 
recombination between characters of the parental strains in the progeny of a genetic 
cross. It was found that the uncloned progeny of a genetic cross were able to resist to 
a high degree of pyrimethamine [behaving as the pyrimethamine-resistant strain] 
while retaining a pattern of pre-erythrocytic schizogony of the pyrimethamine-
sensitive parental strain. Although it was claimed to be evidence of hybridisation in 
the genetic cross by the authors, this work was inconclusive because evidence of 
recombination was not demonstrated in the ‘cloned’ progeny of a genetic cross. 
Since then clear demonstrations of genetic recombination following crossing were 
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made with rodent malaria species (Walliker et al., 1973; Walliker et al., 1975). This 
is due to the availability of cloning methods and molecular genotyping methods (e.g. 
starch gel electrophoresis of isozymes) that allowed the precise genetic 
characterisation of genetically distinct clones. A genetic cross of rodent malaria was 
first conducted between two cloned lines, 17XA and 33XC, of P. y. yoelii that 
differed in pyrimethamine sensitivity and in electrophoretic motility of the enzyme 
protein glucose phosphate isomerase (GPI) (Walliker et al., 1973). Following this 
work, a second genetic cross was conducted between two cloned lines, AS and AJ, of 
P. c. chabaudi, which differed in electrophoretic forms of lactate dehydrogenase 
(LDH) and 6-phospho gluconate dehydrogenase (6PGD) as well as in their responses 
to pyrimethamine (Walliker et al., 1975). In both studies, products of the genetic 
crosses were cloned by limiting dilution and examined for enzyme forms and drug 
responses. It was found that only one form of any character was present in any of the 
cloned progeny of a genetic cross, and that the frequency of recombination between 
variants of these characters corresponded to random reassortment. Such 
recombination between, and segregation of, allelic pairs representing different 
inherited traits conforms to that pattern of inheritance originally observed and 
described by Mendel.    
 
The production of heterozygous oocysts following mixed feeding to mosquitoes, of 
two genetically distinct malaria parasites has been shown to occur experimentally 
with P. falciparum (Ranford-Cartwright et al., 1993). This study examined oocysts in 
mosquitoes fed on mixed clones of P. falciparum designated 3D7 and HB3, in which 
genes coding for merozoite surface proteins MSP-1 and MSP-2 are polymorphic. 
Three types of oocysts were found: some oocysts contained alleles exclusively from 
HB3 (homozygotes), some contained alleles only from 3D7 (homozygotes), and the 
remainder contained alleles from both parents at both loci. Oocysts of the latter 
group were, therefore, hybrids (heterozygotes) which are the products of cross-
fertilisation between gametes of the two different parental genotypes. The 
proportions of homozygous and heterozygous forms were consistent with those 
predicted by Hardy-Weinberg expectations for random fertilisation between gametes 
of the two parental genotypes (Ranford-Cartwright et al., 1993).   
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 In addition to meiosis, genetic recombination during asexual replication of malaria 
parasites in the blood has been documented in P. falciparum (Freitas-Junior et al., 
2000), albeit of at a frequency much lower than in meiosis. The mitotic 
recombination events can occur between non-homologous chromosomes at sub-
telomeric regions within the same genome and appeared to be facilitated through the 
clustering of telomeres at the nuclear periphery (Freitas-Junior et al., 2000). Because 
these regions of the chromosomes usually comprise a number of genes coding for 
variable parasite proteins, such as var genes (Smith et al., 1995; Su et al., 1995), this 
mechanism appears to facilitate recombination of alleles of these genes to promote 





















Figure 1.5. Inheritance of nuclear genes in malaria parasites and the production of
recombinant progeny at meiosis. Note that genetic recombination can be generated by
chromosomal reassortment or by crossing-over events. (A) or (D) Homozygous progeny
produced by selfing between gametes of the same parental clone 1 or 2, respectively. (B)
Heterozygous progeny produced by crossing between gametes of the two different parental
clones, recombinant nuclei (blue ovals) being formed by chromosomal reassortment alone. (C)
Heterozygous progeny produced from cross-fertilisation between gametes of the two different
parent clones, recombinant nuclei (red ovals) being formed by crossing over between the non-
sister chromatids of the homologous chromosomes. (Figure adapted from Walliker et al., 1998) 
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1.8.4 Genetic linkage maps of malaria parasites 
 
Linkage of genetic markers on a chromosome of an organism can be represented in 
the form of a genetic map. This shows the linear order of the genetic markers along 
the chromosome with distances between adjacent markers being proportional to the 
frequency of recombination between them. Genetic linkage maps have provided a 
powerful means to locate genes controlling heritable phenotypes in organisms that 
undergo sexual recombination. The construction of a genetic linkage map for malaria 
parasites involves (1) crossing two genetically distinct clones of the same malaria 
parasite species and (2) cloning out products of the genetic crosses. Individual 
parasite clones from the crosses can be typed with parasite clone-specific, 
polymorphic, DNA markers at hundreds of loci which represent one or the other 
allele of the parental clones at each locus. A pattern of inherited parental alleles 
(haplotype) is defined for each parasite clone. The markers of each parent are 
expected to reassort in the progeny of a genetic cross. However, markers that appear 
to be inherited more often than expected from random reassortment are considered to 
be ‘genetically linked’ in malaria parasites. Genetic markers that represent each such 
linkage group can be hybridised to chromosomes, separated by pulsed field gel 
electrophoresis (PFGE), in order to determine the physical location of each linkage 
group onto a specific chromosome. Together, these processes can yield a genetic 
linkage map across all of the chromosomes of a malaria parasite. 
 
Three genetic crosses in P. falciparum have been generated and published so far. The 
three crosses are: HB3 x 3D7 (Walliker et al., 1987), HB3 x Dd2 (Wellems et al., 
1990; Wellems et al., 1991) and 7G8 GB4 (K. Hayton, unpublished; cited from Su 
et al., 2007), from which 21, 35 and 33 independent recombinant progeny clones 
were established, [the number of clones from these crosses quoted from Su et al., 
(2004) and Su et al., (2007)]. The first genetic linkage map of P. falciparum was 
constructed after the characterisation of 16 independent recombinant progeny of the 
P. falciparum HB3 x Dd2 genetic cross (Walker-Jonah et al., 1992). The map was 
established with 90 parasite clone-specific RFLP markers that were allocated to 14 
inferred linkage groups corresponding to the 14 nuclear chromosomes (Walker-Jonah 
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et al., 1992). Crossover rates obtained from parasite clone-specific RFLP markers 
mapped on P. falciparum chromosomes allowed calculation of the map unit for this 
malaria parasite. A map unit (one centiMorgan) is a unit of distance in a linkage 
group that corresponds to a recombination frequency of 1%. An average map unit in 
the RFLP-based linkage map of P. falciparum was 15 to 30 kilobase pairs per 
centiMorgan of genetic distance (kb cM-1) (Walker-Jonah et al., 1992).  
 
The association between the inheritance of a phenotype (e.g. drug resistance) and the 
inheritance of genetic markers in the cloned progeny of the genetic crosses is used to 
identify chromosomal regions that harbour genes underlying such phenotypes. For 
example, the availability of RFLP inheritance patterns from the HB3 x Dd2 cross 
allowed the location of a locus underlying chloroquine resistance to a 400-kb 
segment of P. falciparum chromosome 7 (Wellems et al., 1991). Likewise, the 
genetic determinants of a male gametocytogenesis defect were mapped to a location 
on P. falciparum chromosome 12 (Vaidya et al., 1995; Guinet et al., 1996) and genes 
conferring sulfadoxine resistance to a locus on P. falciparum chromosome 4 (Wang 
et al., 1997).  
 
Following this work, about 900 microsatellite markers were used to construct a 
genetic linkage map of P. falciparum (Su et al., 1999) using 35 independent progeny 
of the P. falciparum HB3 x Dd2 genetic cross. The markers were then assigned to 14 
inferred linkage groups, using the locations of RFLP markers from the previous 
genetic map (Walker-Jonah et al., 1992) to anchor the 14 linkage groups of 
microsatellite markers to the 14 nuclear chromosomes of P. falciparum. Consistent 
with the previous estimation based on the earlier RFLP-based linkage map for P. 
falciparum (Walker-Jonah et al., 1992), the size of an average genetic map unit 
derived from the microsatellite-based linkage map was 17 kb cM-1 (Su et al., 1999). 
This high-resolution genetic map enabled the location of the pfcrt gene conferring 
chloroquine resistance in this parasite (pfcrt encodes the “chloroquine resistant 
transporter” (Fidock et al., 2000) to a 36-kb region in P. falciparum chromosome 7 




A genetic linkage map of P. c. chabaudi has also been constructed, using the 
inheritance patterns of 45 RFLP markers in 20 independent recombinant progeny 
clones of a genetic cross between the chloroquine-resistant, AS, and chloroquine- 
sensitive clone, AJ (Carlton et al., 1998a). This map comprises 14 linkage groups 
that correspond to the 14 chromosomes. The RFLP inheritance patterns of the cloned 
progeny of the P. c. chabaudi AS x AJ cross indicated a locus responsible for 
chloroquine resistance in this malaria parasite on chromosome 11 (Carlton et al., 
1998a). Subsequently, AFLP has been developed in our laboratory for P. c. chabaudi 
(Grech et al., 2002). It has proved useful in generating a large number of parasite 
clone specific genetic markers in this malaria parasite (Grech et al., 2002). The 
inheritance of 672 AFLP markers from the two parental clones of P. c. chabaudi AS 
and AJ was determined in 28 independent recombinant cloned progeny from the two 
AS x AJ genetic crosses (Martinelli et al., 2005b). These AFLP markers could be 
organised into 22 linkage groups together with a previous set of RFLP markers used 
as an anchor for chromosome identification (Carlton et al., 1998a). Ten of these 
linkage groups correspond to P. c. chabaudi chromosomes 1, and 5 to 13. Twelve 
other groups of AFLP markers could not be assigned to specific chromosomes and 
are called P. c. chabaudi unassigned linkage groups (Martinelli et al., 2005b). The 
overall estimated size of map unit for P. c. chabaudi is 15.1 kb cM-1 (Martinelli et 
al., 2005b). The AFLP-based genetic linkage map for P. c. chabaudi has become a 
tool for identifying the genetic location of AFLP markers that are genetically linked 
to loci conferring important phenotypes. This map was used to successfully locate a 
250-kb region on P. c. chabaudi chromosome 11 which contains a locus underlying 
chloroquine resistance in this parasite (Hunt et al., 2004).  
 
In addition, the AFLP-based genetic linkage map for P. c. chabaudi has already 
enabled us to identify loci linked to genes underlying other medically important 
phenotypes, such as the artemisinine sensitive/resistant traits (Hunt et al., 2007), 
using the Linkage Group Selection approach (LGS) (Culleton et al., 2005; Carter et 
al., 2007) (see section 1.8 for detailed description of LGS). LGS is a genetic method 
that involves the mass screening with quantitative genetic markers of the ‘uncloned’ 
progeny of a genetic cross following its growth under a selection pressure 
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representing the phenotype of interest. In the present work, the AFLP-based genetic 
linkage map is now utilised to identify regions in the P. c. chabaudi genome 
containing genes encoding targets of SSPI in P. c. chabaudi (Chapter 2).  
 
 
1.9 Genomes of malaria parasites 
 
The genome of the malaria parasite comprises three components: (1) a 
mitochrondrial genome, (2) a genome associated with an organelle known as an 
apicoplast and (3) the nuclear genome. 
 
1.9.1 Mitochrondrial and apicoplast genomes 
Each malaria parasite cell has two organellar genomes; the mitochondrial genome 
and the apicoplast genome. The mitochrondrial genome of malaria parasites was first 
identified in the rodent malaria parasite, P. yoelii, as a multiple-copy 6 kb linearly re-
iterated molecule (Vaidya et al., 1987). The mitochondrial genome comprises genes 
encoding two truncated ribosomal RNAs and three components of cellular 
respiration (cytochrome c oxidase subunits I and III, and cytochrome b) (Vaidya et 
al., 1989; Feagin, 1992; Williamson, 1998). Its copy number varies over the species 
of malaria parasite, ranging from 20 copies per cell in P. falciparum (Preiser et al., 
1996) to 150 copies per cell in P. y. yoelii (Vaidya et al., 1987). The apicoplast 
genome is a low-copy number, 35 kb circular molecule (Wilson et al., 1996; Wilson 
et al., 1997; Wilson, 1998). It is composed of genes coding for around 30 proteins, 
most of which are RNA polymerase, and other proteins involved in transcription 
processes (Wilson et al., 1996; Wilson et al., 1997; Wilson, 1998).  
 
The mitochondrial and apicoplast genomes of the human malaria parasite, P. 
falciparum, were shown to be inherited uniparentally (Creasey et al., 1993; Vaidya et 
al., 1993). In the majority of eukaryotes, these genomes are inherited through one 
parent only, mostly the female. This was also proven to be the case in P. 
gallinaceum, since DNA probes specific to the mitochondrial or apicoplast genome 
hybridised with the DNA of female gametes, but not male gametocytes (Creasey et 




1.9.2 Nuclear genome of P. falciparum 
 
The first malaria parasite nuclear genome sequence data was generated from P. 
falciparum clone 3D7, undertaken by an international consortium of genome 
sequencing centres (Hoffman et al., 1997) including The Institute for Genomic 
Research (TIGR, USA), the Wellcome Trust Sanger Institute (UK) and Stanford 
Genome Technology Centre (USA). Each centre used the chromosome-by-
chromosome shotgun strategy to generate sequences of each of the 14 chromosomes, 
which were separated by PFGE. The genome of P. falciparum 3D7 was sequenced to 
an average coverage of 14.5 fold (i.e. every base in the genome is represented in the 
shotgun sequence [raw nucleotide sequence] on average, 14.5 times) [quoted from 
Kooij et al., 2006] (Table 1.3). The raw sequences were then assembled into 
contiguous DNA sequences termed ‘contigs’. These contigs could be subsequently 
orientated and allocated to specific chromosomes in the P. falciparum genome with 
reference to previous P. falciparum map data, such as the microsatellite-based 
genetic linkage map from the HB3 x Dd2 cross (Su et al., 1999). Because the 
genomes of malaria parasite are so Adenine (A) and Thymine (T) rich (McCutchan et 
al., 1984), it is difficult to obtain sequences for some regions due to the instability of 
the fragment in cloning vectors. This results in ‘gaps’ in the genome. At the time of 
the publication of the P. falciparum genome sequence in 2002 (Gardner et al., 2002), 
there were still 79 gaps in the whole genomic sequence. At present, just three 
chromosomes (7, 8 and 13) are still awaiting closure, with only six gaps remaining 
(M Berriman, unpublished, quoted from Kooij et al., 2006) 
      
The P. falciparum clone 3D7 nuclear genome consists of 22.8 megabase pairs (Mb) 
distributed among 14 chromosomes ranging in size from 0.643 Mb for chromosome 
1 to 3.29 Mb for chromosome 14 (Gardner et al., 2002). The genome contains a high 
proportion of AT content (~80.6%). This proportion, however, rises to ~ 90% in 
introns and intergenic regions, and to > 97% in putative centromeric regions 
(Gardner et al., 2002). The nuclear genome of P. falciparum appears to contain 5,268 
predicted genes encoding proteins (Gardner et al., 2002). A summary of general P. 




Comparison of the annotation of the P. falciparum nuclear genome with previously 
published genomes of other organisms, e.g. yeasts, Saccharomyces cerevisiae (Wood 
et al., 2001) and Schizosaccharomyces pombe (Wood et al., 2002), and a plant, 
Arabidopsis thaliana (Arabidopsis Genome Initiatives, 2000), showed that around 
40% of all gene products are similar to those in these other organisms. These proteins 
are predicted to be involved in maintaining cellular functions, such as metabolism 
(8%) and cell-to-cell adhesion or invasion of host cells (1.3%). A further 10% of the 
nuclear-encoded proteins are predicted to be transported to the apicoplast (Gardner et 
al., 2002). These are known to function in synthesis of isoprenoid, haeme and fatty 
acids (Foth et al., 2003). The P. falciparum nuclear genome also contains multigene 
families clustered towards the sub-telomeric regions of chromosomes. Three such 
families, accounting for 5 to 10% of all genes, termed var, rif and stevor, code for 
highly variable proteins known as P. falciparum erythrocyte membrane protein-1     
(PfEMP-1) (Smith et al., 2005, Su et al., 1995), repetitive interspersed family 
(RIFIN) (Cheng et al., 1998; Kyes et al., 1999) and sub-telomeric variable open 
reading frame (STEVOR) (Cheng et al., 1998), respectively. PfEMP-1 and RIFIN 
are exported to the surface of infected erythrocytes and undergo antigenic variation 
(Kyes et al., 2001, Bull et al., 2005). While the function of RIFIN and STEVOR is 
not known, PfEMP-1 mediates adherence to host endothelial receptors, resulting in 
the sequestration of infected erythrocytes in various organs (Pain et al., 2001) and 
thus contributing to the development of severe malaria (Miller et al., 2002). The 
remaining part of the nuclear genome (~ 60%) contains predicted genes encoding 
proteins of unknown function; so-called hypothetical proteins. Nevertheless, among 
them are likely to be novel antigens for malaria vaccine choice as well as de novo 
targets for anti-malarial drugs.   
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1.9.3 Nuclear genomes of rodent malaria parasites 
 
 
With the completion of the P. falciparum genome sequencing project (Gardner et al., 
2002), a series of initiatives has begun to generate more genome information from 
other Plasmodium species. The genome sequencing projects of three rodent malaria 
species were undertaken by the two sequencing centres:  TIGR for the P. y. yoelii 
17XNLclone1.1 genome and the Sanger Institute for the P. c. chabaudi clone AS and 
P. berghei clone ANKA genomes. A whole-genome shotgun sequencing approach 
(i.e. the whole genome subjected to the shotgun sequencing without prior separation 
of individual chromosomes by PFGE) was utilised to sequence and assemble the 
sequence data. The partial genomic sequences from these three clones have been now 
published (Carlton et al., 2002; Hall et al., 2005). The P. y. yoelii genome project has 
completed with average five fold average sequence coverage (Carlton et al., 2002), 
while the P. c. chabaudi and P. berghei genome projects have finished with average 
eight fold average sequence coverage. The summary of the three rodent malaria 
genome projects is given in Table 1.3. 
 
Examination of data from the rodent malaria genome projects shows that the 
genomes of rodent malaria parasites have a standard size of approximately 23 to 30 
Mb distributed among 14 linear chromosomes. Like P. falciparum chromosomes, the 
estimated sizes of rodent malaria parasite chromosomes range from 0.5 to 3.0 Mb, 
using PFGE (Janse et al., 1994). The genomes of rodent malaria parasites are high in 
AT content (70 to 80%). However, because the average sequence coverage of the 
rodent malaria parasite genomes (5 to 8X coverage, quoted from Kooij et al., 2006) 
is lower than that of the P. falciparum genome, a large number of gaps are still 
present in their genomes. Also, the number of contigs is higher and the relative size 
of contigs is much smaller (~2 to 4 kb), compared to those generated by the P. 































Table 1.3. A comparison of general genome characteristics between the human malaria parasite,
Plasmodium falciparum, and three rodent malaria species, Plasmodium yoelii yoelii, Plasmodium chabaudi 
chabaudi and Plasmodium berghei. ND, not determined 








(c) Genome sequence coverage indicates how many times the genome was sequenced 
(d) (A+T) % is defined as the percentage of the total nuclear genomic DNA content (i.e. both coding and
non-coding regions) that is    
Adenine(A)-Thymine(T) pairs. 
(e) Updated information of the Plasmodium genome projects (March 2006) quoted from Kooij et al., (2006)










Each rodent malaria parasite species appears to have 5000 to 6000 predicted genes 
per genome (Table 1.3). Comparative genomic analyses based on bi-directional 
BLAST searches between the rodent malaria genomes and the annotated human 
malaria genome have inferred the annotation of these genes in the rodent malaria 
parasite genomes (Carlton et al., 2002; Hall et al., 2005). As shown in Figure 1.6, the 
first comparative analysis between the P. falciparum and P. y. yoelii genomes 
revealed that about 60 to 70% of the predicted P. y. yoelii proteins had orthologous 
gene pairs (i.e. genes related to each other by descent from a common ancestral DNA 
sequence and not necessarily the having same function) in P. falciparum (Carlton et 
al., 2002). Similar figures for orthologous gene pairs were also found between P. 
falciparum and P. berghei and between P. falciparum and P. c. chabaudi (Hall et al., 
2005) (Figure 1.6). Comparative analyses were also made between the genomes of 
the three rodent malaria species (Carlton et al., 2002; Janssen et al., 2002; Gardner et 
al., 2002; Janssen et al., 2004; Hall et al., 2005). The results showed that about 80 to 
90% of genes encoding proteins were shared between the rodent malaria genomes. 
Almost all of the putative orthologues could be located in the central portions of the 
chromosomes. There are, however, a number of genes that have no orthologues 
between malaria species. Most of these genes are commonly found in the sub-
telomeric regions of chromosomes and are also known to be a repertoire of highly 
variant, species-specific gene families. The three rodent malaria parasites share 
Plasmodium interspersed repeats (pir) superfamily (bir gene family in P. berghei, yir 
gene family in P. y. yoelii, cir gene family in P. c. chabaudi) (Janssen et al., 2002). 
The pir superfamily is also present in the human malaria parasite P. vivax (vir gene 
family) (del Portillo et al., 2001) and in the simian malaria parasite P. knowlesi (kir 
gene family) (Janssen et al., 2004). However, P. falciparum parasites lack the pir 
superfamily, but the sub-telomeric regions of their chromosomes harbour the gene 















































Figure 1.6. The number of orthologous gene pairs in the genome of four Plasmodium
species. (A) shows a comparison between the human malaria parasite, Plasmodium
falciparum, and three rodent malaria species, Plasmodium yoelii yoelii, Plasmodium
chabaudi chabaudi and Plasmodium berghei. (B) shows a comparison between the three
rodent malaria species. Numbers in brackets represent average protein identity. (Carlton et
l., 2002; Hall et al., 2005) a .9.4 Genetic synteny in Plasmodium species 
enetic synteny refers to the degree of conservation of gene order between two 
enomes. The original studies of gene synteny between Plasmodium species were 
onducted from gene-mapping on PFGE-separated chromosomes (Janse et al., 1994; 
arlton et al., 1998b; Carlton et al., 1999). The availability of the genome sequence 
ata from P. falciparum and the three rodent malaria species allowed studies of gene 
ynteny to be performed using bioinformatic techniques across the entire genomes. 
he first genome-wide synteny map was constructed between the P. falciparum and 
. y. yoelii genome (Carlton et al., 2002). Each genome sequence was translated in 
ll 6 reading frames using the MUMer program (Delcher et al., 2002) to identify all 
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exact amino sequence matches longer than 5 amino acids between species. Over 70% 
(~2,200 sequences) of the P. y. yoelii genome content were aligned to specific P. 
falciparum chromosomes, representing a cumulative length of 16.4 Mb of sequence. 
These P. y. yoelii contigs were subsequently joined up to generate “groups of 
contigs” by the use of mate-pair information, PCR amplification of products from the 
gaps between contigs, and identification of genes that spanned the gap (Carlton et al., 
2002). Accordingly, these groups of contigs represented regions of conserved gene 
synteny. Physical mapping of the representatives of these contigs to a partial physical 
map of P. y. yoelii (PFGE-separated chromosomes) (Janse et al., 1994) provided a 
map of conserved gene synteny and identified potential syntenic break points. 
Subsequently, partial genome sequence data of the rodent malaria genome P. berghei 
and P. c. chabaudi were aligned to the P. y. yoelii genome to identify overlapping 
contigs and, therefore, to generate composite contigs of the rodent malaria parasite 
(Kooij et al., 2005).  This data was then used to construct a new synteny map of P. 
falciparum and the composite rodent malaria genome using the MUMer programme, 
as just described. The whole-genome synteny map between P. falciparum and the 
three rodent malaria parasites is illustrated in Figure 1.7. 
 
Throughout the present study, the whole-genome synteny map between P. 
falciparum and the three rodent malaria parasites species has been used as a means to 
locate genetic markers in the Plasmodium genome. Genetic markers of rodent 
malaria parasites which are identified from genetic analysis can be sequenced. 
Orthologous loci of the markers can be found in the more-or-less completely 
annotated genome of the human malaria parasite, P. falciparum. The corresponding 
loci of P. falciparum orthologues of genetic markers in the rodent malaria parasite 
genome can, in turn, be identified through the conserved synteny (Figure 1.7). This 
data has enabled us to identify genomic regions containing genes underlying 
phenotype of interest and to determine whether possible candidate genes are present 




































Figure 1.7. A whole-genome synteny map of the human malaria parasite Plasmodium 
falciparum and three rodent malaria parasites (RMP): Plasmodium yoelii yoelii (Py), 
Plasmodium chabaudi chabaudi (Pc) and Plasmodium berghei. A synteny map of the core 
regions of the 14 chromosomes of P. falciparum (left) and the rodent malaria parasites 
(right) show the 36 synteny blocks, 22 synteny breakpoints, 14 predicted centromeres, and P. 
falciparum-specific indel and translocations in the RMP chromosomes. The 36 synteny
blocks, coloured according to their chromosomal location in the composite rodent malaria
parasite (cRMP) genome are named with a Roman and an Arabic number referring to the
corresponding chromosomal location in P. falciparum and the cRMP genomes, respectively. 
Letters give the order in which the synteny blocks are connected. Telomeres and sub-
telomeric linked ends are shown as white arrows. The bars under the cRMP chromosomes
represent the differences in the organisation of the synteny blocks of Py and Pc from Pb as a 
result of chromosomal translocations. Colours indicate the cRMP chromosome within which 
recombination has taken place and colour gradients represent the ill-defined regions of the 





1.10 Linkage Group Selection  
 
 
The identification of genes in malaria parasites which determine medically important 
traits, such as drug resistance, growth rate, transmissibility and SSPI can have great 
benefits for malaria control. The conventional approach of a genetic analysis of 
malaria parasites that attempts to identify genes underlying such traits involve 
crossing two genetically distinct lines of malaria parasites that differ in phenotypes 
of interest, cloning the products of a genetic cross, and characterising genotypes of 
individual clones with a large number of genetic markers (Walliker, 2005). Recently, 
an alternative approach to identifying genes in malaria parasite crosses has been 
developed and called “Linkage Group Selection” (LGS) (Carter et al., 2007) (see 
Figure 1.8). In this method, the laborious procedure of cloning and characterizing the 
clones of genetic crosses is circumvented. Rather, the entire “uncloned” progeny of 
genetic crosses is placed under a selection pressure that represents a biological 
characteristic of interest, e.g. growth rate or SSPI. DNA of the selected progeny is 
screened en masse with quantitative, parental clone-specific genetic markers, such as 
AFLP, across the genome. It would be expected that alleles of genes not linked to the 
locus affected by the selection pressure would retain approximately the same 
frequency in the cross progeny before and after selection. By contrast, genetic 
markers of the parental clone sensitive to the selection pressure which are linked to a 
locus conferring susceptibility to the selection pressure will be removed or reduced 
in the cross progeny following selection. These ‘selected’ markers can be sequenced, 
and their positions located in the parasite genome in order to identify the linkage 
group that contains the locus sensitive to the selection pressure – hence the name 
“Linkage Group Selection”. Within the linkage group of the selected markers, the 
closer the markers are genetically linked to the target locus, the greater the reduction 
in their representation in the selected population. Thus, a “selection valley” will be 
formed around the locus under selection with its walls sloping down towards the 
























Figure 1.8.  A schematic representation of the principles of Linkage Group Selection 
(LGS). 
(i) LGS involves crossing two strains of malaria parasites that differ in their sensitivity to a
particular selection pressure. Each bars represent a chromosome in the genome of parasite
(resistant parent, green; sensitive parent, yellow). Resistance to the selection pressure is
conferred by a single locus (blue oval), while the flags represent chromosome-wide markers
between the two strains (resistant parent specific markers, Scottish flags; sensitive parent
specific markers, English flags). 
(ii) The resulting recombinant progeny population will contain thousands of parasites, each
bearing a random assortment of parental alleles, and also a random assortment of parental
markers (only 6 examples shown here). This uncloned population is then placed under the
selection pressure representing the phenotype of interest. The process will select for parasites
that possess the resistant allele of the gene that controls the phenotype of interest (blue oval),
any markers linked to this locus will be mainly from the resistant parent, their proportion
increasing as the distance from the locus under selection decreases. 
(iii) In the resulting surviving population, we search for markers of the sensitive parent (English
flags) that are removed or reduced by the selection pressure; the greater the degree of
reduction of a sensitive marker, the closer it is linked to the allele removed by the selection




































Figure 1.9. A simulation of the result of a Linkage Group Selection analysis of a simple
monogenic trait in a malaria parasite. Following growth of uncloned progeny of a genetic
cross between two lines of malaria parasites, one ‘Resistant’ and the other ‘Sensitive’ to a
specific selection pressure, DNA of the selected progeny will be screened en masse for presence
and intensity with the quantitative genetic markers specific to the sensitive parental strain (red
dots). It is, theoretically, expected that any uncloned cross progeny carrying the allele of the
gene (blue box) from the Sensitive parent conferring ‘sensitivity’ to the selection pressure will
be removed from the uncloned progeny population. The target locus of selection directly
affected by the selection pressure will be removed from the progeny, and so markers of the
sensitive parent of other loci on the same linkage group would be reduced in proportion to their
decreasing genetic distance from the target locus. Proportions of parasite DNA carrying the
allele of genes at the genome-wide loci, represented by the relative intensities of quantitative
markers of the Sensitive parent line, are plotted against the genetic distance of each marker in
the Plasmodium chromosome containing the target under selection. Hence, a ‘selection valley’
will be formed. Markers of the Sensitive parent at the lowest point in the selection valley are
expected to be closely linked to the locus determining ‘Resistance’ or ‘Sensitivity’ to the
selection pressure representing the biological property of interest.  57
he application of LGS was validated by our research group using two genetically 
istinct lines, AS-pyr1 and AJ, of the rodent malaria parasite, P. c. chabaudi, that 
iffer in responses to pyrimethamine (Culleton et al., 2005), and for which the 
ontrolling genetic factors were already understood. The pyrimethamine-resistant 
henotype is conferred by a single point mutation in codon 106 of dihydrofolate 
eductase coding gene in P. c. chabaudi (Cheng et al., 1994a). The result showed that 
he base of the pyrimethamine-selected valley was closely linked to the position of 
he dhfr gene, already known to encode resistance or sensitivity to pyrimethamine, 
n a genetic linkage map of P. c. chabaudi on chromosome 7 (Culleton et al., 2005). 
ore recently, LGS analysis has enabled the location of regions in the P. c. chabaudi 
enome containing loci conferring resistance to anti-malarial drugs, artemesinin and 
rtesunate (Hunt et al., 2007). It has led to the location of a potential target of 
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artiminsinin resistance to a 200-kb region on P. c. chabaudi chromosome 2 which 
contains the gene encoding a deubiquitinating enzyme (Hunt et al., 2007).   
 
Thus, the practise of LGS analysis in malaria parasites is now well established and its 
principles have been validated (Culleton et al., 2005). The method of LGS has many 
potential applications in the field of malaria parasite genetics. LGS can be used to 
investigate genes controlling other important phenotypes, such as SSPI and growth 
rate. In order to exploit LGS to investigate SSPI, the uncloned progeny of a genetic 
cross between antigenically distinct strains of malaria parasite need to be grown in 
individual hosts previously immunised with either one or the other of the two 
parental clones used to generate such a genetic cross. The first LGS analysis of SSPI 
was conducted in this laboratory using progeny of a genetic cross between two 
genetically distinct strains of P. c. chabaudi AS-pyr1 and CB. This study identified a 
selection valley on P. c. chabaudi chromosome 8 under SSPI selection. The base of 
which contains the gene encoding the highly variable merozoite surface antigen, 
Merozoite Surface Protein-1 (MSP-1) (Martinelli et al., 2005a), a candidate target of 
SSPI to rodent malarias. However, whether the gene coding Apical Membrane 
Antigen-1 (AMA-1), another SSPI-target candidate, was involved in SSPI could not 
be tested because AS-pyr1 and CB possess identical amino acid sequences within the 
cell surface, ectodomain-coding region of AMA-1 (S. Cheesman and R. Carter, 
unpublished data). Therefore, the present study will be conducted using a new strain 
combination of P. c. chabaudi that inherit distinct allelic forms of the genes for both 
MSP-1 and AMA-1. The progeny of the cross will be subjected to growth in the 
strain-specific immunised mouse as well as being passaged in a non-immune mouse. 
Results of these experiments will be described in Chapter 2.   
 
In the context of growth rate, the uncloned cross progeny between a faster-growing 
and a slower-growing strain of P. y. yoelii will be passaged in the vertebrate host to 
select those parasites that grow fast. This process is expected to select the allele(s) 
controlling growth rate in the faster growing parental strain. The use of LGS 
approach to determine genes controlling growth rate will be described in the Results 
in Chapter 4.  
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1.11 Aims of the project   
 
The first part of the present study focuses on the identification of genes encoding 
target antigens of SSPI in malaria parasites. I conducted LGS analysis using two 
cloned lines of P. c. chabaudi AJ and CB-pyr10 in which both genes encoding two 
major targets of SSPI, MSP-1 and AMA-1, are polymorphic. This aimed to 
determine the involvement of both loci in SSPI. Experiments were designed in which 
the uncloned progeny of the AJ x CB genetic cross were exposed to the strain 
specific protective immune selection pressure (e.g. in mice which had been 
immunised with either strain AJ or CB) as well as being passaged in the absence of 
the relevant selection pressure (e.g. in a non-immune batch mate of the strain specific 
immunised mice). Proportions of parental alleles in the SSPI-selected and unselected 
cross progeny were measured using quantitative genome-wide molecular markers, 
such as AFLP. The regions of the P. c. chabaudi genome containing genes for target 
of SSPI were successfully identified. Results of LGS analysis of SSPI using these 
parasites are presented in Chapter 2.   
 
The second part of the present study focuses on the genetic basis of growth rate in 
the rodent malaria parasite P. y. yoelii. Before reporting on the full LGS analysis of 
growth rate, I present the results of an investigation of the genetic relationship 
between different cloned lines of P. y. yoelii 17X that vary in growth rate. A 
comparative genetic analysis of these parasite lines was made using (i) nucleotide 
sequences for specific genes, which are expected to be polymorphic, and (ii) 
restriction site-associated polymorphism by AFLP. The purpose of this study was to 
determine from which slow-growing line of P. y. yoelii 17X the fast-growing line 
17XYM, using in the LGS analysis of growth rate, had arisen. Results from this 
study are presented in Chapter 3. Finally, I report the results of LGS analysis of the 
genetic determinants of growth rate in P. y. yoelii. Experiments were conducted 
using a genetic cross between the fast-growing, 17XYM, and a slow-growing and 
genetically unrelated line, 33XC, of P. y. yoelii. The uncloned progeny was allowed 
to grow in laboratory mice. The growth rate selected cross progeny were subjected to 
a genome-wide scan by AFLP to determine the locus controlling growth rate in this 
parasite. These experiments are described in Chapter 4.  
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CHAPTER 2: Linkage Group Selection: Towards Identifying 
Genes Controlling Strain Specific Protective Immunity in 
Malaria 
 
A version of this chapter has been published as: Pattaradilokrat S., Cheesman S. J., 
Carter R. (2007) Linkage Group Selection: Towards Identifying Genes Controlling 





A part of anti-parasitic protective immunity against the pathogenic blood stages in 
malarial infections has been shown to be specific to the genotype, or strain, of the 
parasites in humans and laboratory animals. It is expected that the target antigens of 
Strain Specific Protective Immunity (SSPI) would, therefore, be antigenically and 
genetically different among different strains, or genetically distinct lines, of malaria 
parasite. Two highly polymorphic antigens, merozoite surface protein-1 (MSP-1) and 
apical membrane antigen-1 (AMA-1), have been implicated as targets of SSPI in 
human and rodent malarias. Here we describe the use of a genetic and genomic 
approach, Linkage Group Selection (LGS), to locate region(s) containing the 
target(s) of SSPI against the blood stages of the rodent malaria parasite Plasmodium 
chabaudi chabaudi. In a previous analysis using the progeny of a genetic cross 
between two genetically distinct cloned lines, AS-pyr1 and CB, of P. c. chabaudi, a 
region on P. c. chabaudi chromosome 8 that contains the gene encoding the P. c. 
chabaudi MSP-1 was found to be under strong SSPI selection. However, the possible 
involvement of P. c. chabaudi AMA-1 in SSPI could not have been evaluated in this 
cross as AS-pyr1 and CB have identical amino acid sequences within the cell 
surface, ectodomain-coding region of this protein. In the present study, LGS analysis 
of SSPI has been conducted with a different combination of genetically distinct lines, 
CB-pyr10 and AJ, of P. c. chabaudi, in which the genes for both MSP-1 and AMA-1 
proteins are genetically distinct. This analysis has identified the region on P. c. 
chabaudi chromosome 8 containing the gene for MSP-1 as encoding a major target 
of SSPI as was also found in the previous study. The results of this study also 
revealed that two other regions, one on P. c. chabaudi chromosome 9 containing the 
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gene for AMA-1 and the other on chromosome 7, may be associated with SSPI but to 
a lesser degree than that for MSP-1. Together, the evidence from these two 
independent studies indicates that SSPI in P. c. chabaudi in mice is mainly 
determined by a single, narrow region of the P. c. chabaudi genome containing the 





In regions of the world where malaria is endemic, anti-parasitic protective immunity 
against infection with the pathogenic blood stages of the parasites is acquired 
gradually after repeated exposure to malaria (McGregor et al., 1956; McGregor, 
1974; Day et al., 1991). This immunity is non-sterile, leading to a state of 
premunition in which low parasite densities are maintained in the host without 
causing disease symptoms. In contrast to the slow acquisition of protective immunity 
to malaria under natural conditions, such immunity can be achieved relatively 
quickly in humans under clinically controlled conditions and in laboratory animals 
after one, or a few, blood stage-induced infections with a single cloned strain 
(genotype) of malaria parasites followed by drug cure (Jeffrey, 1966; Cardigan et al., 
1969; Powell et al., 1972; Jarra et al., 1985; Jones et al., 2000; Martinelli et al., 
2005a; Cheesman et al., 2006). However, while this immunity can be very effective 
in protecting individuals against blood stage-induced infection with malaria parasites 
of the same genotype, it is often less effective against challenge infection with blood 
stage parasites of a different genotype. These observations imply the existence of 
Strain Specific Protective Immunity (SSPI) in malaria. Thus, the slow acquisition of 
immunity to naturally acquired malarial infection is likely to be at least partly due to 
the existence of polymorphism in the target antigens of protective immunity against 
the parasites (i.e. multiple allelic forms of an antigen-coding gene; Mendis et al., 
1991).  
 
Natural populations of human malaria parasites (Carter et al., 1973; McBride, et al., 
1982; Conway et al., 1991a; Conway et al., 1991b; Babiker et al., 1999; Magesa et 
al., 2002) and laboratory strains of rodent malaria parasites (Carter et al., 1975b; 
Carter, 1978; Beale et al., 1978) are, indeed, genetically highly polymorphic. 
Molecular characterisation of genes for protein antigens expressed on the surface of 
merozoites during blood stage malarial infection has revealed extensive sequence 
polymorphism in many of these antigen-coding genes. Prominent amongst them are 
genes encoding the merozoite surface protein-1 (MSP-1) (Tanabe et al., 1987; Miller 
et al., 1993; S. Cheesman and R. Carter, unpublished data) and the apical membrane 
antigen-1 (AMA-1) (Thomas et al., 1990; Cheng et al., 1994b; Kappe et al., 1996; 
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Marshall et al., 1996, S. Cheesman and R. Carter, unpublished data). Both MSP-1 
and AMA-1 have been implicated as targets of SSPI in Plasmodium falciparum 
malaria in humans (Conway et al., 2000; Polley et al., 2001; Polley et al., 2003a; 
Polley et al., 2003b; Polley et al., 2004; Cavanagh et al., 2004) and in Plasmodium 
chabaudi malaria in rodents (Boyle et al., 1982; Brown et al., 1985; Crewther et al., 
1996; Renia et al., 1997; Rotman, et. al., 1999). 
 
In a previous study using Linkage Group Selection (LGS) (Martinelli et al., 2005a) 
to search for genes encoding targets of SSPI in the P. chabaudi chabaudi rodent 
malaria, we located a region of the genome on P. c. chabaudi chromosome 8 which 
contains the gene for MSP-1 (Martinelli et al., 2005a) as encoding a major target of 
SSPI. However, the two P. c. chabaudi strains, AS-pyr1 and CB, used in that study 
are genetically identical for the cell-surface, ectodomain region of the gene for 
AMA-1 (S. Cheesman and R. Carter, unpublished data), another candidate for SSPI 
in rodent malaria (Crewther et al., 1996). It is highly unlikely, therefore, that this 
LGS analysis could have detected AMA-1 as a target of SSPI (Martinelli et al., 
2005a). In the present study, we have conducted LGS analysis of SSPI on two P. c. 
chabaudi strains, AJ and CB-pyr10, which are genetically different for the genes for 
both MSP-1 and AMA-1 (S. Cheesman and R. Carter, unpublished data). The present 
analysis has again identified the region on P. c. chabaudi chromosome 8 containing 
the gene for MSP-1 to be under strong SSPI selection. A weaker SSPI selection was 
also found in the regions on P. c. chabaudi chromosome 9 containing the gene for 
AMA-1 and on chromosome 7 in which no candidates of SSPI have been identified. 
However, no region in the genome of P. c. chabaudi was identified under strength of 
SSPI selection comparable to that on the region containing the gene for MSP-1. The 
combined results from these two studies indicate, therefore, that the main force of 
SSPI is determined by the single region of the P. c. chabaudi genome containing the 




2.3 Materials and methods  
 
2.3.1 Parasites, laboratory mice and mosquitoes 
 
Two cloned strains of the rodent malaria species P. c. chabaudi denoted CB-pyr10 
and AJ were used in these experiments. CB-pyr10 is a pyrimethamine resistant 
cloned line derived through pyrimethamine selection from CB (a pyrimethamine 
sensitive line), originally cloned from isolate CB (Walliker et al., 1975). In this 
study, CB-pyr10 will be referred to as CB for simplicity. AJ is a pyrimethamine 
sensitive line, cloned from isolate AJ (Carter, 1978). Both cloned lines are known to 
be genetically distinct from each other (Carter, 1978). AJ and CB were isolated from 
wild thicket rats, Thamnomys rutilans, captured in the same locality in the Central 
African Republic in 1969 and 1970, respectively (Carter, 1978; Beale et al., 1978). 
Following their cloning, both parasite lines were maintained in the laboratory by 
serial blood transfer in mice, with occasional transmission through mosquitoes 
Anopheles stephensi and occasional periods in liquid nitrogen as stabilates, according 
to the laboratory record of Richard Carter (The University of Edinburgh). 
  
Females of inbred laboratory mouse strains, CBA/Ca and C57BL/6J, were used, aged 
5 to 6 weeks old on first infection. These mouse strains will be referred here to as 
CBA and C57. Mosquitoes were from a laboratory-bred colony of Anopheles 
stephensi. Mice were housed in polypropylene cages with sawdust bedding at 
Animal Husbandry Unit (The University of Edinburgh). Cages were maintained at a 
constant temperature (25 ± 1°C), on 12:12 hours light:dark cycle). They were 
allowed to feed on 41B rat and mouse maintenance diet (Harlan-Tekld, England) and 
supplied with 0.05% para-aminobenzoic acid (PABA) in drinking water ad libitum 
to enhance parasite growth (Jacobs, 1964). A complete description of mouse 
maintenance is published elsewhere (de Roode et al., 2004)    
 
Mosquitoes were from a laboratory-bred colony of A. stephensi. They were cultured 
in nylon cages kept in a temperature and humidity controlled room (24 to 26°C, 70 to 
85% humidity) on 12:12 hours light:dark cycle). Adult mosquitoes were supplied 
with 10% glucose and 2.00% PABA supplemented water solution. Mosquitoes were 
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maintained with slight modifications from the method previously described 
(Ferguson et al., 2002). In order to obtain high quality adults, 500 larvae were grown 
in a low-density condition, in 1 L of distilled water in a 1,000-cm3 open dish supplied 
with approximately 1 mg of sodium bicarbonate (Na2CO3). After hatching, the larvae 
were given Liquify (Interpet Ltd.) daily for 7 days, and then Tetrafin (Tetra GmbH) 
until they developed into the pupa stage and transferred to the adult mosquito cages 
for emerging. All animal work in this study was carried out in accordance with the 
Animals (Scientific Procedures) Act 1986 UK. 
2.3.2 Induction and characterisation of SSPI between cloned strains CB 
and AJ of P. c. chabaudi 
Groups of CBA mice were immunised by two consecutive rounds of blood stage 
infection with P. c. chabaudi followed by mefloquine cure with slight modifications 
from the method previously described (Cheesman et al., 2006). In brief, each 
experimental mouse was inoculated intra-peritoneally (i.p.) with 5 x 105 parasitised 
red blood cells (pRBC) of either strain, CB or AJ, of P. c. chabaudi. Blood stage 
malarial infections were terminated by four consecutive daily doses of 20 mg/kg 
mouse body weight of mefloquine in 0.1 ml Dimethyl Sulfoxide, by oral gavage. 
Mefloquine treatment started before parasitaemias exceeded 50% but after they had 
passed 20% of infected red blood cells. The blood stage parasites were monitored 
daily by microscopic examination of thin blood smears stained with Giemsa’s stain. 
Following each mefloquine treatment all mice remained blood smear negative. 
Twenty-six days after the last day of the first mefloquine treatment, mice were given 
a second i.p. infection with 5 x 106 pRBC of the P. c. chabaudi strain homologous to 
the first immunising one. Infections were grown for 5 days and drug cure treated as 
before.  
To test for the presence of SSPI, two mice previously immunised by blood stage 
parasite infection with either CB or AJ from each group were randomly chosen 
sixteen weeks after the second mefloquine treatment. Each mouse was challenged 
with a mixture of 5 x 106 pRBC containing an equal proportion of blood stage 
parasites, CB and AJ. An equivalent inoculum from the same mixture was inoculated 
into a non-immune mouse, which was a batch mate of the immunised mice. The 
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resulting infections were examined daily by microscopic analysis. A 20 µl sample of 
tail blood in physiological citrate saline (0.9% (w/v) Sodium Chloride, 1.5% (w/v) 
Trisodium Citrate Dihydrate) was collected from each mouse 5 to 8 days post 
infection, so as to accurately measure proportions of parasites of each strain (CB and 
AJ) using strain specific RTQ-PCR for CB and AJ alleles of the msp-1 gene 
(Cheesman et al., 2003; Cheesman et al., 2006). Tail blood samples were centrifuged 
at 5,500g for 3 minutes. The red blood cell pellet was washed with 200 µl phosphate 
buffered saline (Sigma) and stored at –70°C prior to DNA extraction using a High 
Pure PCR template preparation kit (Roche Diagnostics). RTQ-PCR analysis was 
performed as previously describe by the method of Cheesman et al., (2003; 2006). 
2.3.3 Preparation of a genetic cross between cloned strains CB and AJ 
of P. c. chabaudi   
Single strain infections with CB and AJ were individually grown in donor C57 mice. 
Parasites of the two strains were harvested from the donors and accurately mixed to 
produce three inocula in proportions of 1:1, 1:2 and 2:1 of CB and AJ, respectively. 
The mixtures were inoculated i.p. at 106 pRBC per mouse into three groups of C57 
mice (four mice each). The parasitaemias from the mixed strain infections were 
followed microscopically on thin tail blood smears stained with Giemsa’s stain. Six 
days post inoculation of the parasites, when parasitaemias were ~20% and the 
presence of gametocytes of both sexes was confirmed microscopically, mice from 
each mixed strain infection group were anaesthetised and placed on a mosquito cage, 
each containing ~ 250 female mosquitoes. Mosquitoes were aged 5 to 7 days post 
emergence from pupae. The mosquitoes were allowed to feed on the mice for 20 
minutes without interruption. The mice were thereafter humanely killed before 
recovery from the anaesthesia. Eight days after the blood meal, samples of 
mosquitoes from each cage were dissected and examined for the presence of oocysts 
on their midguts. 11 mosquitoes from those fed on the 1:1 CB:AJ mixture had a 
mean of 9.5 oocysts per gut (Standard Error of Mean, SEM = 9.26); 16 mosquitoes 
from those fed on the 1:2 CB:AJ mixture had a mean of 4.06 oocysts per gut (SEM = 
3.96); 18 mosquitoes from those fed on the 2:1 CB:AJ mixture had a mean of 3.13 








Proportion of CB and AJ in mixtures No. of mosquitoes dissected  Average no.  of No. of mosquitoes Predicted no. of Predicted no. of 
Used to induced the blood infections   for oocysts (infected) oocysts per gut (SEM)   dissected for sporozoites oocysts represented  recombinant lines 
(1):(1) 11 (8) 9.5 (9.26) 190 1,312 2,624 
(1):(2) 16 (7) 4.06 (3.96) 190 337 674 
(2):(1) 18 (13) 3.13 (6.02) 125 283 566 
           total  45 (28)              total  505      total  1,932    total 3,864 
Table 2.1. The parameters used to predict the maximum number of recombinant lines present in the pooled progeny of the genetic 
cross between strains CB-pyr10 and AJ of Plasmodium chabaudi chabaudi. The predicted number of such recombinants is calculated as 
described (see Materials and Methods, section 2.3.3). SEM, standard error of mean. 
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Sixteen days after the blood meal, when sporozoites were present in the mosquito 
salivary glands, the mosquitoes were allowed to feed on 6 non-immune CBA female 
mice in order to naturally transmit sporozoites of the progeny of the AJ x CB genetic 
cross. All surviving mosquitoes of these three batches were then dissected for 
sporozoites from the salivary glands (190 mosquitoes from the 1:1 CB:AJ mixture, 
190 mosquitoes from the 1:2 CB:AJ mixture and 125 mosquitoes from the 2:1 CB:AJ 
mixture). The glands were gently crushed in 0.2 to 0.4 ml volumes of 1:1 Foetal 
Bovine Serum (GIBCO BRL): Ringer’s solution (420 mg L-1 Potassium Chloride, 
250 mg   L-1 Calcium Chloride, 9 g L-1 Sodium Chloride) and injected i.p. into 8 non-
immune CBA mice. All 14 mice, naturally infected or inoculated with sporozoites 
dissected from salivary glands of the mosquitoes, became infected. The blood stage 
parasites representing the progeny of the genetic cross were harvested on day 9 post 
infection (mean parasitaemia = 15%, min = 0.6% and max 61%) and pooled prior to 
inoculation of mice previously immunised with parasites of either one or the other of 
the parental strains CB or AJ of P. c. chabaudi for SSPI selection, or else into a non-
immune batch mate. The remaining pooled blood was frozen as stabilates and stored 
in liquid nitrogen.  
From the data on the number of oocysts per mosquito and the number of mosquitoes 
dissected for inoculation of sporozoites (given above), it is possible to estimate the 
likely maximum numbers of recombinant lines that a genetic cross could have 
generated. On an assumption that gametes of the two parasite strains are generated in 
equal numbers in the mixed strain infection used to make a genetic cross, and that 
fertilisations occur randomly between them, half of all fertilisations will generate 
hybrid zygotes between the gametes of the two parental strains of parasite, while the 
second half will derive equally from the self fertilisations representing one or other 
of the two parental strains. Each hybrid zygote undergoes meiosis and produces four 
recombinant progeny lines. Thus, on average, for every four oocysts in such a 
genetic cross, there will be two parental and two hybrid oocysts, yielding a total of 
eight recombinants. Overall, therefore, there are, on average, two recombinant lines 
for every oocyst present. Using this logic we was able to estimate the likely 




2.3.4 SSPI selection of uncloned cross progeny for Linkage Group 
Selection analysis   
The blood stage parasites from a total of 14 non-immune CBA mice (six and eight 
mice from the natural transmission and the sporozoite-induced infection, 
respectively) were harvested in physiological saline and pooled to produce the blood 
inoculum containing the uncloned CB x AJ cross progeny. One mouse from the 
batches immunised with blood stage parasites of either CB or AJ and previously 
tested for SSPI to these strains was inoculated i.p. with 5 x 106 pRBC of the 
uncloned cross progeny. At time of infection with the cross progeny, the immunised 
mice were twenty weeks after the last day of the second mefloquine treatment (see 
above). The blood stage parasites from the cross progeny grown in these mice which 
had been immunised with CB or AJ were designated “CB-immune selected cross 
progeny” or “AJ-immune selected cross progeny”, respectively. An equal number of 
the cross progeny designated “non-immune selected cross progeny” was passaged 
into a non-immune batch mate of the immunised mice. The resulting infections were 
followed by microscopic examination of thin blood smears stained with Giemsa’s 
stain.  
 
The uncloned cross progeny were grown in the CB- and AJ-immunised mice for 11 
and 12 days, respectively. We harvested blood from these experimental mice at these 
timepoints because the differential effects of SSPI upon parasites of the immunising 
and non-immunising strains were expected to be greatest but before pan specific 
immunity had overwhelmed the infection. This was in order for there to be the 
greatest differences in relative intensity between markers under SSPI selection and 
those which were not.  
 
In the non-immune batch mate, the cross progeny were allowed to grow for 9 days. 
We could expect in the uncloned cross progeny in the non-immune mouse that the 
proportions of parasites carrying genetic markers linked to targets of SSPI would 
remain stable. This is based on the observation that the proportions of the two strains 
in parasite mixtures of AJ and CB were remarkably constant during the course of 
infection (Cheesman et al. 2006).  
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To grow parasites in sufficient quantities to prepare DNA for subsequent analysis, 
106 pRBC from each experimental mouse were inoculated into four non-immune 
mice. The parasites were grown in these mice to parasitaemias of ~ 35 to 50% before 
harvesting and preparing them for DNA extraction. We, therefore, aimed to harvest 
parasites of the uncloned cross progeny grown in the strain specific immunised mice 
on the day of infection  
 
2.3.5 Extraction of genomic DNA from blood-stage parasites  
DNA was extracted from parasites collected after the immune selection experiments. 
In brief, mice were anaesthetised and bled out. The blood were harvested in 5 ml of 
chilled physiological citrate saline and passed through two columns of fibrous 
cellulose CF11powder (Whatman) (Homewood et al., 1976) to remove white blood 
cells. Blood was filtered through Plasmodipur™ filters (Euro-Diagnostics) twice 
Parasites were released by saponin lysis (Bowman et al., 1960) and centrifuged at 
4000g for 7 min at 4°C. The pellets were re-suspended in 400 µl of lysis solution 
(10 mM Tris-HCl, pH 8.0; 50 mM EDTA; 0.1% SDS; 1 mg ml−1Proteinase K) and 
incubated at 42°C overnight. After phenol/chloroform extraction, DNA was 
precipitated by addition of chilled iso-propanol and 3 M sodium acetate pH 5.2 
(Sigma) and treated by standard procedures (Sambrook et al., 1989) prior to 
subsequent molecular analyses.  
 
2.3.6 Quantitative measurement of strain specific Amplified Fragment 
Length Polymorphism (AFLP) Markers  
To locate regions of the P. c. chabaudi genome affected by SSPI selection, we 
generated 33P-radiolabelled AFLP markers from genomic DNA of the CB- and AJ-
immune selected cross progeny, the non-immune selected cross progeny and the two 
parental cloned strains (CB and AJ) by the method of Grech et al., (2002). AFLP 
products were resolved on 6% denaturing polyacrylamide gel electrophoresis and 
visualised using a Phosphoscreen (Amersham) and an X-ray film (Kodak) (see 
Figure 2.1). The intensities of AFLP bands were quantitatively measured using 
ImageQuant™ software version 1.2 Build 039 (Molecular Dynamics), as described 
by Martinelli et al., (2004). The values were converted to a “Relative Intensity Index 
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(RII)”, which is a measurement of the proportions of the parasite population carrying 
a specific allele for CB or AJ represented by individual AFLP markers in the 
immune and non-immune selected materials. This is defined as the intensity of the 
strain specific AFLP marker band in the mixture divided by the intensity of a 
designated non-polymorphic band in the same mixed parasite sample, divided by the 
equivalent ratio of the two relevant bands (strain specific AFLP and non-
polymorphic band) measured in a sample of the pure parental strain (Martinelli et al., 
2004). The RII of parasites bearing specific AFLP markers for CB and AJ in the 
immune selected cross progeny (RIIi) were, thereafter, quantitatively compared to the 
RII of the same markers derived from the non-immune selected cross (RIIni). These 
proportions were, thereafter, used to calculate the “Comparative Intensity (CI)” 
which is a measurement of proportional changes of strain specific AFLP markers 
between the immune and non- immune selected cross progeny. The CI is defined by 
the RII of a strain specific AFLP marker of the immune-selected cross progeny (RIIi) 
divided by the RII of the corresponding marker in the non-immune selected cross 
progeny (RIIni), and expressed as a percentage, i.e., CI = (RIIi/RIIni) x 100 (Martinelli 
et. al., 2005a). Specific AFLP markers of the immunising parasite strain whose CI 






















































Figure 2.1. shows Amplified Fragment Length Polymorphism products using a single
combination of selective primers, conducted on genomic DNA of Plasmodium chabaudi
chabaudi strains AJ and CB of and the strain specific and non-immune selected progeny of a
genetic cross between them. Polymorphic bands are detected on the gel as being present in one
parental strain and absent in the other. These bands become parasite strain specific AFLP markers
(red arrows, AJ markers; blue arrows CB markers). Of each AFLP marker, the first letters (“AJ” or
“CB”) indicates in which strain the identified marker band is visible. The last two letters indicates
the strain in which the marker is absent. The second two letters (i.e. AG) corresponded to the
selective bases used in the 33P-radiolabelled EcoRI selective primers (Grech et al., 2002). The two
numbers in the middle identify the markers in decreasing size. The following two letters
correspond to the selective bases used in the MseI selective primers (Grech et al., 2002). Strain
specific AFLP markers that were strongly reduced following strain specific immune selection
(filled arrows) are expected to be closely linked to the targets of Strain Specific Protective
Immunity (SSPI) (see text). AFLP markers which were not reduced are indicated by open arrows. 
 
AJ AG 03 AG CB 
AJ AG 02 AG CB 
AJ AG 01 AG CB 
CB AG 02 AG AJ 
CB AG 01 AG AJ 
AJ AG 05 AG CB 













































































2.3.7 Physical mapping of AFLP markers under SSPI selection 
 
Strain specific AFLP markers that had CI reduced below 50% following the strain 
specific immune selection were identified and characterised by the method of Hunt et 
al., (2004). The physical location of AFLP markers under SSPI selection was 
conducted as follows. Individual AFLP markers were excised and eluted from the 
polyacrylamide gel into distilled water to obtain DNA fragments of each marker. The 
extracts were PCR amplified using the same pairs of AFLP primers and conditions 
that were used to generate the original AFLP markers. PCR products were directly 
sequenced on both strands using the same AFLP primers. The sequencing reactions 
used ABI BigDye™ Terminator Chemistry on ABI3700 sequencing machine, 
according to manufacturer’s instructions. For PCR products of AFLP markers less 
than 100 bp, DNA sequences were obtained by cloning with a TOPO TA cloning 
kit™ (Invitrogen). Plasmid DNA from each transformed bacterial colony was 
extracted using a QIAprep Spin Mini Prep kit (QIAGEN) and sequenced as 
described above. DNA sequences obtained from the forward and reverse primers 
were visualised using an EditView ABI automated DNA sequence viewer software 
(Perkin Elmer ABI) and assembled manually to generate a single contiguous 
sequence. The sequences of the specific AFLP primers were eliminated from the 
assembled DNA sequence prior to location of the AFLP marker onto the genome 
databases by BLAST search.  
 
Eight-fold coverage contigs of the genome of P. c. chabaudi cloned strain AS (Hall 
et al., 2005), http://www.sanger.ac.uk/cgi-bin/blast/submitblast/p_chabaudi, were searched 
using the BLASTN (DNA vs. DNA) option with sequences derived from the AFLP 
markers. Genomic contigs of P. c. chabaudi which contained DNA sequences 
corresponding to the relevant AFLP marker with lowest Probability (E) score (a cut-
off of 90% sequence identity) were obtained. The chromosomal positions of these 
contigs have not been mapped physically in the P. c. chabaudi genome. Sequences of 
whole P. c. chabaudi contigs were, thereafter, used to locate orthologous loci in the 
Plasmodium falciparum clone 3D7 genome database (Gardner et al., 2002) 
(http://www.ncbi.nlm.nih.gov/sutils/blast_table.cgi?taxid=Protozoa&database), using the 
BLASTP (DNA vs. Protein) option. The genomic locations of the P. falciparum 
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orthologues were, in turn, used to locate chromosomal positions of the AFLP 
markers in the genome of P. c. chabaudi through the conserved genetic synteny 
between the human malaria parasite P. falciparum and rodent malaria parasites 
(Kooij et al., 2005).  
 
2.3.8 Genetic mapping of AFLP markers  
 
In addition to physical mapping, the strain specific were genetically located on a P. c. 
chabaudi genetic linkage map which was previously constructed with reference to 
the progeny of a genetic cross between P. c. chabaudi strains AS and AJ (Martinelli 
et al., 2005b). The locations of 92 AJ AFLP markers identified in the present study 
on the P. c. chabaudi genetic linkage map are shown in Figure 2.4 and Table S1 
(Appendix 1). 
 
2.3.9 RTQ-PCR of CB and AJ alleles of P. c. chabaudi msp-1 and ama-1 
 
RTQ-PCR analysis was performed on a LightCycler instrument (Roche Diagnostics) 
as described by Cheesman et al., (2003) and Cheesman et al., (2006) for allele 
specific amplification assays to measure in the mixtures of parasites the proportions 
of DNA of the CB or AJ allele of the msp-1 or ama-1 gene. The assays were 
standardized for accurate quantification of the CB or AJ alleles of msp-1 or ama-1 of 
the blood stage parasites, using artificial mixtures with known proportions of cloned 
strains CB and AJ as previously described by Cheesman et al., (2003). DNA samples 
of (i) the blood stage mixed strain infections and (ii) the uncloned CB x AJ cross 
progeny grown in the strain specific immunised and non-immune mice were 
prepared as described in previous sections. DNA samples of the pure parental strains 
CB and AJ were 10-fold serially diluted in the range 66-0.0066 ng and used as 
quantification standards to construct a DNA concentration calibration curve. 
Oligonucleotide primers were designed to selectively amplify a strain specific region 
of the msp-1 or ama-1 gene (S. Cheesman, unpublished data). The msp-1 specific 
primers used in the assay were: the CB forward and reverse primers: 5’-
CTGTTACAACCCAAACC-3’ and 5’-AGTTG TTCCTGTGGCAG-3’; and the AJ 
forward and reverse primers: 5’-ACTGAAGCAACAACACCAGC-3’ and 5’-
GTTGTTGATGCACTTGCGGGTTC-3’. RTQ-PCR reactions for the CB and AJ 
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alleles of msp-1 were set up, as previously described (Cheesman et al., 2006). The 
ama-1 specific primers used in the assay were: the CB forward and reverse primer 
5’-AGGTTTCATTATTAACACGAG-3’ and 5’-GATTACTTTTGTCATAAACAG 
CG-3’; and the AJ forward and reverse primer 5’-CTAAA TCATTCTTAGACCC-3’ 
and 5’-GGCATAATTTTTATATTCTG-3’. The nucleotide positions in the forward 
primers that did not match the sequences of the CB and AJ ama-1 alleles are shown 
in bold. RTQ-PCR reactions for quantification of the CB and AJ alleles of ama-1 
were performed in a 10 µl volume of standard buffer containing 4 µM of forward and 
reverse primers in 3 and 2.5 mM MgCl2, respectively. The PCR conditions used were 
as follows: An initial "Hot Start" at 95 °C for 600 sec followed by 40 cycles of 95 °C 
with a 0 sec hold, cooling at 20 °C/sec to 58 °C with a 7 sec hold for CB or cooling 
at 20 °C/sec to 56 °C with a 7 sec hold for AJ, reheating at 20 °C/sec to 72 °C with a 
15 sec hold for CB or 10 sec hold for AJ and finally heating at 20 °C/sec to 72 °C 
with a 0 sec hold. Melting curve data for each PCR run was produced, as follows: 
Heating at 20 °C/sec to 95 °C with 0 sec hold, cooling at 20 °C/sec to 65 °C with 30 
sec hold and reheating at 0.2 °C/sec to 95 °C in a continuous data acquisition mode. 
The final step of RTQ-PCR was at 20°C/sec to 40 °C with a 60 sec hold. Data 
obtained from each LightCycler run were checked to ensure that the correct strain 
specific melting peak and no other non-specific amplicon was produced. The DNA 
concentrations measured on the LightCycler were converted into relative proportions 





2.4.1 Characterisation of SSPI in mice for Plasmodium chabaudi 
chabaudi cloned strains CB and AJ  
 
Immunity against the blood stages of P. c. chabaudi was induced in groups of female 
CBA mice, five to six weeks old on first infection, by two successive single strain 
blood stage-induced infections of either P. c. chabaudi CB or AJ, drug cured with 
mefloquine, as described in Materials and Methods (section 2.3.2). Sixteen weeks 
after the last mefloquine dose, two CB-immunised mice and two AJ-immunised mice 
were challenged with a mixture of an equal proportion of blood stage parasites of CB 
and AJ. A non-immune mouse, which was a batch mate of the immunised mice, was 
inoculated with the same mixture of blood stage parasites of CB and AJ. Total 
parasitaemias were measured daily by microscopic analysis of thin blood smears 
(Figure 2.2A). The proportions of parasites carrying the CB or AJ alleles of P. c. 
chabaudi msp-1 were determined using strain specific RTQ-PCR analysis of DNA 
samples obtained from the mixed strain infections between 5 and 8 days after 
inoculation (see Materials and Methods; section 2.3.9).  
 
In mice previously immunised with either CB or AJ, the total parasitaemias 
following challenge with the mixed strain infections of P. c. chabaudi CB and AJ 
were greatly reduced relative to the total parasitaemia in a non-immune batch mate 
infected with the same mixture (Figure 2.2A). It is clear, therefore, that a strain-
transcending immunity must have been present in the CB and AJ immunised mice as 
both reduced the absolute parasitaemias to a similar degree. Parasitaemias of the 
strain homologous to the immunising one were, however, consistently lower, and the 
parasites were eliminated more rapidly, than those of the heterologous strain in the 
immunised mice (Figure 2.2C and 2.2D). By contrast, CB and AJ were present in 
almost equal proportions throughout the period of observation in the non-immune 
mouse (days 5 to 8) (Figure 2.2B).  
 
The differential effect in the strain specifically immunised mice was greatest on day 
7 of infection when parasites of the homologous strain were undetectable (< 1% 
parasitaemia) by strain specific RTQ-PCR (see Materials and Methods; section 
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2.3.9), while parasites of the heterologous strain survived at parasitaemias of around 
6% and 1 to 3% in CB- and AJ-immunised mice, respectively (Figure 2.2C and 
2.2D). Single strain (CB or AJ) immunised batch mates of the mice tested in this 
experiment were used to apply SSPI selection pressure against the uncloned progeny 















Figure 2.2. Mixed strain infections of Plasmodium chabaudi chabaudi CB and AJ in mice 
pre-immunised with either strain, or in a non-immune batch mate. (A) shows total 
parasitaemias during the course of mixed strain infections in immunised mice and a non-immune 
as measured by microscopic examination of thin blood smears stained with Giemsa’s stain: non-
immune mouse (dotted line with open circles), two CB-immunised mice (dashed lines with filled 
symbols), two AJ-immunised mice (unbroken lines with filled symbols). Strain specific 
parasitaemias (AJ in pink; CB in green) are shown (B) in the non-immune mouse, (C) in the two 
CB-immunised mice and (D) in the two AJ-immunised mice. The strain specific parasitaemias in 
the mixed strain infections were calculated from the total parasitaemias measured on thin blood 
smears stained with Giemsa’s stain and from the proportions of CB and AJ parasites in the 
mixtures as determined using strain specific RTQ-PCR (see text). Squares and triangles represent 
mouse 1 and 2, respectively, in the CB and AJ immunised mice in (A), (C) and (D).   
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2.4.2 SSPI Selection of the uncloned cross progeny between P. c. 
chabaudi CB and AJ  
 
A genetic cross between P. c. chabaudi CB and AJ was generated and yielded the 
predicted maximum number of independent recombinant lines of approximately 
3,800 (Table 2.1), as described in Materials and Methods (section 2.3.3). Sporozoites 
were harvested from the mosquitoes containing the cross and inoculated into non-
immune mice as uncloned cross progeny (see Materials and Methods, section 2.3.4). 
The blood stage parasites of the uncloned cross progeny were subinoculated into 
mice which had been immunised with one or the other of the parental strains. A non-
immune mouse, which was a batch mate of the immunised mice, was inoculated with 
the same mixture of the uncloned CB x AJ cross progeny. The uncloned cross 
progeny was allowed to grow in the CB- and AJ-immunised mice and in the non-
immune batch mate (Figure 2.3). The blood stage parasites in the CB- and AJ-
immunised mice were harvested and expanded by subinoculation of 106 pRBC into 
groups of four non-immune female CBA mice on days 11 and 12 of infection, 
respectively. The cross progeny from the non-immune mouse was similarly 
expanded by subinoculation on day 9 of infection.  These parasites were prepared for 
extraction of parasite genomic DNA for the subsequent analyses, as described in 










Figure 2.3. The course of blood stage-induced infection of the uncloned CB x AJ cross 
progeny grown in a non-immune mouse (dotted line with open circles), in a CB-immunised 
mouse (pink line filled squares) and in an AJ immunised mouse (blue line with filled 
symbols). Arrows indicate day of infection when the uncloned cross progeny grown in the 
immunised mice or the non-immune mouse were sub-inoculated for expansion into non-immune 




2.4.3 Molecular Genetic Analysis of SSPI Selected Uncloned Cross 
Progeny 
 
The genomic DNA of parasites derived from the CB- and AJ-immune selected cross 
progeny and from the cross progeny grown in the control non-immunised batch mate 
was typed with genome-wide quantitative genetic markers produced by Amplified 
Fragment Length Polymorphism (AFLP) (Grech et al., 2002) (see Materials and 
Methods, section 2.3.6). From 97 combinations of selective AFLP primers, 350 
polymorphic bands that differentiated CB and AJ strains of P. c. chabaudi were 
obtained. Of these bands, 197 were present only in AJ and 153 were present only in 
CB. These were used as AFLP markers for the strains AJ and CB, respectively. The 
Comparative Intensity (CI) (see Materials and Methods, section 2.3.6, for a 
definition) (Martinelli et al., 2005a) was calculated for each AFLP marker in the CB 
and AJ-immune selected cross progeny (Table S1, Appendix 1).  
 
Following AJ-specific immune selection, 24 of the 197 AFLP markers for strain AJ 
(AJ markers) (12.2% of AJ specific markers) had CI of less than 50% under AJ-
specific immune selection (i.e. intensity reduction of greater than 50% relative to 
growth of the cross progeny in the non-immune batch mate), listed in Table 2.2. 
These AJ markers under SSPI selection were sequenced, as described in Materials 
and Methods (section 2.3.7). 19 contained a single sequence each, all of which were 
identified in the P. c. chabaudi genome database, at the website 
http://www.sanger.ac.uk/cgi-bin/blast/submitblast/p_chabaudi. The predicted orthologous 
loci of these P. c. chabaudi contigs were, thereafter, located within the P. falciparum 
genome. Because of the high level of conserved synteny between the genomes of P. 
falciparum and the rodent malaria parasites (Kooij et al., 2005), the chromosomal 
locations of the P. falciparum orthologues of AJ markers could, in turn, be mapped 
to the equivalent predicted chromosomal positions in the P. c. chabaudi genome. The 
remaining 5 AJ markers under SSPI selection gave unreadable sequence data. Their 




Of the 19 AJ markers whose predicted orthologues were successfully identified in 
the P. falciparum genome, one mapped to a region on P. falciparum chromosome 4 
which is syntenic with a location on P. c. chabaudi chromosome 7. Nine other 
markers were located to a region on P. falciparum chromosome 9 which is syntenic 
with one on P. c. chabaudi chromosome 8. Three markers were located to a region 
on P. falciparum chromosome 11 which is syntenic with one on P. c. chabaudi 
chromosome 9. Five additional markers were located to a region on P. falciparum 
chromosome 12 which is syntenic with one on chromosome 14 of P. c. chabaudi. A 
final marker responding to SSPI selection was located to a region on P. falciparum 
chromosome 14 corresponding to one on P. c. chabaudi chromosome 12 (Table 2.2).  
In addition, 92 of the 197 AJ markers were located onto ten P. c. chabaudi 
chromosomes and six unassigned P. chabaudi linkage groups of a P. c. chabaudi 
genetic linkage map previously generated from the progeny of a genetic cross 
between AS and AJ strains (Martinelli et al., 2005b). The genetic position of the 92 
markers is displayed versus its CI in Figure 2.4. Of 24 AJ AFLP markers having CI 
of less than 50% under AJ-specific immune selection, 21 AJ markers with CI of < 
50% following AJ-specific immune selection successfully mapped onto three P. c. 
chabaudi chromosomes and two unassigned P. c. chabaudi linkage groups (Table 
2.2). In most cases, the location of the markers by genetic mapping was in agreement 
with that of the physical mapping. However, five markers that were located to P .c. 
chabaudi chromosome 14 by physical mapping mapped genetically to P. c. chabaudi 
chromosome 7 (Table 2.2). The reason for this discrepancy is not known and will 
require further investigation. Four markers whose orthologues could not be identified 
in P. falciparum were genetically located to unassigned P. c. chabaudi linkage 
groups g2 (one marker) and g12 (three markers).   
There are six AJ markers with CI of below 20% following the AJ-specific immune 
selection. These markers had the greatest reduction in intensity and were all located 
on P. c. chabaudi chromosome 8 by both physical and genetic mapping (represented 
in bold in Table 2.2). These AJ markers generally decreased in CI with deceasing 
physical distance (in P. falciparum) or genetic distance (in P. c. chabaudi) from the 
AJ allele of the P. c. chabaudi msp-1 locus (Table 2.2 and Figure 2.4). The 
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proportion of parasite DNA carrying the AJ allele of msp-1 was reduced to 
undetectable levels (<1%) as measured by strain specific RTQ-PCR in the cross 
progeny grown under the AJ-specific immune selection compared to its presence at a 
proportion of 60.0% in the cross progeny grown in the non-immune mouse (Table 
2.2, Figure 2.4). Thus, the P. c. chabaudi msp-1 locus lies at the lowest point that has 
been detected in the strain specific immune-selected valley on P. c. chabaudi 
chromosome 8.  
In addition, three of the 24 AJ markers with CI of < 50% under AJ-specific immune 
selection also formed a linkage group that contains the gene encoding the P. c. 
chabaudi AMA-1 (Table 2.2, Figure 2.4). An ama-1 strain specific RTQ-PCR assay 
for CB and AJ (see Materials and Methods; section 2.3.9) showed that 17.3% of the 
DNA of parasites in the AJ-immune selected cross progeny carried the AJ allele of 
ama-1 (Table 2.2), compared to 79.6% with the AJ allele of ama-1 in the cross 
progeny grown in the non-immune mouse.    
 
In a reciprocal experiment the uncloned progeny of the cross between P. c. chabaudi 
strains CB and AJ were subjected to CB-specific immune selection. The intensities 
of most of the AFLP markers for strain CB (CB markers) were already very faint in 
the unselected (control) cross progeny compared to the intensities of the 
corresponding AFLP bands in the parental strain CB. The general band intensities of 
the CB markers were below the limit of detection by AFLP in the CB-immune 
selected cross progeny (Martinelli et al., 2004). Consequently, we were unable to 
achieve a meaningful analysis of the CB-immune selected cross progeny by AFLP. 
We were, nevertheless, able to investigate the level of CB-specific immune selection 
against the CB allele at the msp-1 and ama-1 loci using RTQ-PCR. In DNA from 
parasites of the CB-immune selected cross progeny, the CB allele of msp-1 was 
undetectable (< 1 %) by RTQ-PCR, compared to 40.0% in the cross progeny grown 
in the non-immune mouse. At the ama-1 locus, 1.8% of the DNA of parasites carried 
the CB allele of ama-1 from cross progeny grown in the CB-immunised mouse, 




























Figure 2.4. The Comparative Intensities of 92 AFLP markers of Plasmodium chabaudi chabaudi strain AJ from the progeny of a genetic cross between 
P. c. chabaudi strains CB-pyr10 and AJ following selection in mice immunised with strain AJ (see text). AJ-specific markers (indicated by black 
diamonds) were located on a P. c. chabaudi genetic linkage map, generated from a genetic cross between AS and AJ (Martinelli et al., 2005b). Numbers after 
letter ‘C’ and ‘g’ represent P. c. chabaudi chromosome numbers and P. c. chabaudi unassigned linkage groups, respectively, in the genetic linkage map 
(Martinelli et al., 2005b). Of the six AJ markers which were most reduced under AJ-specific immune selection (see Table 2.2), five (indicated by asterisks) 
could be located to P. c. chabaudi chromosome 8, forming a selection valley with the P. c. chabaudi msp-1 gene at its lowest point (see text). RTQ-PCR values 
for the proportions of the AJ-immune selected cross progeny carrying the AJ alleles of the Merozoite Surface Protein-1 (msp-1) are indicated by the red 
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immunised mouse
Physical location of P. 
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AJ markers in P. falciparum 
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chromosomes in 
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AJ TG 03 AA CB  21.7   pf 9 - 378**  9   8    22.0 
AJ TA 04 AT CB  20.2   pf 9 - 718   9   8    43.0 
AJ GT 02 TA CB  13.1   pf 9 - 992   9   8    43.0 
AJ AT 01 AG CB  10.4    pf 9 - 1019   9   ND    ND 
AJ TT 03 AT CB  12.15   pf 9 - 1113   9   8    59.4 
AJ TA 07 TA CB  6.01   pf 9 - 1150   9   8    59.4 
AJ TC 01 TG CB  1.5   pf 9 - 1159  9   8    59.4 
AJ allele of msp-1  (0 %, 60%)*  pf 9 - 1201   9   8    50.8  
AJ AG 05 AG CB  1.5   pf 9 - 1263  9   8    55.3 
AJ AT 03 AG CB  47.5   pf 9 - 1368   9   ND   ND 
 
AJ AC 01 CT CB  31.8   pf 11-1084   11    9   51.7 
AJ AG 01 TC CB  25.9   pf 11-1245   11    9   63.5 
AJ AT 03 TA CB  22.7   pf 11-1084   11    9   67.2 
AJ allele of ama-1    (17.3 %, 79.6%)*  pf 11-1290   11    9   71.1 
 
AJ AT 01 GT CB  28.4   ND   ND    7   37.3 
AJ TG 01 AT CB  21.09   pf 12 -1259   12    7   77.7                
AJ AT 01 TC CB  39.1   pf 12 -1267  12    7    77.7 
AJ TA 06 TA CB  23.37   pf 12 -1290  12    7    77.7 
AJ TG 01 TC CB  29.0   pf 12 -1346   12    7    77.7 
AJ TT 02 TG CB  27.0   pf 12 -1355  12    7    81.4 
AJ AG 01 CA CB  43.54   pf 4 - 787   4   7   99.6 
 
AJ AG 02 AG CB  27.2   pf 14 -2756  14    ND   ND 
AJ TT 01 TC CB  26.88   ND   ND    g2   ND 
AJ AG 01 TA CB  40.0   ND   ND    g12   ND 
AJ AT 02 TT CB  22.22   ND   ND    g12   ND 






Table 2.2. Physical and genetic locations of AFLP markers of strain AJ of Plasmodium cha mparative Intensity (CI) reduced below 50% in the progeny of
the genetic cross between CB-pyr10 and AJ following selection in an AJ-immunised mouse arkers with CI of <20% in the AJ-immune selected cross progeny
mapped to positions closely linked to the gene encoding the P. c. chabaudi merozoite surface pro  in bold. ND not determined. 
 
 *  The first and second numbers in the bracket represents percentage of parasite DNA carrying pink background) and ama-1 (blue background) in the AJ-immune
selected cross progeny and the non-immune selected cross progeny, respectively, as measured by 
** Numbers after ‘pf’ indicate the Plasmodium falciparum chromosome number and distance alon o basepairs, respectively    
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Linkage Group Selection is a molecular and genetic approach that applies a specific 
selection pressure to the uncloned recombinant progeny of a genetic cross between 
two genotypes (strains) of the same species of malaria parasites that differ in their 
phenotypic responses under the specified selection pressure (Culleton et al., 2005; 
Carter et al., 2007). Here we have used LGS in an attempt to identify the region(s) in 
the genome of the rodent malaria parasite Plasmodium chabaudi chabaudi which 
harbours the gene(s) that is the target of SSPI against the blood stages of this 
parasite. We have taken two genetically distinct strains of P. c. chabaudi, CB and AJ, 
which induce SSPI with respect to each other in laboratory mice, and crossed them to 
produce recombinant progeny. We then applied SSPI selection to the uncloned 
recombinant progeny by growing the cross progeny in mice made immune to one or 
the other of the two strains of the parasite (strain specific immunised mice). As a 
reference, the same uncloned progeny were also grown in a non-immune batch mate 
of the strain specific immunised mice. The cross progeny grown in the CB- or AJ-
immunised mouse, or the non-immune batch mate, were screened for the presence 
and intensity of quantifiable genome-wide AFLP markers distinguishing CB and AJ.  
 
Following growth of the cross progeny in the AJ-immunised mouse, a small 
proportion of markers of the immunising strain (AJ markers) was judged to be 
significantly reduced (CI of <50%) relative to the progeny grown in the non-immune 
mouse (Martinelli et al., 2005a). These markers were located in the genome by either 
physical or genetic mapping, or both, as described in Results (section 2.4.3). Several 
AJ markers that were located to a region on P. c. chabaudi chromosome 8 formed the 
deepest identified selection valley in this analysis (Figure 2.4). Within this selection 
valley, the two AJ markers under the strongest AJ-specific immune selection 
spanned a predicted ~120 kilobase pair (kb) region (based upon the predicted 
physical locations of the orthologues of these two markers in the P. falciparum 
genome). This region contains a gene for the P. c. chabaudi MSP-1, a principle 
candidate for a target antigen of SSPI. RTQ-PCR analysis confirmed that the 
uncloned cross progeny carrying the AJ allele of the msp-1 gene was virtually 
eliminated after selection in  the  AJ-immunised  mouse.   The reciprocal  result  was  
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obtained  after selection of the cross progeny in a CB-immunised mouse. In this case, 
parasites carrying the CB allele of the P. c. chabaudi msp-1 locus were virtually 
eliminated. These results demonstrate that parasites carrying AJ or CB alleles in the 
region of the msp-1 locus were under very strong selection in AJ- or CB-immunised 
mice, respectively. A previous LGS analysis of SSPI in the progeny of a genetic 
cross between strains AS-pyr1 and CB of P. c. chabaudi also found that the region 
containing the msp-1 locus was under the strongest detected strain specific protective 
immune selection for this combination of strains (Martinelli et al., 2005a). Together, 
these results strongly support the view that the region on P. c. chabaudi chromosome 
8 around the msp-1 locus contains a gene or genes encoding a major target antigen or 
antigens of SSPI.  
 
In addition to those AJ markers associated with the selection valley around msp-1, 
several other AJ markers had CIs of less than 50% after selection in the AJ-
immunised mouse (Table 2.2 and Figure 2.4), suggesting the possible presence of 
other targets of SSPI.  
 
Several of these more weakly reduced AJ markers formed linkage groups having 
possible association with selection valleys. One such group, containing seven weakly 
reduced AJ markers, was located on P. c. chabaudi chromosome 7 and spanned a 
predicted ~ 62.3 centiMorgan (cM) of genetic distance (Table 2.2) by genetic 
mapping. However, there was discrepancy in the location of some markers in this 
group by physical mapping (Table 2.2). Two other such markers were located on P. 
c. chabaudi unassigned linkage groups 2 and 12 (Table 2.2). The reductions in 
intensity of all these markers after selection in the AJ-immunised mouse were, 
however, much less than those associated with the msp-1 locus, suggesting relatively 
small contributions toward SSPI. No obvious candidate gene for a target antigen of 
SSPI has been identified within these genomic regions.  
 
Three of the relatively weakly affected AJ markers were located on P. c. chabaudi 




candidate target of SSPI (Crewther et al., 1996). The results suggest that AMA-1, or 
the product of a gene closely linked to the ama-1 gene, may be a target of SSPI, but 
one that is less strongly affected than the target(s) associated with the gene for   
MSP-1. 
 
As already noted we had previously conducted LGS analysis of SSPI with a 
combination of P. c. chabaudi strains, AS-pyr1 and CB (Martinelli et al., 2005a). 
However, in contrast to the situation in the present cross between AJ and CB, the 
AS-pyr1 and CB strains have DNA sequences which are identical at the ama-1 locus 
for the extracellular domain of the AMA-1 protein (Cheesman and Carter, 
unpublished data). It is, therefore, highly unlikely that evidence of the involvement 
of AMA-1 in SSPI could have been found in the AS-pyr1 and CB cross, nor was it 
(Martinelli et al., 2005a). In order to evaluate the involvement of AMA-1 in SSPI, in 
collaboration with Dr Robin Anders, La Trobe University, in Melbourne, Australia, 
we are planning to test the effects of vaccination with recombinant AMA-1 using 
constructs based on the AJ or CB allele of P. c. chabaudi. This would allow to us 
determine if vaccination with recombinant AMA-1 can induce strong SSPI in 
laboratory rodents. Should such an effect be observed, we will conduct LGS analysis 
upon the progeny of an AJ x CB genetic cross in mice immunised with an AJ and CB 
AMA-1 vaccine to address this question. Currently, the refolded recombinant AMA-
1 proteins expressed in E. coli have been produced in Dr Anders’ laboratory using 
their established protocols (Crewther et al., 1996). Vaccination studies are now 
underway.  
 
There is a possibility that there are other regions of the P. c. chabaudi genome that 
may be under SSPI selection pressure but have not been detected, as no AFLP 
markers have been mapped on P. c. chabaudi chromosomes 2, 3, 4 and 14 and only a 
few on chromosomes 10 and 12 (Figure 2.4). Nevertheless, quite large 
chromosomally unassigned linkage groups were identified (Figure 2.4). These almost 
certainly represent groups of linked markers on all, or most, of the missing 
chromosomes (Martinelli et al., 2005b). Since no clear selection valley has been 
located on any of these unassigned linkage groups, it is unlikely that the present 
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analysis failed to identify any other major SSPI-associated selection valleys that 
might exist. 
 
It is noteworthy, however, that there is a limitation of LGS to the discovery of genes 
encoding antigens for SSPI. For instance, LGS would not be able to identify genes 
coding for proteins exhibiting clonal antigenic variation to be the cause of the 
observed differences between any two parasite lines which appeared to show mutual 
SSPI in mice. The clonal antigenic variation in P. c. chabaudi is probably mediated 
by the cir gene family which codes for variant surface antigens (Janssen et al., 2002). 
The main reason for this is that there will be a subpopulation of parasites that switch 
off the expression of alleles of the variant antigen which are targeted by protective 
immunity by antigenic switching but switch on the expression of different alleles not 
recognised by protective immunity. This phenomenon has been recently 
demonstrated in the rodent malaria parasite Plasmodium yoelii yoelii (Cunningham et 
al., 2005).This process allows parasites to evade host protective immune response 
and allows parasites to maintain the alleles of the variant surface antigens conferring 
immune protection in their populations.  
 
LGS analyses of SSPI conducted on the progeny of two different genetic crosses, one 
between AJ and CB-pyr10 (in this present study) and the other between AS-pyr1 and 
CB (the parental clone of CB-pyr10) (Martinelli et al., 2005a) have consistently 
revealed prominent selection valleys at the same location on P. c. chabaudi 
chromosome 8. In both cases, the base of the SSPI-selected valley covered a region 
within ~ 60 kb on either side of the msp-1 locus. We conclude, therefore, that the P. 
c. chabaudi msp-1 locus, or a gene very closely linked to it, dominated the SSPI 
selection in both of these cases.  
 
Although our work has not yet proved that the P. c. chabaudi MSP-1 protein is itself 
a target of SSPI in malaria, such a result would be consistent with the literature that 
indicates the involvement of MSP-1 in the strain specific protective immune 
response in the rodent malarias. Thus, on passive transfer into non-immune mice, 
monoclonal antibody (mAb) NIMP23, which had been raised against MSP-1 of P. c. 
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chabaudi strain AS and shown to bind the MSP-119 portion of the protein (McKean et 
al., 1993b), inhibited the growth of blood stages of the homologous strain (AS) 
(Boyle et al., 1982), but had no effect on a heterologous challenge infection with the 
CB strain of P. c. chabaudi (Brown et al., 1985). Following these studies, McKean 
and colleagues were able to identify an epitope to which mAb NIMP23 bound and 
which was located at the C-terminus of P. c. chabaudi MSP-1 (McKean et al., 
1993b). This part of MSP-1 was shown to be genetically distinct between strains AS 
and CB (McKean et al., 1993a; S. Cheesman and R. Carter, unpublished data). The 
coding sequence in the same region of MSP-1 is also different between strains AJ 
and CB (McKean et al., 1993a; S. Cheesman and R. Carter, unpublished data), which 
are the two parental strains used in the present LGS analysis of SSPI. However, 
between strains AS and AJ, two strains which show virtually no SSPI with respect to 
each other (R. Carter and A. Martinelli, unpublished data), there is no difference in 
the amino acid sequence of MSP-1 in this region (McKean et al., 1993a). The 
sequence polymorphisms identified at the C-terminus of MSP-1 in P. c. chabaudi 
are, therefore, consistent with the involvement of MSP-1 in SSPI in this parasite.  
 
Evaluating the involvement of MSP-1 in SSPI is now a priority for future research. 
One approach used to address this topic involves (1) cloning out the SSPI-selected 
cross progeny and (2) characterising the haplotypes at the base of the selection valley 
in the resulting cloned lines (Carter et al., 2007) (see Figure 2.5). In theory, it is 
expected that in cloned lines of the SSPI-selected cross progeny, alleles of the 
sensitive parent at the locus containing the target of SSPI will be removed. 
Nevertheless, there will be some SSPI-resistant parasite progeny clones in which 
recombination events have taken place between the allele of the target locus of SSPI 
from the resistant parent (locus ‘B’) and markers (e.g. locus ‘A’ or ‘C’) from the 
sensitive parent that are closely linked to the target locus (Figure 2.5). Identification 
of such recombinant cloned lines of the SSPI selected cross progeny will enable us to 
pinpoint the locus under SSPI selection to the interval between these recombination 
events (Carter et al., 2007). Should such a defined locus contain only the allele of the 
msp-1 gene, this will identify the msp-1 gene as a principle target of SSPI. Currently, 
there is an ongoing project in our laboratory which has taken this approach to 
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identify genes encoding targets of SSPI using the SSPI-selected progeny of a genetic 
cross between P. c. chabaudi AS-pyr1 and CB (Martinelli et al., 2005a) (S. 














Figure 2.5 A schematic representation of haplotypes of two cloned progeny of a genetic 
cross between strain specific protective immune (SSPI)-resistant and sensitive lines which 
have recombination events within a region containing a target of SSPI selection. Locus ‘B’ 
represents the target of SSPI. Loci ‘A’ and ‘C’ represent genes whose the position is closely 
genetically linked to the target locus of SSPI. Alleles of the SSPI-resistant and sensitive parental 
clones are indicated by green and orange, respectively. (Figure adapted from Carter et al., 2007). 
 
 
Moreover, transfection systems could be used to evaluate the candidacy of MSP-1. 
This approach will involve a production of a transgenic parasite line of P. c. 
chabaudi whose original (wild-type) allele of the msp-1 gene is replaced with an 
allele from a genetically distinct strain. Subsequently, the transgenic parasite can be 
used for immunisation and testing of strain specificity of protective immunity in 
mice previously immunised with parasites that have a wide-type msp-1 allele. Should 
the wild-type strain be virtually eliminated and the transgenic msp-1 parasite, whose 
genetic background is identical to the wild-type parasites except for the msp-1 locus,  
survive following a challenge infection between these two lines, this would indicate 
that MSP-1 is an antigen that triggers SSPI. Currently, the transfection systems have 
been developed, and are now routinely used, for the rodent malaria parasites 
Plasmodium berghei (Waters et al., 1997; Tomas et al., 1998; Janse et al., 2006) and 
Plasmodium yoelii (Jongco et al., 2006), the primate malaria parasite Plasmodium 
knowlesi (van der Wel et al., 1997) and the human malaria parasite P. falciparum 
(Crabb et al., 1997; Waterkeyn et al., 1999; Crabb et al., 2004; Balu et al., 2005). 
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This technology would be equally applicable for evaluating an involvement of MSP-
1 in SSPI in P. c. chabaudi. 
 
Alternatively, vaccination with recombinant P. c. chabaudi MSP-1 using constructs 
based on the AJ or CB alleles of P. c. chabaudi can be conducted to determine if 
immunisation with MSP-1 can elicit strong SSPI in the host animal. If such an effect 
is observed, an LGS analysis can be conducted upon the progeny of a genetic cross 
between P. c. chabaudi strains AJ and CB in mice immunised with an AJ or CB 
MSP-1 vaccine. Taken together, these approaches should allow us to identify P. c. 
chabaudi MSP-1 as the major target of SSPI in mice. 
 
In conclusion, SSPI to blood stage malarial infections has been observed in malarias 
of rodents (Jarra et al., 1985; Martinelli et al., 2005a; Cheesman et al., 2006). Using 
LGS analysis, we have located the region on P. c. chabaudi chromosome 8 which is 
under significant SSPI selection and which contains the gene for the P. c. chabaudi 
MSP-1 antigen. No other region in the P. c. chabaudi genome was revealed to 
contain a similarly strong target of SSPI.  
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CHAPTER 3: Congenicity and Genetic Polymorphism in 
Cloned Lines Derived from a Single Isolate of the Rodent 
Malaria Parasite Plasmodium yoelii yoelii  
 
 
A part of this chapter has been published as: Pattaradilokrat S., Cheesman S.J., 
Carter R. (2008) Congenicity and Genetic Polymorphism in Cloned Lines Derived 





Many of the most commonly studied lines of the rodent malaria parasite Plasmodium 
yoelii yoelii are derived from a single parasite isolate designated 17X. There are, 
however, large phenotypic (growth rate) and genetic differences among these lines of 
17X that have been distributed to laboratories worldwide. We describe herein the 
results of a comparative genetic analysis between the cloned lines of 17X that are 
different in growth rate, based on (i) nucleotide sequence data from specific genes 
and (ii) restriction site polymorphism by Amplified Fragment Length Polymorphism 
(AFLP). Our findings indicate that there are two completely distinct genotypes 
among lines of P. y. yoelii 17X. Within one of these, genotype-1, represented by 
17XNIMR, two growth phenotypes are present, a slow growth rate phenotype (e.g. 
17XNIMR) and a fast growth rate phenotype (e.g. 17XYM). Within genotype-1, 
there were some genomic differences between lines with fast and slow growth rate, 
17XYM and 17XNIMR, which are manifest as size variation of some chromosomes 
and a small number of AFLP polymorphism. The other genotype, genotype-2, 




3.2 Short Communication  
 
Many of the most frequently used laboratory lines of the rodent malaria parasite 
Plasmodium yoelii yoelii are derived from a single parasite isolate, 17X, collected 
from the blood of a wild thicket rat Thamnomys rutilans captured near the field 
station at La Mobokè near Bangui in the Central Africa Republic in 1965 (Landau et 
al., 1965) (see also Chapter 1, section 1.6). The parasites of isolate 17X were 
introduced into laboratory rodents and transmitted through laboratory-reared 
Anopheline mosquitoes (Landau et al., 1966). Many lines of P. y. yoelii 17X have 
since been cloned and distributed to laboratories worldwide (Figure 3.1 and Table 
3.1).  
 
Amongst lines of 17X are parasites that vary in growth rate and in their ability to 
cause mild or lethal infections in the rodent host (Figure 3.1). Most lines of 17X have 
a slow growth rate and produce a typically mild, self-limited infection in mice 
(Figure 3.1). Such infections are characterised by a marked preference for immature 
red blood cell (reticulocyte) invasion (Landau et al., 1978) and parasitaemia rises 
slowly from 1 to 5% on the third or fourth day of blood-induced infection to reach 15 
to 20% after 2 to 3 weeks (Walliker et al., 1973). The parasites are typically cleared 
in the third or fourth week and the host achieves full recovery. By contrast, three 
lines of a much faster growth rate have arisen independently on three separate 
occasions from the stock P. y. yoelii malaria designated 17X (Figure 3.1 and Table 
3.1). These parasites retain their invasion preference for reticulocytes in early 
infection in mice, and rapidly deplete the reticulocytes from the circulation. Then, 
they tend to infect mainly mature red cells (normocytes) from the third and fourth 
day of infection (Yoeli et al., 1975; Walliker et al., 1976; Walliker 1981; Burns et 
al., 1989). These parasites multiply at almost exponential rates through most of the 
period of infection, usually killing mice within 7 days (Yoeli et al., 1975; Walliker et 




























Figure 3.1. Summary history and genotype analyses of laboratory-cloned lines of the rodent 
malaria parasite Plasmodium yoelii yoelii derived from a single isolate called 17X. Parasite 
isolate 17X was obtained from a wild thicket rat, Thamnomys rutilans, called 17X captured in the 
Central African Republic in 1965 (Landau et al., 1965). Parasites in the original isolate 17X 
consisted of two species originally named Plasmodium chabaudi and Plasmodium berghei yoelii 
(Landau et al., 1966). P. b. yoelii was renamed Plasmodium yoelii yoelii in 1974 (Killick-
Kendrick, 1974). Only lines of P. y. yoelii 17X are displayed here. Asterisks (*) indicate cloned 
lines. The cloned line 17XA was selected from strain 17X for resistance to pyrimethamine (see 
text). Fast or slow growth refers to the behaviour of the parasites in blood infections in laboratory 
mice (yellow background). Where known, these lines of 17X are characterised by one or the 
other of two genotypes (genotype-1 and -2) based upon sequence data of the genes for blood 
stage parasite proteins, Merozoite Surface Protein-1 and Apical Membrane Antigen-1 (see text). 
LSHTM, London School of Hygiene & Tropical Medicine (UK); NIH, National Institutes of 










Table 3.1. Source of the rodent malaria parasite Plasmodium yoelii yoelii isolate 17X and of 
lines derived from it. Cloned lines examined experimentally in the present work are indicated in 
bold. Asterisks (*) represent cloned lines. Fast or slow growth refers to the behaviours of the 
parasites in blood stage- induced infections in laboratory mice. LSHTM, London School of 
Hygiene & Tropical Medicine (UK); NIH, National Institutes of Health (USA); NIMR, National 




The purpose of the present work was to determine the genetic relationships between 
lines of P. y. yoelii 17X including those that differed in growth rate. These lines of P. 
y. yoelii studied here consisted of the fast-growing line, 17XYM, and the slow-
growing lines, 17XNIMR, 17XA and 17XNLclone1.1 (used for nucleotide sequence 
comparison). 17XA was derived following selection for resistance to the anti-
malarial drug pyrimethamine (Walliker et al., 1971; Walliker et al., 1973). The other 
three lines of 17X studied here are sensitive to this drug. The history of each line is 
shown in Table 3.1. The genetic comparisons made between them involved (1) 
nucleotide sequence comparisons of the genes encoding a part of P. y. yoelii Apical 
Membrane Antigen-1 (AMA-1) and Merozoite Surface Protein-1 (MSP-1) and (2) a 
genome-wide scan for restriction site-associated polymorphism using the method of 
Amplified Fragment Length Polymorphism (AFLP) (Grech et al., 2002). The 5’ and 
3’ nucleotide sequences of AMA-1 and MSP-1 were chosen because these loci have 
been previously shown to exhibit polymorphism between isolates, and strains, of P. 
y. yoelii (Daly et al. 1992; Kappe et al., 1996; Benjamin et al. 1999).  
 
The fast-growing line, 17XYM, and the slow-growing lines, 17XNIMR and 
17XNLclone1.1, are identical in the 5’ nucleotide sequence of the gene for AMA-1 
and are designated genotype-1 in Figure 3.1. All of the above lines are genetically 
distinct from 17XA at 22 positions in this region of the AMA-1 gene, which is 
designated genotype-2 in Figure 3.1 (see also Table 3.2A and Figure 3.2, for 
methods). This represents 5.06% sequence difference between 17XA and any of the 
other three lines of 17X analysed (Table 3.2A). These results confirm the previous 
finding that 17XYM and 17XA are genetically distinct from each other at the ama-1 
locus (Kappe et al., 1996).  
 
Similarly, there are no polymorphisms in the 3’ nucleotide sequence of the gene for 
MSP-1 between 17XYM (Lewis, 1989; Benjamin et al., 1999), 17XNIMR (A. 
Holder, personal communication) and 17XNLclone1.1 (Carlton et al., 2002), all 
genotype-1 in Figure 3.1 (Table 3.2B and Figure 3.3). The nucleotide sequence of 
these parasite lines is also identical to the slow-growing cloned line 17X (NIH) (Daly 
et al., 1992) and the two other fast-growing cloned lines, 17X (Paris) (Daly et al., 
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1992) and 17XL (NIH) of P. y. yoelii (Burns et al., 1988), indicated as genotype-1 in 
Figure 3.1 (Figure 3.3; see also Table 3.1 for the history of these lines). All of the 
above lines are genotypically distinct from 17XA (Daly et al., 1992) at 22 positions 
in this region of the msp-1 gene, which is designated genotype-2 in Figure 3.1 (Table 

























Table 3.2. Pair wise analysis of (A) the 5’ nucleotide sequences of the genes encoding Apical 
Membrane Antigen-1 and (B) the 3’ nucleotide sequences of the genes encoding Merozoite 
Surface Antigen-1 between the four cloned lines, 17XNLclone1.1, 17XNIMR, 17XYM, 
17XA of Plasmodium yoelii yoelii. (A) shows the numbers of polymorphic residues between 
each of the two lines identified in the 435 base pair nucleotide sequence of the gene for AMA-1 
which corresponds to positions 94-528 of the nucleotide sequence of 17XNLclone1.1, deposited 
in the GenBank® database under the accession number XM_724270 (Carlton et al., 2002) as well 
as in the P. y. yoelii genome database (The Institute for Genomic Research website) under the 
locus name PY01581 (see also Figure 3.2). (B) shows the numbers of polymorphic residues 
between each of the two lines identified in the 285 base pair nucleotide sequence of the gene for 
MSP-1 which corresponds to positions 4966-5250 of the nucleotide sequence of 17XNLclone1.1, 
deposited in the GenBank® database under the accession number XM_721164 (Carlton et al., 
2002) as well as in the P. y. yoelii genome database (The TIGR website) under the locus name 
PY05748 (see also Figure 3.3). Numbers in brackets represent percent nucleotide sequence 
difference, which is defined as the percentage of polymorphic residues present in each sequence 



















Figure 3.2. Multiple alignment of the 5’ nucleotide sequences of the genes encoding Apical
Membrane Antigen-1 (AMA-1) from the four cloned lines, 17XNLclone1.1, 17XNIMR, 17XYM and
17XA of the rodent malaria parasite Plasmodium yoelii yoelii. The residue numbering, shown along the
side, corresponds to the nucleotide sequence from 17XNLclone1.1 as deposited in the GenBank under the
accession number XM_724270 (Carlton et al., 2002). The nucleotide sequences from 17XNIMR, 17XYM
and 17XA were amplified by polymerase chain reaction (PCR) of genomic DNA of blood stage parasites
for each line as follows. Oligonucleotide primers were 5’-GCTCTATTT ATCTAATAAACCTG-3’ and
5’-GGATCATTACTACAATATCTTG-3’, corresponding to positions 32-54 and 635-614 of the
nucleotide sequence from P. y. yoelii 17XYM that was deposited in the GenBank® database under the
accession number U45970 (Kappe et al., 1996). PCR reactions were performed in a 50 µl volume
consisting of 100 ng genomic DNA, 4 µM forward and reverse primers, 1.5 mM MgCl2, 0.6 mM dNTPs, 5
U Immolase™ DNA polymerase (Bioline) and 1 x Immobuffer™ (Bioline). PCR conditions were as
follows: one cycle of 95°C for 7 min, 46°C for 1 min, 72°C for 1 min, one cycle of 94°C for 3 min, 47°C
for 1 min, 72°C for 1 min, followed by 26 cycles of 95°C for 1 min, 48°C for 1 min, 72°C for 1 min and
final extension at 72°C for 10 min. The PCR products were examined on Ethidium-Bromide stained
agarose gels. Each sample produced single amplicons of the predicted length. The PCR products were
purified with QIAquickPCR purification kit (Qiagen). The amplicons were sequenced using an ABI
Prism® BigDye™ Terminator (Applied Biosystems) cycle sequencing ready reaction kit (version I) in the
forward and reverse directions, using the primers described above. DNA sequences for each parasite
cloned line were visualised using EditView ABI automated DNA sequence viewer software (Perkin Elmer
ABI) and assembled manually to generate a single contiguous sequence. The nucleotide sequence for each
parasite line was confirmed on both strands in duplicate. The 435-base pair nucleotide sequences obtained
for each strain were aligned using the sequence alignment software provided by EMBL-EBI ClustalW
(http://www.ebi.ac.uk/clustalw/). (-) indicates identical nucleotide sequence between the four cloned lines
analysed. 
 
§ The 5’ nucleotide sequence of the gene encoding AMA-1 from 17XNIMR was deposited in the
GenBank® database under the accession number EF690378.  
¤ The 5’ nucleotide sequence of the gene encoding AMA-1 from our Edinburgh 17XYM was deposited in
the GenBank® database under the accession number EF989729. This sequence was found to be different
from that of 17XYM in the laboratory of J. H. Adams (The University of Notre Dame, USA) as deposited
in the GenBank® database under the accession number U45970 (Kappe et al., 1996) at nucleotide positions
99 (base A to C), 285 (base G to A) and 295 (G to A). The first base corresponds to the nucleotides from
our Edinburgh 17XYM sequence 
¤¤  The 5’ nucleotide sequence of the gene encoding AMA-1 from our Edinburgh 17XA was deposited in
the GenBank® database under the accession number EF989730. This sequence was found to be different
from that of 17XA in the laboratory of J. H. Adams (The University of Notre Dame, USA) as deposited in
the GenBank® database under the accession number U45971 (Kappe et al., 1996) at nucleotide positions


































Figure 3.3 Multiple alignment of the 3’ nucleotide sequences of the genes encoding 
Merozoite Surface Protein-1 from the six cloned lines, 17XNLclone1.1, 17XNIMR, 17XYM, 
17XL (NIH), 17X (NIH) and 17XA and one strain 17X (Paris) of the rodent malaria 
parasites Plasmodium yoelii yoelii. The residue numbering, shown along the side, corresponds 
to the nucleotide sequence from 17XNLclone1.1 as deposited in the GenBank® database under 
the accession number XM_721164 (Carlton et al., 2002). The nucleotide sequences from 
17XYM, 17XL (NIH), 17X (NIH), 17X (Paris), 17XA are deposited in the GenBank® database 
under the accession numbers J04668 (Lewis, 1989), J03612 (Burns et al., 1988), M87553 (Daly 
et al., 1992), M87555 (Daly et al., 1992) and M87556 (Daly et al., 1992), respectively. The 
nucleotide sequence from 17XNIMR was provided by Dr. Anthony Holder (National Institute for 
Medical Research, UK) (personal communication). The 285-base pair sequences were aligned 
using the ClustalW software. (-) indicates identical nucleotide sequence between lines of 17X 




From 65 randomly chosen combinations of selective AFLP primers (Table 3.3 and 
Table S2.1-S2.6, Appendix 2) (Grech et al., 2002), we found 279 AFLP markers that 
distinguished 17XYM (genotype-1) and 17XA (genotype-2). Of these markers, 130 
were present only in 17XYM and 149 only in 17XA. 283 AFLP markers 
distinguished 17XNIMR (genotype-1) and 17XA (genotype-2). Of these markers, 
136 were present only in 17XNIMR and 147 only in 17XA. In contrast, only six 
AFLP markers distinguished 17XYM (fast growth rate, genotype-1) and 17XNIMR 
(slow growth rate, genotype-1). Of these markers, all were found only in 17XNIMR. 
These results indicate that 17XYM and 17XNIMR are almost totally congenic, 
consistent with the complete sequence identity in the 5’nucleotide sequence of the 
gene for AMA-1 and the 3’nucleotide sequence of the gene for MSP-1 in 17XYM 
and 17XNIMR (see above). By contrast, 17XA differs from all the other lines of 17X 
analysed in this study. The results suggest that the fast-growing cloned line 17XYM 
arose from the genotype represented by 17XNIMR, and certainly not that represented 
by 17XA.    
 
There are, however, a small number of differences in the AFLP bands between the 
fast-growing line 17XYM and the representative of its presumed progenitor, the 
slow-growing line 17XNIMR (Table 3.3). This suggests that significant genomic 
changes have occurred between them. In order to examine this at a karyotypic level, 
we performed PFGE analysis on genomic DNA prepared from the blood stage 
parasites of 17XNIMR and 17XYM (see Figure 3.4 for PFGE conditions and also 
Chapter 4, section 4.3.8 for the method), as previously described (Owen et al., 1999; 
Khan et al., 2001). 
 
It was observed that a band in 17XNIMR representing co-migrating P. y. yoelii 
chromosomes 13 and 14 had higher molecular weight than that in 17XYM under the 
PFGE conditions for separation of high molecular weight chromosomes (Figure 3.4). 
This indicates that there are karyotypic and some other genomic differences, such as 
those we observed with AFLP, between these two apparently congenic lines of 17X 






























Table 3.3. Summary of the numbers of parasite clone-specific polymorphic bands 
(Amplified Fragment Length Polymorphism markers) identified in the three cloned lines, 
17XNIMR, 17XYM, 17XA of the rodent malaria parasite Plasmodium yoelii yoelii using 65 
combinations of selective EcoRI and MseI AFLP primers. AFLP was conducted on genomic 
DNA for each parasite line prepared from the blood-stage parasites, as previously described 
(Grech et al., 2002). Each sample was analysed in duplicate and only reproducible AFLP bands 





















































Figure. 3.4. Karyotypes of the cloned lines 17XNIMR and 17XYM of the rodent malaria 
parasite Plasmodium yoelii yoelii analysed by Pulsed Field Gel Electrophoresis (PFGE). 
Panels A and B present parasite chromosomes separated by two PFGE conditions optimised for 
separation of low and high molecular weight chromosomes, respectively. The chromosome 
numbers of 17XYM are shown on the left-hand side of the gels (Owen et al., 1999; Khan et al., 
2001). The chromosome numbers of 17XNIMR, as shown in the right-hand side of the gels, have 
been tentatively assigned by comparison to 17XYM (hence the question marks at the side of the 
chromosome bands of 17XNIMR. In panel A, electrophoresis conditions were 50 v, 360-sec 
pulse time for 72 hours; 50 v, 720 sec pulses for 72 hours, using a contour-clamped homogenous 
electric field apparatus (CHEF-DRII, Bio-Rad) and 0.8% chromosomal grade agarose gel 
(Sigma). Large chromosomes migrate unresolved as a compression zone. In panel B, 
electrophoresis conditions were 100 v, 360-sec pulse time for 72 hours; 100 v, 720 sec pulses for 
24 hours, using a CHEF-DRII and 0.7% agarose gel. Ethidium bromide-stained gels were 
















The purpose of the present work was to make a comparative genetic study of cloned 
lines in the Edinburgh collection that vary in growth rate and are derived from the 
single parasite isolate 17X of P. y. yoelii. Comparisons made between these lines 
were conducted upon (1) nucleotide sequence analyses of the specific genes and (2) 
AFLP analysis. In the present work, we were able to demonstrate the existence of 
two genotypes within cloned lines derived from isolate 17X of P. y. yoelii. 
Genotype-1 is represented by a slow-growing line, e.g. 17XA.Genotype-2 is 
represented by a slow-growing line, e.g. 17XNIMR, and a fast-growing parasite, e.g. 
17XYM. The latter genotype may probably include fast-growing lines, 17XL (NIH) 
and 17X (Paris), and slow-growing lines, 17X (NIH) and 17XNL.  
 
Our result indicated that 17XA is genetically polymorphic from other lines of P. y. 
yoelii 17X analysed in this study. Our finding is in agreement with results from a few 
previous observations that indicated the extensive sequence polymorphism between 
17XA and 17XYM in the genes for MSP-1 and AMA-1 (Daly et al. 1992; Benjamin 
et al. 1999; Kappe et al. 1996). Other studies also showed that the genome of 17XA 
was found to contain a different distribution and a different copy number of the 
genes coding for 235 kDa rhoptry proteins (Py235) from that of 17XYM (Khan et 
al., 2001; Iyer et al., 2006). Moreover, unpublished data from our laboratory, based 
on nucleotide sequence analysis of the gene for dihydrofolate reductase (DFHR), 
showed that 17XA carried a different allelic type of the dhfr gene from 17XYM. 
Based on these observations, it is highly unlikely, therefore, that, in spite of the 
shared isolate 17X origin, the fast-growing line 17XYM arose from the genetic stock 
represented by 17XA. 
 
Rather, the results of the present work indicated that the 5’ and 3’ nucleotide 
sequences of the genes for AMA-1 and MSP-1 of the fast-growing line 17XYM and 
the slow-growing line 17XNIMR were identical. Furthermore, AFLP analysis 
between 17XYM and 17XNIMR showed that the majority of AFLP bands between 
these lines were similar. These observations have demonstrated for the first time the 
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genetic congenicity between the fast-growing line 17XYM and the slow-growing 
line 17XNIMR. This suggests, therefore, that 17XNIMR could be a representative of 
a genetic stock from which 17XYM arose. Since previous work proposed that the 
sudden appearance of 17XYM was probably due to a simple mutation in the genome 
of a slow-growing line 17X of P. y. yoelii (Walliker et al., 1976), an identification of 
genes that are polymorphic between the fast and slow-growing congenic lines, 
17XYM and 17XNIMR, would reveal likely or possible candidate genes associated 
with differences in growth rate in this parasite.  
 
There is evidence, from work with the human malaria parasite Plasmodium 
falciparum, indicating that genomic and karypotypic variations are, indeed, related to 
variation in parasite proliferation rate in cultured red blood cells. Wellems and others 
(1987) showed that strain HB3 of P. falciparum which lacks a ~200 kb subtelomeric 
region on P. falciparum chromosome 13 containing the gene for histidine-rich 
protein had a lower proliferation rate of the blood stages relative to that of strain 
3D7. Furthermore, in a genetic cross between these two parasite lines, all 15 of 15 
progeny carried this subtelomeric sequence and they exhibited a proliferation 
advantage over the HB3 parent under in vitro culture conditions, suggesting this 
locus marks a linkage group that confers a strong growth advantage to the progeny 
(Wellemes et al., 1987). Following this work, the gene coding for protein EBL-1 
previously implicated in host erythrocyte invasion was mapped onto the subtelomeric 
region associated with high proliferation rate phenotypes in clones 3D7 and Dd2 of 
P. falciparum, but absent in clone HB3 which had lower proliferation rate. (Peterson 
et al., 2000). Furthermore, in an analysis of two genetic crosses between 3D7 and 
HB3 and between Dd2 and HB3, progeny of the two crosses possessed the 
chromosome segment containing the ebl-1 gene from the 3D7 or Dd2 parents had 
higher proliferation rate than HB3 (Peterson et al., 2000). These observations 
indicate, therefore, that the genomic alternations on the subtelomoeric region P. 
falciparum chromosome 13 are strongly associated with growth rate differences in 




In the present work, we have already observed that some genomic alternations 
between the fast and slow congenic lines, 17XYM and 17XNIMR. Results showed 
that 17XNIMR had additional 6 AFLP markers and a larger size of co-migrating 
chromosomes 13 and 14 than 17XYM. However, whether these differences are 
attributed to the chromosomal loss or translocation is currently unknown. These will 
require further investigation. Furthermore, it would be of interest to determine the 
possible significance of these genomic differences to variation in blood stage growth 
rate between the fast- and slow-growing lines of these parasites.  
 
In conclusion, the parasites in worldwide circulation as P. y. yoelii 17X comprise two 
distinct genetic stocks. One is represented by 17XA. The other is represented by 
17XNIMR and 17XYM as analysed in the present investigation. This group probably 
includes 17XNLclone1.1, 17X (NIH), 17XL (NIH) and 17X (Paris) based upon the 
partial coding sequence of the genes coding for MSP-1 and AMA-1. Within this 
group of parasites of probable congenic origin, the fast-growing line 17XYM has 
significant genomic alterations, such as the loss of a small number of AFLP markers 
and size differences in some chromosomes, both of which distinguish it from its 
associated congenic stock. As the fast-growing line 17XYM arose spontaneously 
during infection with a mild strain of P. y. yoelii 17X (Yoeli et al., 1975), the 
identification of an apparently congenic parasite with a slow growth rate phenotype, 
17XNIMR, will be useful in determining genes underlying growth rate differences in 
these malaria parasites. This information is particularly relevant following 
identification of a region of the parasite’s genome containing genetic determinants of 





CHAPTER 4: Linkage Group Selection: Towards Identifying 





The clinical outcome of malarial infections in humans and other animal hosts can be 
highly variable. One factor positively correlated with the pathological severity of an 
infection is growth rate of a malaria parasite in the blood. The genetic determinants 
of growth rate are, however, not known. Here we have utilised a combined genetic 
and genomic approach, Linkage Group Selection (LGS), in attempt to locate regions 
in the genome of the rodent malaria parasite Plasmodium yoelii yoelii that contain 
genes controlling blood stage growth rate. Our approach is based upon crossing a 
slow-growing line, 33XC, and a faster-growing line, 17XYM, of P. y. yoelii and 
growing the entire uncloned progeny of a genetic cross in laboratory rodents. The 
blood stages of the uncloned cross progeny were then grown as three successive 
blood infections in mice. This is expected to select for those parasites of the uncloned 
cross progeny that have inherited the allele controlling the growth rate of the faster 
growing parental clone. The growth rate selected cross progeny were analysed with 
numerous quantifiable genetic markers to identify the signature of growth selection. 
In the present study, LGS analysis of growth rate has been conducted in the progeny 
of two independent genetic crosses between 33XC and 17XYM of P. y. yoelii.  The 
results indicate that a single ~1 megabase pair region on P. y. yoelii chromosome 13 
is under strong growth selection in both crosses, although there are also other regions 
of the P. y. yoelii genome, including that on co-migrating chromosome 5 or 6, which 
may be weakly affected by growth selection. This finding, which is agreement with 
the results of a classical linkage analysis by Walliker et al., (1976), demonstrates that 
a major genetic determinant of growth rate in P. y. yoelii is found in a single region 
on chromosome 13. 
 





Malaria parasites of the same species exhibit phenotypic diversity in growth of the 
blood forms in both human and animal malarias (James et al., 1932; Yoeli et al., 
1975; Simpson et al., 2002). Such variation can be of medical importance because 
blood stage growth rate of a malaria parasite has been shown to be positively 
associated with an increase risk of pathological severity and fatality. For instance, a 
case study of the human malaria parasite Plasmodium falciparum in South East Asia 
indicated that parasites isolated from patients with complicated malaria and fatal 
cases had a faster growth rate than those with uncomplicated disease (Dondrop et al., 
2005), although this was not the case in P. falciparum malaria studied in children in 
Kenya and Mali (Deans et al., 2006). Blood-induced infections with a fast growth 
line of the rodent malaria parasite Plasmodium yoelii yoelii cause a high parasite 
density in the blood, leading to severe anaemia and death of the host (Yoeli et al., 
1975; Walliker et al., 1976; Walliker, 1981; Burns et al., 1989). Growth rate of blood 
stage parasites is also considered to be a virulence factor that could determine the 
potential of a host’s survival (Mackinnon et al., 1999). The blood stage growth rate 
may also lead to differences in the competitive success (de Roode et al., 2005a; Bell 
et al., 2006) and the transmission of the parasites to mosquitoes (Ferguson et al., 
2003; Paul et al., 2004; de Roode et al., 2005b). 
 
Variation in growth rate in the rodent malaria parasite P. y. yoelii is commonly 
related to erythrocyte invasion preference, i.e. the ability to invade red blood cells of 
different ages. Most lines have a slow growth rate and show a strong preference for 
immature erythrocytes (reticulocytes) (Carter et al., 1977; Landau et al., 1978). Since 
reticulocytes normally constitute between 1 to 2% of the total red blood cells 
(Bessman, 1990), the blood stage parasites of P. y. yoelii remain at relatively low 
densities during the course of infection. Parasites of this phenotype generally cause a 
mild, self-limited infection in laboratory mice (Walliker et al., 1971; Walliker et al., 
1973). In contrast to the above, parasites of P. y. yoelii lines 17XYM (Walliker et al., 
1976; Knowles et al., 1980; Walliker, 1981), 17XL (NIH) (Finerty et al., 1976; 
Finerty et al., 1977; Burns et al., 1989) and 17X (Paris) (Burns et al., 1989) have a 
much faster growth rate. Erythrocyte invasion of these parasites is strongly biased 
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toward reticulocytes only in early infection; after four or five days of infection it 
switches to invade exclusively mature erythrocytes (normocytes). In laboratory mice, 
parasitaemias usually reach 60 to 80% within a week of blood-induced infection, 
which causes rapid death of the animals (Yoeli et al., 1975; Walliker et al., 1976; 
Burns et al., 1989). 
    
Determining the genetic determinants of growth rate could provide insights into why 
some malaria parasites grow faster and become more virulent to their host than 
others. A genetic cross between the fast-growing line, 17XYM, and a slow-growing 
line, A/C, of P. y. yoelii (Walliker et al., 1976) was conducted to investigate the 
genetic basis of blood stage growth rate in P. y. yoelii. The progeny clones showed 
recombination between the fast growth rate character and other genetic markers 
(isozyme characters and pyrimethamine resistant/sensitive characters). In the cloned 
progeny of a genetic cross the fast growth rate character was also found to segregate 
from the slow growth rate character. Thus, the fast and slow growth rate characters 
have undergone a pattern of inheritance typical of that expected for a simple nuclear 
gene mutation (Walliker et al., 1976). However, the exact genetic determinant(s) of 
this trait could not be identified.   
 
Here we describe the application of a combined genetic and genomic approach which 
we called Linkage Group Selection (LGS) (Culleton et al., 2005; Carter et al., 2007) 
to identify the regions in the genome of P. y. yoelii containing genes controlling 
growth rate differences in these malaria parasites. The approach characterises the 
uncloned progeny of a genetic cross between fast- and slow-growing lines, 17XYM 
and 33XC, grown for three rounds of infection in laboratory mice by quantitatively 
measuring proportions of genetic markers representing alleles of the slow-growing 
parent at genome-wide loci. The present study has identified a major genomic region 
on P. y. yoelii chromosome 13 under strong growth selection. There is also evidence 
that other regions, such as that identified on co-migrating P. y. yoelii chromosome 5 
or 6, are weakly associated with the growth selection in these parasites. Consistent 
with the finding of the classical linkage analysis by Walliker et al., (1976), the 
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present finding indicates, therefore, that a single genetic locus on P. y. yoelii 
chromosome 13 confers growth rate in this parasite. 
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4.3 Materials and Methods 
 
4.3.1 Parasites, Mice and Mosquitoes 
 
The cloned lines of P. y. yoelii used here are denoted 17XYM and 33XC. Parasites of 
17XYM line have a fast growth rate phenotype and cause a fulminating and fatal 
infection (Walliker et al., 1976; Walliker, 1981; see also Chapter 3, for the detailed 
history of 17XYM). Parasites of this phenotype emerged in a single step during 
passage of 17X, a mild strain of P. y. yoelii (Yoelii et al., 1975). Parasites of 33XC 
line have a slow growth rate phenotype and cause a mild infection (Walliker et al., 
1973).  Both lines were independently derived from wild thicket rats Thamnomys 
rutilans, captured in the Central African Republic in 1965 (Landau et al., 1965; 
Landau et al., 1966). Both lines have been known to be genetically distinct from each 
other based on electrophoretic forms of the enzyme glucose phosphate isomerase 
(Walliker et al., 1973; Yoelii et al., 1975) and nucleotide sequences of the genes 
coding for Merozoite Surface Protein-1 (Benjamin et al., 1999) and Apical 
Membrane Antigen-1 (AMA-1) (unpublished data). The methods employed for 
routine blood and mosquito passage and for deep freezing blood forms were similar 
to those described previously (Walliker et al., 1973; Walliker et al., 1975). 
 
Hosts were inbred CBA/Ca and C57B1/6J female mice, aged 6 to 8 weeks at the time 
of a primary infection. For simplicity, the mouse strains CBA/Ca and C57B1/6J will 
be referred to here as CBA and C57, respectively. Mice were maintained as 
described elsewhere (de Roode et al., 2004; see also Chapter 2, section 2.3.1). 
Mosquitoes were Anopheles stephensi from a laboratory-bred colony and maintained 
in a dedicated insectary, as previously described (Ferguson et al., 2002; see also 
Chapter 2, section 2.3.1).  All experiments in this study were conducted in 
accordance with the Animals (Scientific Procedures) Act 1986 (UK). 
 
4.3.2 Single and mixed clone infections with 17XYM and 33XC 
 
Blood stage parasites of 17XYM and 33XC were initiated from deep frozen 
stabilates by intra-peritoneal (i.p.) injection into donor CBA mice. The infections 
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were monitored daily by microscopic analysis of Giemsa stained thin tail blood 
smears and red blood cell densities were measured using a Coulter Counter 
(Beckman Coulter), according to the manufacturer’s instructions. For inoculations, 
the blood stage parasites were suspended in physiological citrate saline [0.9% (w/v) 
Sodium Chloride, 1.5% (w/v) Trisodium Citrate dihydrate, pH 7.2] at 1 x 106 
parasitised red blood cells (pRBC) per 0.1 ml volume. Mice were allocated at 
random to four experimental groups. Two groups, each containing four mice, were 
i.p. inoculated with a mixture consisting of 17XYM and 33XC in proportions of 1:1 
and 1:9, respectively. Each mouse received 1 x 106 pRBC. A further two groups, 
each containing five mice, were i.p. inoculated with the same number of either 33XC 
or 17XYM.  The infections were monitored daily by microscopy as before. A 20 µl 
volume of tail blood was collected daily from each mixed clone infected mouse. 
DNA was extracted from infected mouse blood as previously described (Cheesman 
et al., 2003; Cheesman et al., 2006). 
  
4.3.3 Pyrosequencing  
 
Pyrosequencing™ (PSQ) was performed on DNA prepared from blood samples 
taken from the mixed-clone infections (see above) with slight modifications from the 
methods previously described (Cheesman et al., 2007). An assay was designed to 
estimate proportions of parasites of 17XYM and 33XC lines based on an allele-
specific, single nucleotide polymorphism (SNP) within the gene coding for AMA-1. 
The assays utilised the following primers and conditions. The forward and reverse 
primers were 5’-AGGTGCATGGTTCTGGTATAAGAG-3’ and 5’-Biotinylated-
GGAAATGCCAATCCTCCACTT-3’. PCR reactions were carried out in a 50 µl 
volume consisting of 100 ng DNA, 1.5 mM MgCl2, 0.3 mM forward and reverse 
primers, 2 mM dNTPs, 1 unit of Bio-X-ACT™ Polymerase (Bioline) in 1 x 
Optibuffer™ (Bioline). PCR conditions were as follows: 1 cycle of an initial ‘hot 
start’ at 95˚C for 7 min, 64˚C for 1 min, 72˚C for 1 min, followed by 1 cycle of 95˚C 
for 3 min, 64˚C for 1 min, 72˚C for 1 min, followed by 40 cycles of 95˚C for 30 sec, 
64˚C for 1 min, 72˚C for 1 min and a final elongation step heating at 72˚C for 10 
min. PCR products were run on 1.5% agarose gels. Each sample produced single 
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amplicons of the predicted length. PCR products (175 base pairs in size) were, 
thereafter, subjected to a sequencing reaction according to the manufacturer’s 
instructions (Biotage), with a sequencing primer 5’-GGTATAACTATTCAAAATTC 
-3’. Nucleotide-specific light signals generated by the sequencing reactions were 
detected on a Biotage Pyrosequencer HS96A. Light signals at the SNP position were 
transformed into relative peak heights, representing proportions of parasites carrying 
the 17XYM and 33XC alleles of the gene for AMA-1 present in a sample analysed. 
PSQ assays were standardised to accurately measure proportions of parasites in a 
mixture within ±<5% (Cheesman et al., 2007).  
 
To obtain clone-specific parasitaemias proportions of 33XC and 17XYM determined 
by PSQ, as just described, were multiplied by the absolute parasitaemias of mixed 
clone infections on the same day. The 95% confidence intervals (2 x Standard Error 
of Mean) were calculated. Analysis of variance (ANOVA) was performed using 
SPSS version 11.5. Differences were deemed significant with a P value < 0.01.   
 
4.3.4 Genetic cross 
 
We conducted two genetic crosses between P. y. yoelii 17XYM and 33XC on two 
separate occasions as follows. Single clone infections of 17XYM and 33XC were 
grown individually in donor mice. Blood from these mice was mixed to produce 
inocula containing equal proportions of the two clones. Blood inocula were i.p. 
inoculated into three CBA and C57 mice that were used to carry out the first and 
second genetic crosses, respectively. Each mouse received 1 x 106 pRBC. Infectivity 
to mosquitoes was similar, and high, using both strains of mice (see below). Four 
days post inoculation, parasitaemias were approximately 20% and 6% in CBA and 
C57 mice, respectively, and the presence of gametocytes of both sexes was 
microscopically confirmed in mice. Mosquitoes were allowed to feed on the mice, as 
previously described (Culleton et al., 2005). Seven days post feed, six female 
mosquitoes from each batch were dissected and examined for the presence of oocysts 
in their midguts. In the first cross, 5 of the 6 dissected mosquitoes were infected and 
had a mean of 33 oocysts per midgut. In the second cross, all of the 6 dissected 
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mosquitoes were infected and had a mean of 50 oocysts per midgut.  Seventeen days 
post feed, the presence of sporozoites in salivary glands of the mosquitoes was 
microscopically confirmed. Salivary glands were dissected from 200 and 359 
mosquitoes from the first and second batches, respectively, for harvesting 
sporozoites, as previously described (Pattaradilokrat et al., 2007; see also Chapter 2, 
section 2.3.3). Sporozoites harvested from each cross were i.p. inoculated into three 
and four CBA mice, respectively, to obtain blood stage parasites for growth selection 
(see the following section). From the number of mosquitoes dissected for each cross, 
we calculated the likely maximum number of independent recombinant clones which 
each cross could have generated (Table 4.1), as previously described (Pattaradilokrat 





















Table 4.1. Parameters used to calculate the predicted numbers of independent recombinant 
lines of parasites from two independent genetic crosses between the cloned lines 17XYM 
and 33XC of Plasmodium yoelii yoelii. Parameters used to predict the maximum numbers of the 
recombinant lines in each uncloned progeny are calculated, as previously described 
(Pattaradilokrat et al., 2007; see also Chapter 2, section 2.3.3) 
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4.3.5 Growth selection of 17XYM and 33XC cross progeny  
 
When the sporozoite-induced infections reached average parasitaemias of 1 to 2%, 
the blood forms were harvested and pooled in physiological citrate saline to produce 
a blood inoculum containing 1x106 pRBC per 0.1 ml. A total of 1x106 blood stage 
parasites of the first cross were grown for three rounds of infections in female CBA 
mice, aged 6 to 8 weeks. Three mice were used in each round. The infections were 
monitored daily by microscopy. The uncloned progeny parasites were allowed to 
develop 20% parasitaemias or above before the blood stage parasites were harvested 
and/or serially passaged into new host. Based upon the observations from the mixed 
infection studies that growth rate of parasites of 17XYM was significantly different 
from growth rate of parasites of 33XC on day 5 post infection at which absolute 
parasitaemias were above 20% (see Results, section 4.4.1), this is expected to select 
against those parasites that have a slow growth rate phenotype. Parasites of the first 
cross were harvested 4 days post inoculation in each of the three blood passages. 
Blood stage parasites of the second genetic cross were, likewise, grown in three 
successive blood infections in groups, each containing four CBA mice. Parasites of 
the second genetic cross were harvested 6 days post inoculation after the first passage 
and 5 days post inoculation after the second and third passages. Parasite DNA was 
extracted prior to Amplified Fragment Length Polymorphism (AFLP), as previously 
described (Grech et al., 2002).  
 
4.3.6 Proportional AFLP  
 
DNA samples prepared from the growth rate selected cross progeny and from the 
two parental clones, 17XYM and 33XC, were analysed by AFLP as previously 
described by Grech et al., (2002). Briefly, 33P-labelled AFLP products were 
separated on 6% denaturing polyacrylamide gel and exposed to a Phosphoscreen 
(Molecular Dynamics) and processed using a Storm 860 Phosphorimager (Molecular 
Dynamics), as previously described (Martinelli et al., 2004). The resulting images 
were analysed using ImageQuant™ version 1.2 software (Molecular Dynamics) 
according to the manufacturer’s instructions. Polymorphic bands could then be 
visualised on the gel as being present in one parental clone and absent in the other, 




AFLP band intensities for the slow-growing parental clone 33XC present in the cross 
progeny after three serial passages were quantitatively measured (Martinelli et al., 
2004) and expressed relative to the intensity of a non-polymorphic band within the 
same lane, defining the ‘Intensity Index’ (II) (Martinelli et al., 2004). The II of the 
AFLP band in the cross progeny after three passages was divided by the II of the 
corresponding AFLP band of the parental clone 33XC. This ratio defines the 
‘Relative Intensity Index’ (RII) (Martinelli et al., 2004). It has been shown that the 
RII of an individual AFLP marker is directly proportional to the ratio of parasites 
carrying that marker in a complex genetic mixture (Martinelli et al., 2004). 
Comparison of the RIIs of the AFLP bands of the first and second growth rate 
selected cross progeny in each of the three serial passages was performed using 
Microsoft Excel 2000 (Microsoft).  
 
4.3.7 Physical mapping of AFLP markers  
 
AFLP markers were located on the P. y. yoelii genome as follows. DNA sequences 
were obtained from the markers, as previously described (Hunt et al., 2004; see also 
Chapter 2, section 2.3.7). All AFLP markers produced a single sequence as 
confirmed on both strands in triplicate. Five-fold (5X) coverage contigs of the P. y. 
yoelii 17XNLclone1.1 genome (Carlton et al., 2002), http://www.tigr.org/tdb/e2k1/pya1/, 
were searched using the BLASTN (DNA vs. DNA) option with sequences derived 
from the AFLP markers. The genomic contig of P. y. yoelii which contained DNA 
sequences corresponding to the relevant AFLP marker with lowest Probability (E) 
score (a cut-off of 90% sequence identity) were obtained. Because the physical 
locations of these contigs in the P. y. yoelii genome have not been identified, 
sequences of the P. y. yoelii contigs containing the AFLP marker were then used to 
identify orthologues in the P. falciparum clone 3D7 genome (Gardner et al., 2002) 
(http://www.ncbi.nlm.nih.gov/sutils/blast_table.cgi?taxid=Protozoa&database), using the 
BLASTP (DNA vs. Protein) option. The genomic locations of the P. falciparum 
orthologues were subsequently used for physical mapping to chromosomal locations 
in the genome of P. y. yoelii through the conserved genetic synteny between the 
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human malaria parasite P. falciparum and the rodent malaria parasites (Kooij et al., 
2005). 
 
4.3.8 Pulsed Field Gel Electrophoresis  
 
Host cell free-parasite pellets were prepared from the blood stages of P. y. yoelii 
17XYM and 33XC, as described by Grech et al., (2002). The pellets were 
resuspended with an appropriate volume of PBS pH 7.2 and mixed with an equal 
volume of 2.0% low melting temperature (LMT) agarose (Sigma). The mixtures 
were added into 10 x 5 x 1.5 mm3 molds (BioRad) and allowed to set at 4˚C for 20 
min. The solidified agarose blocks were then released into lysis buffer [0.5 M EDTA, 
10 mM Tris-HCl pH 9.5, 1% (v/v) N-lauroylsarcosine (Sigma), 0.2 mg ml-1 
ProteinaseK (Sigma)] and incubated at 42˚C for 48 hr with one change of the buffer 
after 24 hr. Blocks were stored in 0.05 M EDTA pH 8.0 at 4˚C until use.  
 
PFGE was performed on the contour-clamped homogeneous electric field (CHEF)-
DRII apparatus (Carle et al., 1984; Carle et al., 1987). A half slice of the agarose 
blocks was washed three times in DNase-free wash buffer [20 mM Tris-HCl pH 8.0, 
50 mM EDTA pH 8.0] at room temperature. The slices were embedded in 0.7% 
LMT agarose gel (Sigma) in 0.5 x TBE buffer [45 mM Tris-Borate, 1 mM EDTA] 
and allowed to set at room temperature for 1 hour. CHEF chamber buffer was 0.5 x 
TBE buffer and pre-circulated at a constant temperature of 8˚C. PFGE conditions 
were optimised for separation of high molecular weight chromosomes. 
Electrophoresis conditions were as follows: 100 volts, 360-sec pulse time for 72 hr; 
100 volts, 720-sec pulses for 24 hr, using a CHEF-DRII and 0.7% agarose gel (Owen 
et al., 1999; Khan et al., 2001). The gels were stained with 1 µg ml-1 Ethidium 
Bromide at room temperature for 1 hour, de-stained in 0.5 x TBE for 30 min with 
gentle agitation and visualised under UV transillumination and photographed. 
 
4.3.9 Preparation of DNA probes  
 
The genomic contigs of the P. y. yoelii strain 17XNLclone1.1 genome, 
corresponding to the P. y. yoelii 33XC AFLP markers, were used to design DNA 
 115
 116
probes. Primers were designed using a web-based primer designed tool called 
Primer3 (http://frodo.wi.mit.edu/cgi-bin/primer3/primer3.cgi) (Rozen et al., 2000) to 
amplify specific loci of P. y. yoelii 33XC. The primers used for each of the AFLP 
markers and conditions for PCR are given in Table 4.2. PCR products of the 
predicted length were purified using a PCR purification kit (QIAGEN) and 
sequenced using ABI BigDye Terminator Chemistry on ABI3700 sequencing 
machine, according to manufacturer’s instructions (Applied Biosystem). All PCR 
products contained sequences that matched those of the AFLP markers. The PCR 
products were then radiolabelled with ~ 3000 Ci mmol-1 α-[32P] dATP (Amersham) 
using a Prime-It® Random Primer labelling kit (Stratagene) and purified with a 
NucTrap® Probe purification Column (Stratagene).  
 
4.3.10 Hybridisation  
   
The P. y. yoelii chromosomes separated by PFGE were transferred onto Hybond N+ 
membrane (Amersham), following the manufacturer’s protocols. Southern blots were 
incubated in QuikHyb® Hybridisation solution (Stratagene) for 30 min before the 
addition of the 32P-radiolabelled probe. Pre-hybridisation and hybridisation 
incubation temperatures were kept constant at 62 ˚C.  Hybridisations were conducted 
using a hybridisation oven (Hybaid). The labelled probe was mixed with 100 µl of 10 
mg ml-1 sonicated herring sperm DNA (Invitrogen) and 1 ml of QuikHyb® 
Hybridisation solution, and the mixture was boiled for 2 min. The probe was added 
immediately and hybridised onto the pre-incubated blot for 1 hr. Blots were washed 
twice for 15 min at room temperature with a 2 x SSC buffer [0.3 M sodium chloride, 
30 mM Trisodium Citrate dehydrate pH 7.0], and washed twice for 30 min at 62˚ C 
with pre-warmed wash solution [0.2 x SSC buffer and 0.1% (w/v) sodium dodecyl 
sulfate] for a high-stringency wash. The washed blots were exposed to a 
Phosphoscreen overnight prior to visualisation with ImageQuant™ software 
(Molecular Dynamics). The blots were stripped and stored as recommended by the 





















Table 4.2. A summary of primers used to generate DNA probes for four Plasmodium yoelii 
yoelii 33XC AFLP markers most reduced in cross progeny following growth selection, as 
















PCR reactions for each marker were carried out in a 150 µl volume consisting of 300 ng genomic 
DNA of P. y. yoelii 33XC, 2.5 mM MgCl2, 0.3 mM forward and reverse primers (as above), 400 
µM dNTPs, 5 U Taq DNA polymerase in storage Buffer B (Promega) and 1 x Taq polymerase 10 
x Buffer, Magnesium free (Promega). PCR conditions were as follows: 30 cycles of 94˚C for 45 
sec, 55-60˚C (depending on the primers, see Annealing Temperature above) for 1 min, 72˚C for 1 
min, and a final elongation step heating at 72˚C for 10 min. PCR products were run on 1.5% 
agarose gel. Each sample produced single amplicon of the predicted length, ~600 to 800 base 





4.4.1 Growth of 17XYM and 33XC in the single and mixed clone 
infections  
 
Growth of 17XYM and 33XC in the single and mixed clone infections was studied in 
CBA mice, aged 6 to 8 weeks old. Two groups of mice (n = 4) were i.p. inoculated 
with 1 x 106 pRBC mixtures consisting of 17XYM and 33XC in proportions of 1:1 
and 1:9, respectively. A further two groups of batch mates (n = 5) were i.p. 
inoculated with the same numbers of the blood stage parasites of either 17XYM or 
33XC. The daily parasitaemias of the single and mixed clone infections in mice are 
shown in Figure 4.1A to 4.1C. The proportions of 17XYM and 33XC in the mixed 
clone infections were determined using a quantitative SNP-based assay 
Pyrosequencing™ (Cheesman et al., 2007) for the 17XYM and 33XC alleles of the 
gene coding for AMA-1 (see Materials and Methods, section 4.3.3). The clone 
specific parasitaemias of 17XYM and 33XC in the mixed clone infections (Figure 
4.1B and 4.1C) were compared on each day of infection using an analysis of variance 
(ANOVA) (see Materials and Methods, section 4.3.3).   
 
In the single clone infections, the percent parasitaemia of parasites of 17XYM rose to 
a mean of 20% by day 4 post infection and reached a mean of 70% by day 6 (n = 5). 
By contrast, the percent parasitaemia of parasites of 33XC rose slightly to a mean of 
1-2% by day 4 post infection. This remained constant at day 6, the last day of 
sampling for this group. It is clear, therefore, that parasites of 17XYM had a much 
faster growth rate than those of 33XC from days 4 onwards (P < 0.01) (Figure 4.1A).  
 
In mixed clone infections containing proportions of 1:1 (Figure 4.1B) and 1:9 (Figure 
4.1C) parasites of 17XYM achieved much higher parasitaemias than those of 33XC 
from days 5 and day 6 onwards (P <0.01) when the total parasitaemias reached a 
mean of around 25% and 20%, respectively. Although the parasitaemias of parasites 
of 17XYM in the 1:9 YM:33XC mixed infection increased more slowly than in the 
1:1 YM:33XC mixed infection, the parasitaemias of parasites of 33XC in both mixed 
infections remained stable at around 1-2% throughout a period of observation. This 
result was due purely to the fact that the number of parasites of 17XYM in the 1:1 
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YM:33XC mixed infection was higher than in the 1:9 YM:33XC mixed infection. 
These experiments demonstrate, therefore, that parasites of 17XYM had a faster 
growth rate than those of 33XC in the single and mixed-cloned infections containing 
both proportions. 
 
From this data, it is possible to select for uncloned progeny parasites of a genetic 
cross between 17XYM and 33XC that have a fast growth rate by allow them to 
develop to a mean parasitaemia of 20% or above in laboratory mice in LGS 


















Figure 4.1. Growth of (A) single and (B and C) mixed clone infections of 17XYM and 33XC 
of the rodent malaria parasite Plasmodium yoelii yoelii. The parasitaemias during the course 
of single clone infections with either 17XYM (pink solid line) or 33XC (blue solid line) are 
shown in panel A. The clone specific parasitaemias (17XYM, pink dashed lines; 33XC, blue 
dashed lines) and the absolute parasitaemias (black solid lines) in mixed clone infections with 
parasites of 17XYM and 33XC in proportions of 1:1 and 1:9 are shown in panels B and C, 
respectively. Error bars give the 95% confidence intervals of the means. ‘n’ is the total number of 
mice used in the experimental groups. Asterisks (*) represent statistically significant differences 








4.4.2 Growth of the uncloned 17XYM and 33XC cross progeny  
 
Two independent genetic crosses between 17XYM and 33XC were made, as 
described in Materials and Methods (section 4.3.4). The highest numbers of 
independent recombinant lines that could have been obtained in the first and second 
genetic crosses were estimated to be approximately 13,200 and 35,900 (Table 4.1). 
Blood stage parasites of the uncloned progeny of the first and second genetic crosses 
were each grown in three successive infections in groups of three and four CBA 
mice, respectively, aged 6 to 8 weeks, as described in Materials and Methods 
(section 4.3.5). The infections were examined daily by microscopy (Figure 4.2). The 
surviving parasites from each round of growth selection were harvested, as described 
in Materials and Methods (section 4.3.5). Parasite DNA was prepared prior to the 












Figure 4.2. Growth of the uncloned progeny of the two genetic crosses between Plasmodium 
yoelii yoelii lines 17XYM and 33XC in three successive passages in laboratory mice. The 
absolute parasitaemias of the uncloned progeny of (A) the first genetic cross and (B) the second 
cross after first passage (dashed line), second passage (dotted line) and third passage (solid line) 
were measured by microscopy. Days post infection on which blood stage parasites in first, 
second and third passages were harvested for LGS analysis are indicated by green, blue and red 
arrows, respectively. Error bars give the 95% confidence intervals of the means. The letter ‘n’ 
represents the number of mice in the experimental groups in each successive blood-induced 
infection.    
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4.4.3 Identification of AFLP markers under strong growth selection  
 
Parasite DNA of the uncloned progeny from the two genetic crosses in the three 
successive passages was typed with a large number of quantitative genetic markers 
generated by AFLP, as described in Materials and Methods (section 4.3.6). From 68 
randomly chosen combinations of selective AFLP primers, we identified 197 parasite 
clone specific polymorphic AFLP bands (AFLP markers) between 17XYM and 
33XC. Of these bands, 89 were present only in 17XYM and 108 in 33XC and used 
as markers for the fast-growing parental clone 17XYM and the slow-growing 
parental clone 33XC, respectively. Following growth selection of cross progeny, the 
RIIs of 108 AFLP markers of the slow-growing parent 33XC were determined 
(Table S3, Appendix 3; see Materials and Methods, section 4.3.6, for the definition 
of the RII). The RIIs of individual markers in the two crosses were plotted against 
each other in Figure 4.3 for each of the three passages.  
 
Five 33XC AFLP markers had RIIs of below 0.20 following three rounds of growth 
selection, i.e. intensity of an AFLP marker carried by parasites of the growth rate 
selected progeny reduced by 80% relative to its intensity of parasites of the parental 
clone (Figure 4.3 and Table 4.3A). Three of the five affected 33XC markers 
including 33XC AG01TA 17XYM, 33XC AG01AG 17XYM and 33XC CA05TT 
17XYM were already reduced in the first passage in the growth rate selected 
uncloned progeny of the two genetic crosses (Figure 4.3 and Table 4.3A). The 
remaining two 33XC markers, 33XC CA05TA 17XYM and 33XC GT02TT 






























Figure 4.3. Pairwise comparison of the Relative Intensity Indices (RIIs) of Plasmodium 
yoelii yoelii 33XC AFLP markers from the uncloned progeny of the two genetic crosses 
between P. y. yoelii 17XYM and 33XC following growth selection in laboratory mice. (A), 
(B) and (C) show the RIIs of 108 P. y. yoelii 33XC markers in the progeny of the two genetic 
crosses in the first, second and third passages, respectively. The X-and Y-axes represent the RIIs 
of the P. y. yoelii 33XC markers of the first and second cross progeny, respectively. Five P. y. 
yoelii 33XC markers were consistently and strongly reduced under growth selection in both 
crosses (green squares). These markers were as follows: 33XC CA05TT 17XYM, brown circle; 
33XC AG01AG 17XYM, yellow oval; 33XC AG01TA 17XYM, green triangle; 33XC CA05TA 
17XYM, pink diamond. Each of these five markers and one marker, 33XC AA01CT 17XYM, 





4.4.4 Physical Mapping of AFLP markers under selection 
 
The five 33XC markers under growth selection were located to the P. y. yoelii 
genome as follows. DNA sequences of the five affected 33XC markers were 
obtained and P. y. yoelii 17XNLclone1.1 genomic contigs containing DNA 
sequences that matched those of the affected markers were identified by BLASTN 
searching of the P. y. yoelii genome (the Institute for Genomic Research), as 
described in Materials and Methods (section 3.3.7). The predicted orthologues of the 
genes on the identified P. y. yoelii genomic contigs were, thereafter, located within 
the P. falciparum genome. Because of the high level of conserved synteny between 
the genomes of P. falciparum and the rodent malaria parasites  (Kooij et al., 2005), 
the chromosomal locations of the P. falciparum orthologues of P. y. yoelii 33XC 
markers could, in turn, be mapped to the equivalent predicted chromosomal positions 
in the P. y. yoelii genome (Table 4.3B).   
Two of the five strongly reduced 33XC markers were found in P. y. yoelii contigs 
containing P. y. yoelii-specific genes (Table 4.3B) that had no orthologues in the P. 
falciparum genome (Kooij et al., 2005). One 33XC marker, 33XC CA05TA 
17XYM, which was strongly reduced only following the second passage, was located 
in a gene of a multigene family coding for the telomerase reverse transcriptase 
(TERT). The other, 33XC GT02TT 17XYM, which was strongly reduced only 
following the third passage, was found in a gene coding for putative YIR3, a member 
of the multigene family coding for the Yoelii Interspersed Repeats (YIR). The P. y. 
yoelii chromosomal locations of these two affected markers were not known and 
were indicated as not determined in Table 4.3B.  
The other three 33XC AFLP markers that were strongly reduced following the first 
passage were successfully located to a single region on P. y. yoelii chromosome 13 
(Table 4.3B). One marker, 33XC CA05TT 17XYM, had an orthologue on P. 
falciparum chromosome 13, while the other two markers, 33XC AG01TA 17XYM 
and 33XC AG01AG 17XYM, had orthologues on P. falciparum chromosome 14. 
Both locations were syntenic with a single region on P. y. yoelii chromosome 13. The 
P. falciparum genomic regions containing the orthologues of the three most reduced 
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33XC markers on P. y. yoelii chromosome 13 (see above) defines approximately ~1 
megabase pairs (Mb) of sequence (Table 4.3B and Figure 4.4). This region contains 
at least 254 predicted genes in P. falciparum (data from September 2007; 
http://www.ncbi.nlm.nih.gov/mapview/map_search.cgi?taxid=36329&query=) and 204 
predicted genes in P. y. yoelii as deduced from the synteny between them (Kooij et 
al., 2005).  
We also identified a P. y. yoelii 33XC AFLP marker, 33XC AA01CT 17XYM, 
which was not reduced following growth selection (Figure 4.3). However, an 
orthologue of this marker was located on P. falciparum chromosome 13, which was 
syntenic with a region on P. y. yoelii chromosome 13 and lay approximately ~ 152 
kilobase paris (kb) from the nearest location on the linkage group containing the 
three strongly and consistently reduced 33XC markers (Figure 4.4). This marker 































Table 4.3. Summary of (A) the Relative Intensity Indices (RIIs) and (B) the physical 
locations of the Plasmodium yoelii yoelii 33XC AFLP markers of the uncloned progeny from 
the two genetic crosses between 17XYM and 33XC which were most strongly reduced after 
growth selection. ID, identity 
 §   The genomic contigs and the gene ID of P. y. yoelii (Carlton et al., 2002) and the gene ID and 
physical locations in the Plasmodium  falciparum genome (Gardner et al., 2002) as described 
in the GenBank®.   
 ۞ The gene annotation based upon the P. y. yoelii 17XNLclone1.1 genome (the TIGR website; 
http://www.tigr.org/tdb/e2k1/pya1/pya1.shtml ).    
#   Detailed syntenic relationships between P. falciparum and P. y. yoelii were described by 









































Figure 4.4. The Relative Intensity Indices (RIIs) of the four Plasmodium yoelii yoelii 33XC 
AFLP markers on chromosome 13 following growth selection of the progeny of the genetic 
cross between 17XYM and 33XC. The vertical axis represents the RII. The horizontal axis 
represents the physical distance on P. y. yoelii chromosome 13 in kilobase pair (kb). The RIIs of 
the 33XC markers in the first, second, and third passages are indicated by green, blue and red 
colours, respectively.  Of the four 33XC markers, three markers including (I) 33XC AG01AG 
17XYM, (II) 33XC AG01TA 17XYM, (III) 33XC CA05TT 17XYM were strongly reduced 
following growth selection and the other marker, (IV) 33XC AA01CT 17XYM, which was a 
non-reduced marker (see text). The RII data shown here was obtained from the growth selected 
uncloned progeny of the first genetic cross (A) and the second genetic cross (B) (see 
Supplementary data). Numbers above the double-headed arrows indicate distances between each 
of the 33X markers in kb based on the orthologues of the 33XC markers in P. falciparum 
genome. Extrapolation to P. y. yoelii chromosome 13 is from synteny between these two species 




4.4.5 Confirmation of genomic regions of selection  
To confirm the locations of the 33XC markers that were mapped by genetic mapping 
on P. y. yoelii chromosome 13, we hybridised 32P-radiolabelled sequences derived 
from each of the 33XC markers onto a chromosome blot containing chromosomes of 
the two parental clones 17XYM and 33XC, separated by the method of pulsed field 
gel electrophoresis (PFGE), as described in Materials and Methods (section 4.3.8 to 
4.3.10). All four 33XC markers hybridised to a single band corresponding to the co-
migrating P. y. yoelii chromosomes 13 and 14 (Figure 4.5) of 17XYM and 33XC 
clones.  
We attempted to hybridise the two other affected 33XC AFLP markers whose 
locations could not be identified by physical mapping, due to the absence of the 
orthologues in P. falciparum. One marker, 33XC CA05TA 17XYM, found in the 
gene for TERT protein, hybridised to a band corresponding to the co-migrating P. y. 
yoelii chromosomes 5 and 6 (Figure 4.5). However, we were not able to perform 
hybridisation for the other marker, 33XC GT02TT 17XYM. The main reason for this 
was that we were not able to design a specific DNA probe for this marker. This was 
due to the fact that the marker was found in the gene coding for putative YIR3 
protein, a member of the largest gene family in P. y. yoelii (Carlton et al., 2002). The 
chromosomal location of this marker in the P. y. yoelii genome was not known by 






























Figure 4.5. Physical locations of Plasmodium yoelii yoelii 33XC AFLP markers on 
chromosome blots of (panel A) 17XYM and (panel B) 33XC, separated by pulsed field gel 
electrophoresis (PFGE). The chromosome numbers are shown on the left-hand side of the gels 
in each panel (Owen et al, 1999; Khan et al., 2001). The chromosome numbers of 33XC have 
been tentatively assigned by comparison to 17XYM (hence, the question marks at the side of the 
chromosome bands of 33XC). Chromosome blots were hybridised with DNA sequences 
corresponding to the P. y. yoelii 33XC AFLP markers as follows: (I) 33XC AG01AG 17XYM, 
(II) 33XC AG01TA 17XYM, (III) 33XC CA05TT 17XYM, (IV) 33XC CA05TA 17XYM and 
(V) 33XC AA01CT 17XYM (see Materials and Methods, section 4.3.8-4.3.10). 
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4.5 Discussion  
 
Using the Linkage Group Selection (LGS) approach, we have identified regions in 
the rodent malaria parasite P. y. yoelii genome containing genes that determine 
growth rate of the blood stages of these parasites. First, we crossed two genetically 
distinct lines of P. y. yoelii that differ in blood stage growth rate, 17XYM (fast 
growth) and 33XC (slow growth), to generate recombinant progeny. We then grew 
blood stage parasites of uncloned cross progeny for three rounds of infections in 
naïve mice. The uncloned cross progeny in each infection was then allowed to 
develop high parasitaemias. This is expected to select for those parasites which 
possess the alleles determining growth rate of the faster growing parental line. 
Parasite DNA from the uncloned progeny of the two genetic crosses after the three 
successive passages was screened for the presence and intensity of genome-wide 
AFLP markers that allowed measuring of the proportions of 17XYM and 33XC in 
the mixture. Following growth of the progeny of the two genetic crosses in the three 
successive infections, a small number of AFLP markers of the slow-growing parent, 
33XC, were consistently and strongly reduced in intensity, with RIIs below 0.2. The 
locations of these most reduced markers were searched for in the P. y. yoelii genome, 
as described in Results (see section 4.4.3).  
 
Three of the five most strongly selected 33XC markers were already strongly 
reduced in the first passage following growth selection of both crosses. All these 
markers were located to a region on P. y. yoelii chromosome 13 and formed a linkage 
group that spanned a predicted ~1 Mb of genetic distance. Closely linked to it was a 
33XC marker that was not reduced under growth selection. This marker thus places 
an outer limit to the genomic region under strong growth selection on P. y. yoelii 
chromosome 13. Consistent with the above, CHEF and hybridisation results showed 
these four 33XC markers hybridised to a single position on chromosome blot 
corresponding to co-migrating P. y. yoelii chromosomes 13 and 14. These results, 
therefore, have identified a single non-recombined region on P. y. yoelii chromosome 
13 which is under strong growth selection. It may be that this entire linkage group 
must be inherited as a non-recombined genetic unit, in order to confer fast growth 
rate upon the parasites. Alternatively, it may be that, for some other reason, this 
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section of P. y. yoelii chromosome 13 cannot recombine between the alleles of the 
two parental clones. Within this is at least one gene which determines a fast growth 
trait.    
 
The two other markers under strong selection were only reduced after the second and 
third passages respectively. Both markers were found in P. y. yoelii-specific 
multigene families, one in the family coding for TERT and the other in the family 
coding for YIR.  Within P. y. yoelii genome data, 6 tert genes and 838 yir genes (693 
full genes and 145 partial genes) are present and the exact roles of these gene 
families are not known (Carlton et al., 2002; see also the TIGR P. y. yoelii genome 
database http://www.tigr.org/tdb/e2k1/pya1/LocusNameSearch.shtml). Due to the absence 
of orthologues in P. falciparum, according to the genetic synteny map of Kooij et al., 
(2005), these markers could not be located in the P. y. yoelii genome by physical 
mapping. Nevertheless, CHEF and Southern hybridisation analysis indicated that the 
marker found in the gene for TERT was located to the position of co-migrating P. y. 
yoelii chromosomes 5 and 6, suggesting that at least one of these chromosomes also 
contains a genomic region under growth selection. The other marker, found in the 
gene for YIR, could not be located by either physical mapping or CHEF and 
hybridisation analysis. Its location in the P. y. yoelii genome is currently not known.  
 
The effects of growth selection on the two markers found in the P. y. yoelii-specific 
gene families, TERT and YIR, were less pronounced than those upon the three 
markers that formed a single linkage group on P. y. yoelii chromosome 13. This ~1 
Mb linkage group appears, therefore, to contain the major genetic determinant(s) of 
growth rate in P. y. yoelii 17XYM. The original description of the 17XYM line 
reported that parasites having fast growth rate had emerged in a single step during 
blood passage of 17X, a mild line of P. y. yoelii (Yoeli et al., 1975). In a genetic 
cross between 17XYM and another slow-growing line of P. y. yoelii, line A/C, the 
fast and slow growth characters recombined with other genetic markers, and 
segregated in the cloned progeny, implicating a single locus for genes conferring 
these growth characters (Walliker et al., 1976). This is consistent with the present 
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finding by LGS of a single region of the P. y. yoelii genome that determines growth 
rate differences between 17XYM and 33XC.  
 
It is noteworthy, however, that, in the present study, we were able to locate only one 
33XC marker which was not under growth rate selection on P. y. yoelii chromosome 
13. Thus, we will need additional quantifiable markers on this chromosome 13 in 
order to precisely locate the affected region under growth rate selection. One 
approach is to generate additional AFLP markers from the two parental lines with 
different combinations of selective AFLP primers (Grech et al., 2002). If necessary, 
SNP-based PSQ assays can be developed to increase the number of quantifiable 
genetic markers on P. y. yoelii chromosome 13 (Cheesman et al., 207). These assays 
would enable us to accurately quantify proportions of the parasites carrying alleles 
representing SNPs within the region under growth rate selection, or other regions of 
the genome under investigation. With a further tens of quantifiable genetic markers 
developed across the P. y. yoelii chromosome 13, we would be able to narrow the 
location under selection and increase a possibility of identifying loci associated with 
growth rate differences in the parental strains used in the cross.     
 
More recently, we identified a slow-growing line of 17X, 17XNIMR (Pattaradilokrat 
et al., 2008), which appeared to be from the same genetic stock as 17XYM. This 
could be useful in identifying candidate genes controlling growth rate through 
detailed genetic comparison of these two putatively congenic lines. Identification of 
candidate genes controlling growth rate within the region on P. y. yoelii chromosome 
13 under strong growth selection involves the sequencing of all such genes in 
17XYM and 17XNIMR. This process would yield genes for the individual proteins 
that are polymorphic between them. This could, in principle, be no more than a 
single nucleotide polymorphism. Subsequently, likely or possible candidate genes 
can be tested further in transfection experiments, which have been developed for P. 
y. yoelii (Jongco et al., 2006). Moreover, bioinformatic analysis, such as prediction 
of membrane location and stage-specific expression profile (which can be assessed at 
the PlasmoDB and EBI websites http://www.plasmodb.org/plasmo/home.jsp and 
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http://us.expasy.org/sprot/), may also be used to predict a possible function of the 
identified gene. Together, these approaches should lead to identification and 
validation of the gene, or genes, that determine growth rate in the linkage group 
under strong growth selection on P. y. yoelii chromosome 13.  
 
It has been proposed that candidate genes determining growth rate differences in this 
malaria parasite could be those coding for (i) proteins associated with differential 
induction of host proinflamatory cytokine responses in the early infection (Omer et 
al., 2003), (2) proteins involved in different rates of DNA replication (Reilly et al., 
2007), or (3) proteins expressed on the merozoites surface and involved in 
recognition and invasion of host erythrocytes (Grüner et al., 2004; Iyer et al., 2007a).  
 
First, it may be that growth rate differences between strains of P. y. yoelii are related 
to differences in their ability in suppressing innate immune responses during the 
course, especially the early course, of an infection. Thus, Omer and others (2003) 
showed that C57BL/6 mice infected with a slow-growing strain 17X (NIH) strain of 
P. y. yoelii produced TGF-β from 5 days post infection; this was correlated with 
resolution of parasitemia and full recovery. In contrast, infection with the lethal strain 
17XL (NIH) induced high levels of circulating TGF-β within 24 h; this was 
associated with delayed proinflamatory cytokine IFN-γ and TNF-α responses, failure 
to clear parasites, and 100% mortality (Omer et al., 2003). However, candidate genes 
coding proteins inducing the differential cytokine production in this parasite have not 
yet been identified.  
 
Second, there may be genotype-specific differences in the duration, or the number of 
rounds, of DNA replication in each erythrocytic cycle [i.e. a faster DNA replication 
rate would lead to shorter erythrocytic cycles and could be associated with faster 
growth rate]. However, there is no proof that such differences are associated with 
differences in growth rate in P. y. yoelii, although a study by Reilly and colleagues 
(2007) showed that the human malaria parasite P. falciparum strain Dd2 has shorter 
erythrocytic cycle duration and produces more merozoites per schizont than P. 




 Third, growth rate differences in this malaria parasite could also be associated with 
differences in how easily merozoites can invade the host erythrocytes (Preiser et al., 
1999) and differences in ability to invade and develop in erythrocytes of different 
ages (Walliker et al., 1976; Jayawardena et al., 1983; Burns et al., 1989). Previous 
work indicated that a multigene family coding for 235 kDa rhoptry proteins (Py235) 
located at the rhoptries of merozoites (Oka et al., 1984) might be involved in 
erythrocyte invasion preference and, in turn, blood stage growth of this malaria 
parasite (Freeman et al., 1980; Holder et al., 1981). For instance, monoclonal 
antibodies (mAbs) specific for a Py235 member can interfere with parasite invasion 
of mature erythrocytes (Freeman et al., 1980), and immunisation with Py235 
protected mice against a lethal challenge infection with parasites of 17XYM (Holder 
et al., 1981). Subsequently, several studies have focused on examining antigenic 
polymorphisms and/or differences in the copy number of the Py235 gene family 
between the fast growing line, 17XYM, and a small number of slow-growing lines 
derived from isolate P. y. yoelii 17X from which 17XYM arose, including 17XNIMR 
(Owen et al., 1999; Narum et al., 2001), 17XA (Khan et al., 2001; Iyer et al., 2006) 
and 17XNL (Iyer et al., 2006). The genome of 17XYM appeared to contain one less 
member of the Py235 family than that of 17XA (Khan et al., 2001) and of 17XNIMR 
(Owen et al., 1999). However, in an analysis of cloned progeny from a genetic cross 
between 17XNIMR and 17XYM, the presence or absence of this additional locus did 
not correlate with the fast or slow growth phenotype in these malaria parasites (Owen 
et al., 1999). Furthermore, Iyer and others (2006) showed that the overall copy 
number of Py235 detected in 17XYM is similar to that of 17XNL 1.1 (Iyer et al., 
2006). It is highly unlikely, therefore, that the antigenic diversity and differences in 
the copy number of the genes for Py235 are associated with variation in growth rate 
in these parasite strains. 
 
On the other hand, Preiser and Jarra (1998) showed that expression patterns of Py235 
proteins were notably different between the fast- and slow-growing lines, 17XYM 
and 17XA, of P. y. yoelii. They suggested that differential expressions of specific 
members of Py235 in this malaria parasite might facilitate switching of erythrocyte 
invasion preference and an increase in blood stage growth rate. Using quantitative 
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real-time PCR and Western blot analysis Iyer et al. (2007b) demonstrated that 
expression levels of a small number of members of Py235 in the fast growing line 
17XYM are much greater than those of the slow growing strain 17XA. Thus, this 
data leads a hypothesis that specific members of the Py235 multigene family express 
proteins that mediate host red blood cell selection and, hence, increased blood stage 
growth rate. However, we were not able to use LGS analysis to address the above 
question. The main reason for this is that Py235 genes exhibit a newly discovered 
form of clonal antigenic variation, whereby each individual merozoite derived from a 
single parent schizont has the propensity to express different Py235 proteins (Preiser 
et al., 1999; Snounou et al., 2000). Should such phenotypic switching account for the 
observed differences in growth rate between two parental parasite lines, LGS would 
fail to reveal selection valleys in response to selection for growth rate. On the other 
hand, where genotypic differences do underline growth rate between the two parental 
lines of a genetic cross, LGS should be able to uncover the relevant genes as already 
demonstrated in the present work.   
 
In conclusion, phenotypic diversity in blood stage growth rate and virulence in the 
host is commonly found in malarial parasites infecting humans and rodents (James et 
al., 1932; Yoeli et al., 1975; Simpson et al., 2002).  LGS analysis of growth rate has 
identified a genomic region on P. y. yoelii chromosome 13 under strong growth rate 
selection. A weaker growth selection was also found in a region on co-migrating P. 
y. yoelii chromosome 5 or 6. No other regions in the genome of P. y. yoelii were 
identified under the strength of growth selection comparable to that on P. y. yoelii 
chromosome 13. The present finding, which is consistent with the classical genetic 
analysis of Walliker et al., (1976), indicates that growth rate in P. y. yoelii is likely to 
be mainly determined by a single region on P. y. yoelii chromosome 13. 
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CHAPTER 5: Discussion and Summary 
 
 
The identification of genes in malaria parasites which control medically important 
phenotypes, such as drug resistance, transmissibility, strain specific protective 
immunity (SSPI) and growth rate in the vertebrate host, would assist the 
development of strategies for malaria control. Existing methods for genetic studies of 
malaria parasites, including classical linkage analysis and a quantitative trait loci 
analysis, have led to the successful identification of the malaria parasite genes 
conferring drug resistance (Carlton et al., 1998a; Wellems et al., 1990; Wellems et 
al., 1991; Su et al., 1997; Wang et al., 1998) and gametocytogenesis (Vaidya et al., 
1995; Guinet et al., 1996). The work involved, however, is expensive and extremely 
labour intensive. Therefore, a newly devised genetic approach of Linkage Group 
Selection (LGS) that bypasses the laborious procedure of cloning and characterising 
cross progeny is used here towards gene discovery. This approach involves (1) the 
application of a specific selection pressure, e.g. SSPI, to the uncloned recombinant 
progeny of a genetic cross between two members of a single species that differ 
phenotypically and measurably in their responses to the selection pressure, and (2) 
evaluation of the effects of the selection upon the progeny at genome-wide loci using 
quantitative genetic markers (Culleton et al., 2005; Carter et al., 2007).  
 
The focus of the present study was to search for genetic determinants controlling 
strain specific protective immunity (SSPI) and growth rate in the rodent malaria 
parasites Plasmodium chabaudi chabaudi and Plasmodium yoelii yoelii, respectively. 
These two phenotypes were chosen for study because both phenotypes were likely to 
be interrelated and involved in determining the survival of malaria parasites in the 
host. This, in turn, contributes to the clinical outcome of a malarial infection. Parasite 
growth rate is likely to be related to the immunogenicity of the malaria parasite. This 
is because strains of malaria parasites that differ in growth rate may differ in their 
efficiency in inducing protective immunity during the course of an infection. In other 
words, the immune system of the host might respond differently to an infection with 




In the cross between the two genetically distinct strains, AJ and CB-pyr10 of P. c. 
chabaudi, that showed strong SSPI, the genetic determinants of growth rate could 
not, however, have been evaluated by LGS as these two strains have similar growth 
rate throughout the course of infection in a non-immune mouse (see Chapter 2, 
section 2.4.1). Nevertheless, growth rate differences in rodent malaria are well 
documented between lines of P. y. yoelii, such as lines derived from a single isolate 
17X (see Chapter 3). In a classical genetic study by Walliker et al., (1976) using a 
cross between the fast-growing strain 17XYM and a slow-growing strain A/C of P. y. 
yoelii, the fast growth character segregated from the slow growth character in the 
cloned progeny, suggesting a single locus for genes conferring these growth 
characteristics. Therefore, in the present study, we performed LGS analysis of 
growth rate in a new cross between 17XYM and a genetically unrelated, slow-
growing line 33XC, to discover genes that are responsible for growth rate in this 
malaria parasite.  
 
The outcomes of the LGS analyses of SSPI and growth rate are discussed as follows:    
 
5.1 Linkage Group Selection analysis of Strain Specific Protective 
Immunity  
 
A previous LGS analysis of SSPI conducted using a genetic cross between P. c. 
chabaudi lines AS-pyr1 and CB (Martinelli et al., 2005a) identified an SSPI-selected 
valley in a region on P. c. chabaudi chromosome 8 whose base was found to contain 
the gene for Merozoite Surface Protein-1 (MSP-1), a known major candidate as a 
target of SSPI. However, the possible involvement of another candidate for SSPI, P. 
c. chabaudi Apical Membrane Antigen-1 (Crewther et al., 1996) which is located on 
chromosome 9, could not have been evaluated in this cross. This was due to the fact 
that there were no polymorphisms within the cell surface, ectodomain region of this 
protein between AS-pyr1 and CB. In the present study, LGS analysis of SSPI was 
made on a new genetic cross between P. c. chabaudi lines AJ and CB-pyr10 in which 
genes for MSP-1 and AMA-1 are both polymorphic. The present study has again 
identified a region associated with the gene for MSP-1 which is under strong SSPI 
selection. The results showed that the msp-1 gene in P. c. chabaudi was the locus at 
which the strongest detected reduction under strain specific immune selection 
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occured. Nevertheless, the region containing the AMA-1 gene may contain a target 
of SSPI, but one that is less strongly affected than the target associated with the gene 
for MSP-1. Therefore, these results suggest that the gene for MSP-1, or genes closely 
linked to it, is a major target of SSPI.  
 
One of the important questions concerning the application of LGS to the discovery of 
genes for SSPI is the influence of the host genotype, and/or the physiological state of 
the host, on strain-specific immune components against malaria. Since LGS analyses 
of SSPI on the progeny of the AJ and CB-pyr10 and AS-pyr1 and CB crosses have 
been conducted hitherto using a single genetic type and condition of host animal 
(female CBA/Ca mice, 4-5 month old at the time of challenge with the cross progeny 
for LGS studies), it would be of great interest to determine whether the identified 
target loci are the same or different in host of different genetic background, age or 
sex. Should the host genotype be found to affect the results obtained by LGS 
analysis, it would be possible to further explore the influence of host genotype using 
MHC congenic mouse strain, i.e. mice having different haplotypes at the MHC locus 
against the same genetic background. Currently, there is an ongoing project that aims 
to induce and determine the strain specificity of protective immunity in laboratory 
mouse strains Balb/c and C57 (Cheesman S. and Carter R., personal 
communication).        
 
In our laboratory, there are also a number of additional strain combinations of P. c. 
chabaudi that have been characterised for their mutual strain-specific immune 
relationships (Cheesman et al., 2006; Cheesman S. and Carter R., unpublished data). 
Crosses of selected combinations of the strains which show solid SSPI can be 
analysed by LGS and the loci encoding antigens of SSPI will be identified and 
compared with our present findings. Furthermore, LGS will equally applicable for 
studies of the target loci of SSPI in other malaria species, such as the human malaria 
parasite P. falciparum – the most deadly and medically significant species. The LGS 
approach is ideally suited to this malaria parasite due to the existence of strain 
specificity of protective immunity in humans (Jeffery et al., 1969; Cardigan et al., 
1969), the availability of the genetic crosses between combinations of strains that 
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vary in these traits (Walliker et al., 1976; Wellems et al., 1990; Wellems et al., 1991; 
Su et al., 2007), the high-throughput methodology for genotyping the parasites and 
for analysing the quantitative traits of the clones of a genetic cross (Su et al., 2007). 
Such experiments may be also conducted in chimpanzee or Aotus monkeys in which 
the genetic crosses have been grown. The information from such studies will lead to 
a greater understanding of immunity to malaria in general and it will crucially inform 
decision on the choice of candidate antigens for vaccine developments. In addition, 
LGS can be exploited to further investigate the target loci of SSPI in other 
Apicomplexan parasites, which are important pathogens of domestic animals. An 
example is the coccidian parasite Eimeria tenella, whose genetics is conventionally 
Mendelian and in which mutual SSPI has been well documented (Blake et al., 2004).  
 
 
5.2 Congenicity and Genetic Polymorphism between Cloned lines of 
Plasmodium yoelii yoelii 17X 
 
In Chapter 3, experiments were described in which a comparative genetic analysis 
was made between cloned lines of Plasmodium yoelii yoelii that differed in growth 
rate and were derived from a single isolate designated 17X. The results indicate that 
there are two completely different genotypes among lines of P. y. yoelii 17X. Within 
these two genotypes, genotype-1 is represented by parasites with a slow growth rate 
phenotype, e.g. 17XA. The other genotype, genotype-2, is represented by parasites 
with either a slow growth rate phenotype, e.g. 17XNIMR, or a fast growth rate 
phenotype, e.g. 17XYM. This finding is consistent with results from previous 
studies, based upon nucleotide sequence analyses of the gene for MSP-1, that 
indicate that 17XA is completely genetically distinct from other lines of P. y. yoelii 
17X (Daly et al., 1992, Benjamin et al., 1999). 
 
It is noteworthy that only parasites of genotype-1 have only been found in isolate 
17X of P. y. yoelii maintained at Edinburgh only. By contrast, parasites of genotype-
2 have been present in all isolates of 17X worldwide. A likely explanation is that 
parasites of genotype-1 and genotype-2 are both common in isolate 17X, but 
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parasites of genotype-2 might be present at a much lower proportion than parasites of 
genotype-1. The main reason for this was that parasites of genotype-2, e.g. 17XA, 
were derived after selection for resistance to the anti-malarial drug pyrimethamine 
(Walliker et al., 1971; Walliker et al., 1973), while parasites of genotype 1 were 
obtained by cloning out directly from the isolate 17X of P. y. yoelii (Yoeli et al., 
1975; Burns et al., 1989; Carlton et al., 2002; Walliker D., unpublished data). This is 
supported by the finding that parasites of genotype-1 were shown to be sensitive to 
pyrimethamine (Yoelii et al., 1975; Walliker et al., 1976). A possibility that 17XA 
(genotype-2) were derived from a cross-contamination or mislabelling can, 
nevertheless, not be entirely ruled out unless parasites of the normal isolate 17X are 
subjected to pyrimethamine drug selection and are characterised for the presence of 
genotype-2 in the drug-selected parasite population. Should genotype-2 parasites be 
detected in the pyrimethamine-selected population, this would suggest the co-
existence of parasites of genotype-1 and 2 in the original isolate 17X.  
 
The presence of two genotypes within the P. y. yoelii strain 17X has an important 
implication for studies of the genetic basis of growth rate in this malaria parasite. The 
discovery of a slow-growing line 17X, e.g. 17XNIMR, congenic to the fast-growing 
line 17XYM can be useful in determining candidate genes underlying growth rate 
differences in these malaria parasites since the fast-growing line 17XYM arose 
suddenly during blood infection with a slow-growing strain of P. y. yoelii 17X (Yoeli 
et al., 1975), probably due to a single mutation (Walliker et al., 1976). A whole 
genome sequencing approach could lead to discovery of all polymorphic genes 
between the fast and slow congenic parasite lines. Nevertheless, we were able to 
conduct LGS analysis of growth rate in the cross between two genetically unrelated 
parasites that differed in growth rate, to narrow regions of the parasite’s genome to 
be sequenced. In the present work, we have performed LGS analysis of growth rate 
between 17XC and 33XYM and identified that a region on P. y. yoelii chromosome 
13 contain a major candidate gene(s) controlling growth rate in this malaria parasite. 
From this information, we will only need to sequence the chromosome 13 between 
17XYM and 17XNIMR to obtain all candidate genes controlling growth rate.  
Subsequently, transfection systems can be used to test the involvement of candidate 
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genes in growth rate control and these are now available in P. y. yoelii (Jongco et al., 
2006). These approaches should allow us to identify the gene, or genes, that 
determine growth rate in the linkage group under strong growth selection on P. y. 
yoelii chromosome 13.  
     
5.3 Linkage Group Selection analysis of Growth Rate 
  
As described in Chapter 4, LGS analysis of growth rate was conducted with a genetic 
cross between a fast-growing line, 17XYM, and a genetically unrelated, slow-
growing line, 33XC, of Plasmodium yoelii yoelii. A major unexpected result was the 
finding that it was not possible to identify a typical selection valley in any of the 
chromosomes of this parasite. Rather, strong growth selection acted on a group of 
genetically linked markers that were mapped across a 1-megabase pair (Mb) region 
on P. y. yoelii chromosome 13, i.e. about a half of the estimated size of the 
chromosome. This implies that a major genetic determinant, or genetic determinants, 
of growth rate in this parasite was mapped onto a single large non-recombined 
section of P. y. yoelii chromosome 13. This finding is consistent with the result of the 
classical genetic study by Walliker et al., (1976), which indicates that growth rate in 
this parasite is conferred by a single genetic locus.  
 
Currently, there is an ongoing project in our laboratory using the LGS approach to 
identify genes controlling differences in growth rate in another rodent malaria 
species, Plasmodium chabaudi adami (Gadsby N. J. and Carter R., personal 
communication). The study conducted on a genetic cross between a fast-growing line 
(DS) and a slow-growing line (DK) of P. c. adami has also identified a large non-
recombined region of more than half a megabase pair, which is under strong growth 
selection. Evidence from these two independent LGS studies indicates, therefore, that 
large genomic regions inherited in these parasites, each as a single non-recombined 
genetic locus, are under growth selection pressure and contain a genetic 
determinant(s) of blood stage growth rate. 
 
There are two possible explanations for these observations. First, it could be that this 
region contains a group of genes that are functionally linked in determining growth 
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rate such that this entire linkage group must be inherited as a non-recombined genetic 
unit in order to confer fast or slow growth rate upon the parasites. Alternatively, it 
may be that alleles of genes of the two parental clones within this region of P. y. 
yoelii chromosome 13 cannot recombine with each other for structural chromosomal 
reasons.  
 
In order to test these hypotheses, the progeny of a genetic cross between slow- and 
fast-growing lines would have to be cloned out before the growth selection had taken 
place in the mice. This would allow us to obtain slow-growing cloned progeny of the 
genetic cross, which would otherwise be eliminated by growth selection pressure. 
Then, such fast- and slow-growing cloned progeny would need to be characterised 
for their haplotypes within the linkage group on P. y. yoelii chromosome 13 which is 
selected by growth selection. If these clones, derived before growth selection, 
possess the alleles of both parents within the linkage group on chromosome 13 under 
growth selection, then this would indicate that genetic recombination can occur 
within this region. In this case, the reason why, in the growth rate selected cross 
progeny, this linkage group on chromosome 13 appears not to recombine must have 
been due to its selection as an unrecombined unit by the growth selection pressure. 
However, if, in the clones derived before the selection, alleles only from one or the 
other parental type are present in this region, then this would indicate that 
recombination within this linkage group on chromosome 13 is not possible. Such 
investigation is now being performed in our laboratory. 
 
At present, there are genetically distinct strains of the malaria parasites of rodent and 
human which have marked differences in blood stage growth rate and their 
underlying genetic determinants are not yet identified. For instance, P. c. chabaudi 
strain AS produces a very mild infection compared to P. c. chabaudi strain ER, 
which achieves higher peak parasitaemias and causes more severe pathology to the 
host (Cheesman S. and Carter R., unpublished data). Likewise, the P. falciparum 
strain Dd2 has a shorter ring stage, generates more merozoites per schizont, invades 
new RBCs at a higher rate and, hence, has a faster growth rate than HB3 strain 
(Reilly et al., 2007). Since genetic crosses have been made between these lines 
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(Wellems et al., 1990; Wellems et al., 1991), the high-throughput methods for 
genotyping (Grech et al., 2002; Martinelli et al., 2004; Su et al., 2007) and the 
complete genome sequence data are available (Gardner et al., 2002 and Hall et al., 
2005), it will be relatively simple to apply LGS to investigate genetic basis of growth 
rate in this malaria parasite. Together with the findings of the present work, the 
information on genes controlling growth rate will be relevant to our understanding of 
pathogenicity of a malarial infection.  
    
5.4 Limitations of LGS  
 
Our present results demonstrate the success of LGS in the location of genes that are 
responsible for two major selectable phenotypes, SSPI and blood stage growth rate, 
of malaria parasites. There are, nevertheless some limitations concerning the 
application of LGS in the present study. For example, LGS analysis of SSPI could 
not be used to determine whether clonal antigenic variation in the expression of the 
proteins expressed on the infected erythrocyte surface accounts for the differences 
between two parasite lines that appeared to show strong SSPI (see Discussion in 
Chapter 2). Furthermore, in LGS analysis of growth rate, LGS could fail to 
determine whether the difference expression levels of specific members of a 
multigene family are associated with the differences between two parental lines used 
in generating a genetic cross (see Discussion in Chapter 4). However, where 










5.5 Executive summary 
 
The principle findings of the present genetic studies are as follows: 
 
1. SSPI in Plasmodium chabaudi chabaudi in mice is mainly determined by a 120-kb 
region on chromosome 8 containing the gene for Merozoite Surface Protein-1.    
 
2. Lines of Plasmodium yoelii yoelii strain 17X consist of two completely distinct 
genotypes. One of these genotypes, genotype-1, is represented by a slow-growing 
line 17XNIMR and a fast-growing line 17XYM. Within genotype-1 there are, 
however, a small number of genomic differences between lines with slow and fast 
growth rate. The other, genotype-2, is represented by a slow-growing line 17XA.   
 
3. The fast blood stage growth rate phenotype in Plasmodium yoelii yoelii is mainly 
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 173Appendix 1 
 
Table S1. The Relative Intensity Indices of the 197 AFLP markers of strain AJ of Plasmodium 
chabaudi chabaudi of the AJ x CB cross progeny grown in an AJ-immunise mouse and a non-
immune batch mate and their Comparative Intensities. AFLP markers were named as previously 
described in Figure 2.1 (Chapter 2). 92 AJ markers identified in the present study had positions 
corresponding to those of AFLP markers, which differentiated AJ from AS, on the P. c. chabaudi 
genetic linkage map (Martinelli et al., 2005b). 24 AJ AFLP markers that had CIs of below 50% were 
considered to be under SSPI selection, as shown in pink background. Calculations of the RII and CI 
were done, as described in Materials and Methods in Chapter 2 (section 2.3.6).   
 
Name of AJ   Corresponding       Comparative 
AFLP markers AJ markers on the Relative Intensity Index Intensity 
identified in the the P. c. chabaudi       (%) 
AJ x CB genetic AS x AJ genetic linkage  Non-immune AJ-immune   
cross map (Martinelli et al. 2005b) selected progeny selected progeny   
AJ AA 01 AA CB  0.941 0.486 51.619 
AJ AA 02 AA CB   0.917 0.736 80.180 
AJ AA 03 AA CB  0.955 0.828 86.743 
AJ AA 01 AC CB AJ AA 02 AC  0.890 0.450 50.562 
AJ AA 02 AC CB  0.740 0.380 51.351 
AJ AA 01 AG CB AJ AA 01 AG  1.000 0.690 69.000 
AJ AA 01 AT CB  0.700 0.440 62.857 
AJ AA 02 AT CB AJ AA 02 AT  0.860 0.500 58.140 
AJ AA 03 AT CB  0.840 0.600 71.429 
AJ AA 01 TA CB  0.910 0.700 76.923 
AJ AA 02 TA CB AJ AA 01 TA  1.070 0.640 59.813 
AJ AA 03 TA CB AJ AA 02 TA  1.331 0.699 52.486 
AJ AA 01 TC CB  0.790 0.540 68.354 
AJ AA 02 TC CB AJ AA 01 TC  0.880 0.460 52.273 
AJ AA 03 TC CB AJ AA 02 TC  0.620 0.350 56.452 
AJ AA 01 TG CB AJ AA 01 TG  0.970 0.740 76.289 
AJ AA 02 TGCB  0.840 0.420 50.000 
AJ AA 01 TT CB AJ AA 02 TT  0.708 0.612 86.495 
AJ AA 03 TT CB AJ AA 02 TT  0.818 0.499 61.757 
AJ AA 01 CA CB AJ AA 01 CA  0.589 1.066  180.952 
AJ AA 02 CA CB  0.473 0.764  161.538 
AJ AA 03 CA CB AJ AA 02 CA  0.937 1.266  135.135 
AJ AA 01 CT CB  1.758 0.909 51.706 
AJ AA 02 CT CB AJ AA 01 CT  0.725 1.375 89.655 
AJ AA 01 GA CB AJ AA 01 GA  0.576 0.315 54.733 
AJ AA 01 GT CB  0.794 0.427 53.833 
AJ AC 02 AA CB AJ AC 02 AA  0.941 0.486 51.619 
AJ AC 01 AC CB  0.917 0.736 80.180 
AJ AC 02 AC CB  0.955 0.828 86.743 
AJ AC 01 AG CB  0.890 0.450 50.562 
AJ AC 02 AG CB AJ AC 01 AG  0.740 0.380 51.351 
AJ AC 03 AG CB  1.000 0.690 69.000 
AJ AC 01 AT CB AJ AC 01 AT  0.700 0.440 62.857 
AJ AC 02 AT CB  0.860 0.500 58.140 
AJ AC 03 AT CB  0.840 0.600 71.429 
AJ AC 01 TA CB AJ AC 01 TA  0.910 0.700 76.923 
AJ AC 02 TA CB  1.070 0.640 59.813 




Name of AJ   Corresponding       Comparative  
AFLP markers AJ markers on the Relative Intensity Index Intensity 
identified in the P. c. chabaudi        (%) 
AJ x CB genetic genetic linkage  Non-immune AJ-immune   
cross map (Martinelli et al. 2005b) selected progeny selected progeny   
AJ AC 01 TT CB AJ AC 01 TT  0.966 0.652 67.442 
AJ AC 02 TT CB  1.171 0.641 54.745 
AJ AC 03 TT CB AJ AC 02 TT  1.020 0.740 72.549 
AJ AC 04 TT CB  0.830 0.630 75.904 
AJ AC 05 TT CB  0.780 0.580 74.359 
AJ AC 01 CA CB  0.910 0.470 51.648 
AJ AC 02 CA CB AJ AC 01 CA  0.820 0.430 52.439 
AJ AC 01 CT CB AJ AC 01 CT  0.720 0.229 31.801 
AJ AC 01 GA CB  0.740 0.380 51.351 
     
AJ AG 01 AA CB  0.600 0.600 100.000 
AJ AG 02 AA CB AJ AG 01 AA  0.770 0.830 107.792 
AJ AG 01 AC CB AJ AG 02 AC  0.650 0.330 50.769 
AJ AG 02 AC CB AJ AG 03 AC  1.020 0.530 51.961 
AJ AG 01 AG CB AJ AG 01 AG  0.840 0.540 64.286 
AJ AG 02 AG CB  0.650 0.177 27.231 
AJ AG 03 AG CB  0.610 0.350 57.377 
AJ AG 04 AG CB AJ AG 04 AG  0.720 0.430 59.722 
AJ AG 05 AG CB AJ AG 05 AG  0.860 0.010 1.513 
AJ AG 06 AG CB  0.450 0.240 53.333 
AJ AG 01 AT CB  0.700 0.360 51.429 
AJ AG 02 AT CB AJ AG 02 AT  0.670 0.350 52.239 
AJ AG 03 AT CB AJ AG 03 AT  0.800 0.450 56.250 
AJ AG 04 AT CB  0.820 0.410 50.000 
AJ AG 05 AT CB  0.750 0.410 54.667 
AJ AG 06 AT CB  0.760 0.450 59.211 
AJ AG 01 TA CB AJ AG 02 TA  0.750 0.300 40.000 
AJ AG 01 TC CB AJ AG 01 TC  0.810 0.210 25.926 
AJ AG 01 TG CB AJ AG 01 TG  0.620 0.440 70.968 
AJ AG 01 CA CB AJ AG 01 CA  0.713 0.311 43.548 
AJ AG 02 CA CB  0.600 1.100 183.333 
AJ AG 01 CT CB AJ AG 01 CT  0.410 0.250 60.976 
AJ AG 01 GT CB  0.820 0.760 92.683 
AJ AG 02 GT CB AJ AG 01 GT  0.979 0.495 50.520 
     
AJ AT 01 AA CB AJ AT 01 AA  0.890 0.920 103.371 
AJ AT 02 AA CB  0.732 0.470 64.208 
AJ AT 03 AA CB AJ AT 02 AA  0.730 0.740 101.370 
AJ AT 04 AA CB  0.900 0.850 94.444 
AJ AT 05 AA CB  0.747 0.813 108.929 
AJ AT 01 AC CB AJ AT 01 AC  0.790 0.520 65.823 
AJ AT 02 AC CB AJ AT 03 AC  1.000 0.660 66.000 
AJ AT 01 AG CB  0.860 0.090 10.465 
AJ AT 02 AG CB  0.645 0.330 51.163 
AJ AT 03 AG CB  1.010 0.480 47.525 
AJ AT 04 AG CB  0.700 0.450 64.286 
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Name of AJ   Corresponding       Comparative  
AFLP markers AJ markers on the Relative Intensity Index    Intensity 
identified in the P. c. chabaudi       (%)  
AJ x CB genetic genetic linkage  Non-immune AJ-immune   
cross map (Martinelli et al. 2005b) selected progeny      selected progeny  
AJ AT 01 AT CB AJ AT 02 AT  0.790 0.400 50.633 
AJ AT 02 AT CB  1.040 0.970 93.269 
AJ AT 01 TA CB  0.790 0.680 86.076 
 AJ AT 02 TA CB  0.930 0.600 64.516 
AJ AT 03 TA CB AJ AT 04 TA  0.806 0.183 22.705 
AJ AT 01 TC CB AJ AT 02 TC  0.690 0.270 39.130 
AJ AT 01 TG CB AJ AT 01 TG  1.402 0.856 61.081 
AJ AT 02 TG CB AJ AT 02 TG  0.773 0.536 69.284 
AJ AT 03 TG CB  0.750 0.660 88.000 
AJ AT 01 TT CB AJ AT 01 TT  0.930 0.850 91.398 
AJ AT 02 TT CB AJ AT 03 TT  1.120 0.249 22.232 
AJ AT 01 CA CB AJ AT 01 CA  0.780 0.510 65.385 
AJ AT 02 CA CB AJ AT 02 CA  0.843 0.504 59.813 
AJ AT 03 CA CB  1.077 1.431 132.857 
AJ AT 01 CT CB AJ AT 03 CT  0.990 0.840 84.848 
AJ AT 03 CT CB  0.880 0.580 65.909 
AJ AT 01 GA CB  0.870 0.610 70.115 
AJ AT 02 GA CB AJ AT 02 GA  0.670 0.400 59.701 
AJ AT 01 GT CB AJ AT 01 GT  1.274 0.363 28.495 
AJ AT 02 GT CB  0.720 0.540 75.000 
 
     
AJ TA 01 AC CB AJ TA 01 AC  0.790 0.520 65.823 
AJ TA 02 AC CB AJ TA 03 AC  0.760 0.430 56.579 
AJ TA 01 AG CB AJ TA 01 AG  0.700 0.660 94.286 
AJ TA 01 AT CB AJ TA 01 AT  0.579 0.319 55.152 
AJ TA 02 AT CB AJ TA 02 AT  0.619 0.359 57.906 
AJ TA 03 AT CB  0.419 0.291 69.388 
AJ TA 04 AT CB AJ TA 04 AT   0.946 0.190 20.198 
AJ TA 05 AT CB  0.872 0.508 58.256 
AJ TA 01 TA CB  0.944 0.500 52.941 
AJ TA 02 TA CB AJ TA 01 TA  0.815 0.543 66.667 
AJ TA 03 TA CB  0.983 1.069 108.772 
AJ TA 04 TA CB  1.017 0.826 81.301 
AJ TA 05 TA CB  0.690 0.490 71.020 
AJ TA 06 TA CB AJ TA 02 TA  1.070 0.250 23.366 
AJ TA 07 TA CB AJ TA 03 TA  0.970 0.058 6.016 
AJ TA 01 TC CB AJ TA 01 TC  1.030 1.030 100.000 
AJ TA 01 TG CB  0.830 0.480 57.831 
AJ TA 02 TG CB  0.760 0.590 77.632 
AJ TA 01 TT CB  1.022 0.826 80.851 
AJ TA 02 TT CB  1.262 0.839 66.488 
AJ TA 03 TT CB AJ TA 01 TT  0.505 0.402 79.612 
AJ TA 01 CT CB  0.780 0.470 60.256 
AJ TA 01 GA CB  1.040 0.530 50.962 
AJ TA 02 GA CB  0.840 0.660 78.571 
AJ TA 03 GA CB  1.330 1.330 100.000 
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Name of AJ   Corresponding       Comparative  
AFLP markers AJ markers on the Relative Intensity Index Intensity 
identified in the P. c. chabaudi       (%)  
AJ x CB genetic genetic linkage  Non-immune AJ-immune   
cross map (Martinelli et al. 2005b) selected progeny selected progeny   
AJ TC 01 AA CB  0.179 0.175 97.765 
AJ TC 02 AA CB  0.780 0.540 69.231 
AJ TC 03 AA CB  1.050 0.540 51.429 
AJ TC 01 AG CB  1.060 0.600 56.604 
AJ TC 02 AG CB  1.400 0.900 64.286 
AJ TC 01 AT CB AJ TC 01 AT  1.050 0.600 57.143 
AJ TC 02 AT CB  0.760 0.530 69.737 
AJ TC 03 AT CB  0.820 0.760 92.683 
AJ TC 04 AT CB  0.940 0.580 61.702 
AJ TC 01 TA CB AJ TC 02 TA  0.770 0.400 51.948 
AJ TC 01 TG CB AJ TC 01 TG  0.590 0.009 1.525 
AJ TC 01 CA CB  1.290 1.030 79.845 
AJ TC 02 CA CB  0.900 0.640 71.111 
AJ TC 03 CA CB  1.320 1.170 88.636 
AJ TC 04 CA CB  1.080 0.920 85.185 
AJ TC 01 CT CB  0.670 0.340 50.746 
AJ TC 01 GT CB AJ TC 01 GT  0.740 0.650 87.838 
AJ TC 02 GT CB  0.810 0.550 67.901 
     
AJ TG 01 AA CB AJ TG 01 AA  1.580 0.810 51.266 
AJ TG 02 AA CB  1.460 0.930 63.699 
AJ TG 03 AA CB AJ TG 03 AA  1.150 0.250 21.739 
AJ TG 04 AA CB  1.200 1.020 85.000 
AJ TG 05 AA CB  0.550 0.430 78.182 
AJ TG 06 AA CB  0.710 0.380 53.521 
AJ TG 01 AT CB AJ TG 02 AT  1.280 0.270 21.094 
AJ TG 02 AT CB AJ TG 03 AT  0.780 0.270 34.615 
AJ TG 03 AT CB  0.750 0.590 78.667 
AJ TG 04 AT CB  0.800 0.800 100.000 
AJ TG 05 AT CB  0.940 0.880 93.617 
AJ TG 06 AT CB  0.770 0.480 62.338 
AJ TG 07 AT CB  0.700 0.460 65.714 
AJ TG 01 TC CB AJ TG 01 TC  0.616 0.179 29.032 
AJ TG 01 CT CB AJ TG 01 CT  0.676 0.454 67.172 
AJ TG 02 CT CB  2.456 1.463 59.561 
AJ TG 03 CT CB AJ TG 02 CT  0.985 0.634 64.376 
AJ TG 01 GT CB  0.670 0.370 55.224 
AJ TG 02 GT CB AJ TG 01 GT  0.890 0.780 87.640 
AJ TT 01 AA CB  1.220 0.700 57.377 
AJ TT 02 AA CB AJ TT 01 AA  0.760 0.600 78.947 
AJ TT 03 AA CB AJ TT 02 AA  0.600 0.390 65.000 
AJ TT 04 AA CB AJ TT 03 AA  1.022 0.760 74.364 
AJ TT 05 AA CB  0.617 0.530 85.900 
AJ TT 06 AA CB  0.880 0.650 73.864 
AJ TT 07 AA CB  0.786 0.650 82.697 
AJ TT 08 AA CB  1.090 0.610 55.963 
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Name of AJ   Corresponding       Comparative  
AFLP markers AJ markers on the Relative Intensity Index Intensity 
 identified in the P. c. chabaudi    (%)  
AJ x CB genetic genetic linkage  Non-immune AJ-immune   
cross map (Martinelli et al. 2005b) selected progeny selected progeny   
AJ TT 01 AC CB  0.790 0.870 110.127 
AJ TT 02 AC CB AJ TT 01 AC  0.760 0.440 57.895 
AJ TT 01 AT CB  0.850 0.910 107.059 
AJ TT 02 AT CB             0.850                          0.550  64.706 
AJ TT 03 AT CB AJ TT 02 AT  0.979 0.119 12.155 
AJ TT 04 AT CB  1.080 0.640 59.259 
AJ TT 05 AT CB  1.180 1.150 97.458 
AJ TT 01 TA CB  0.849 0.580 68.316 
AJ TT 02 TA CB  0.690 0.660 95.652 
AJ TT 03 TA CB AJ TT 02 TA  0.770 0.660 85.714 
AJ TT 01 TC CB AJ TT 02 TC  1.090 0.293 26.881 
AJ TT 01 TG CB AJ TT 02 TG  0.940 0.850 90.426 
AJ TT 02 TG CB AJ TT 03 TG  1.000 0.271 27.083 
AJ TT 01 TT CB  0.920 0.480 52.174 
AJ TT 02 TT CB AJ TT 02 TT  1.070 0.570 53.271 
AJ TT 01 CA CB AJ TT 01 CA  1.060 0.880 83.019 
AJ TT 02 CA CB AJ TT 02 CA  0.840 0.470 55.952 
AJ TT 01 CT CB  1.150 0.730 63.478 
AJ TT 02 CT CB AJ TT 02 CT  1.440 0.849 58.958 
AJ TT 03 CT CB  0.720 0.430 59.722 
AJ TT 04 CT CB AJ TT 03 CT  0.730 0.370 50.685 
AJ TT 01 GA CB  3.140 1.660 52.866 
AJ GT 01 TA CB AJ GT 01 TA  0.535 0.606 113.158 
AJ GT 02 TA CB AJ GT 02 TA  0.455 0.060 13.187 






Table S2.1 The number of parasite clone-specific bands (AFLP markers) differentiating 
17XA from 17XYM of the rodent malaria parasite Plasmodium yoelii yoelii generated by 65 
combinations of selective EcoRI and MseI AFLP primers (Grech et al., 2002). Subtotals of 
the numbers of AFLP markers are shown for each pair of the specific EcoRI and MseI PCR 
selective primers together with the grand total number of AFLP markers for each cloned line. 



























Table S2.2 The number of parasite clone-specific bands (AFLP markers) differentiating 
17XYM from 17XA of the rodent malaria parasite Plasmodium yoelii yoelii generated by 65 
combinations of selective EcoRI and MseI AFLP primers (Grech et al., 2002). Subtotals of 
the numbers of AFLP markers are shown for each pair of the specific EcoRI and MseI PCR 
selective primers together with the grand total number of AFLP markers for each cloned line. 






Table S2.3 The number of parasite clone-specific bands (AFLP markers) differentiating 
17XA from 17XNIMR of the rodent malaria parasite Plasmodium yoelii yoelii generated by 
65 combinations of selective EcoRI and MseI AFLP primers (Grech et al., 2002). Subtotals 
of the numbers of AFLP markers are shown for each pair of the specific EcoRI and MseI PCR 
selective primers together with the grand total number of AFLP markers for each cloned line. 



















































Table S2.4. The number of parasite clone-specific bands (AFLP markers) differentiating 
17XNIMR from 17XA of the rodent malaria parasite Plasmodium yoelii yoelii generated by 
65 combinations of selective EcoRI and MseI AFLP primers (Grech et al., 2002). Subtotals 
of the numbers of AFLP markers are shown for each pair of the specific EcoRI and MseI PCR 
selective primers together with the grand total number of AFLP markers for each cloned line. 




















































Table S2.5. The number of parasite clone-specific bands (AFLP markers) differentiating 
17XYM from 17XNIMR of rodent malaria parasite Plasmodium yoelii yoelii generated by 
65 combinations of selective EcoRI and MseI AFLP primers (Grech et al., 2002). No AFLP 
























































Table S2.6. The number of parasite clone-specific bands (AFLP markers) differentiating 
17XNIMR from 17XYM of rodent malaria parasite Plasmodium yoelii yoelii generated by 
65 combinations of selective EcoRI and MseI AFLP primers (Grech et al., 2002). Subtotals 
of the numbers of AFLP markers are shown for each pair of the specific EcoRI and MseI PCR 
selective primers together with the grand total number of AFLP markers for each cloned line. 







































 Appendix 3  
 
Table S3. The Relative Intensity Indices (RIIs) of the 108 AFLP markers of Plasmodium 
yoelii yoelii cloned line 33XC in relation to cloned line 17XYM obtained from parasite DNA 
of the uncloned progeny of the two genetic crosses between 17XYM and 33XC in three 
successive passages. AFLP markers were named as follows (Grech et al., 2002). The first letters 
‘33XC’ indicate the clone of P. y. yoelii in which the AFLP band is present. The last letters 
‘17XYM’ indicate the clone of P. y. yoelii in which the AFLP band is absent. The second two 
letters (i.e. AA, AG) correspond to the selective bases in the EcoRI AFLP selective primers. The 
numbers in the middle identify the size of the band relative to other polymorphic bands in the 
same lane. The numbers are increased in the decreasing size. The following two letters 
correspond to the selective bases used in the MseI AFLP selective primers (Grech et al., 2002). 
Five of the 108 33XC AFLP markers were consistently and strongly reduced in intensity 
following growth selection, as indicated in pink background. Calculations of the RIIs were 
performed, as described in Materials and Methods.  
 
 




  RIIs of 33XC markers of the growth rate selected  RIIs of 33XC markers of the growth rate selected 
  progeny of the first genetic cross  progeny of the second genetic cross 
                  
  Marker name  the 1st passage  the 2nd passage  the 3rd passage   the 1st passage  the 2nd passage the 3rd passage 
1 33XC AA 01 AC 17XYM 0.295434925 0.47847385 0.232443509   0.599105315   0.564342244 0.546446374
2 33XC AA 01 TA 17XYM 0.312272248 0.19640257 0.17557996   0.498160389   0.403175736 0.391998188
3 33XC AA 02 TA 17XYM 0.884420331 0.74046781 0.765556469   0.489140513   0.676219429 0.599033939
4 33XC AA 01 TG 17XYM 0.436696876 0.41204717 0.315470266   0.265476283   0.227795479 0.235638853
5 33XC AA 01 GA 17XYM 0.38566183 0.34493504 0.283288919   0.5285334   0.400873304 0.307254402
6 33XC AA 01 GT 17XYM 0.749726446 0.40709072 0.260274123   0.592531101   0.557326194 0.504605992
7 33XC AA 01 CT 17XYM 0.541581602 0.481811676 0.285606969   0.427946034   0.457548264 0.375347564
8 33XC AA 02 CT 17XYM 0.672092261 0.806467891 0.671533542   0.760906893   0.624775477 0.542046557
9 33XC AC 01 AG 17XYM 0.664423174 0.693721017 0.612728128   0.602324063   0.621071377 0.712015122
10 33XC AC 01 AT 17XYM 0.612050266 0.591197313 0.450740947   0.269833625   0.31870032 0.473319654
11 33XC AC 01 TA 17XYM 0.147733607 0.133726276 0.129590811   0.564358282   0.586879203 0.455193495
12 33XC AC 02 TA 17XYM 0.938543406 0.887003672 0.800476144   0.519736469   0.478354337 0.408469036
13 33XC AC 04 TA 17XYM 0.835698116 0.695843431 0.611111422   0.547597714   0.481409128 0.499831106
14 33XC AC 01 CA 17XYM 0.756890577 0.660314044 0.60074651   0.581857749   0.61967758 0.574136706
15 33XC AC 01 GA 17XYM 1.242250885 0.97959603 1.248866234   0.353685777   0.42940646 0.505240955
16 33XC AC 02 GA 17XYM 1.080050259 0.872527374 1.010426474   0.453172281   0.50057966 0.578584093
17 33XC AG 01 AA 17XYM 0.585626 0.553178 0.765408   0.373034234   0.39006597 0.524492172
18 33XC AG 01 AC 17XYM 0.848289 0.957341 0.923375   0.681963461   0.53803381 0.391529736
19 33XC AG 01 AG 17XYM 0.073746 0.066953 0.06465   0.096490145 0.076961342 0.038234506 
20 33XC AG 01 TT 17XYM 0.861749 1.120956 0.879934   0.89134788   0.71016381 0.737286105
21 33XC AG 02 TT 17XYM 0.652961 0.813365 0.629911   0.748391245   0.67374435 0.577639419
22 33XC AG 03 TT 17XYM 0.772854 0.732723 0.898194   0.389838331   0.29952681 0.286011008
23 33XC AG 01 TA 17XYM 0.1041225 0.05612534 0.04525252   0.102599196 0.06680967 0.08926207 
24 33XC AT 01 AA 17XYM 0.210952 0.19584 0.180646   0.645354701   0.626968992 0.475318255
25 33XC AT 01 AC 17XYM 0.341526 0.394581 0.475094   0.417408187   
   
0.421457491 0.342400392
       





   RIIs of 33XC markers of the growth rate selected  RIIs of 33XC markers of the growth rate selected 
  progeny of the first genetic cross  progeny of the second genetic cross 
            
  Marker name  the 1st passage  the 2nd passage  the 3rd passage   the 1st passage  the 2nd passage the 3rd passage 
26 33XC AT 02 AC 17XYM 0.694807 0.719761 0.66969   0.562560924   0.497555042 0.349438092
27 33XC AT 01 TT 17XYM 0.789647 0.75634 0.907525   0.578266401   0.569191449 0.559241204
28 33XC AT 02 TT 17XYM 0.469553 0.387864 0.392147   0.302598359   0.291722003 0.29746128
29 33XC AT 01 GT 17XYM 0.404256 0.54969 0.558608   0.445485804   0.406723976 0.377766707
30 33XC AT 02 GT 17XYM 0.403647 0.276431 0.249699   0.591385375   0.657458535 0.506014505
31 33XC AT 03 GT 17XYM 0.374208 0.335887 0.476909   0.716297918   0.753220172 0.592751318
32 33XC TA 01 AC 17XYM 0.463158842 0.526202217 0.639659121   0.482022179   0.43415725 0.438869338
33 33XC TA 01 TA 17XYM 0.905203234 0.85570362 0.908410382   0.490283484   0.52911913 0.477206215
34 33XC TA 01 TC 17XYM 0.685044442 0.693513342 0.563770488   0.624939826   0.53959334 0.605121974
35 33XC TA 01 TG 17XYM 0.415790022 0.369791861 0.343064098   0.684228156   0.76769665 0.498583158
36 33XC TA 02 TG 17XYM 0.264865565 0.234979505 0.299556279   0.626165937   0.72004058 0.561956319
37 33XC TA 02 CA 17XYM 0.354095568 0.246297983 0.156877113   0.666726616   0.743177089 0.718541546
38 33XC TA 03 CA 17XYM 0.766752239 0.648425594 0.682207699   0.460401287   0.562379171 0.625383396
39 33XC TA 01 GA 17XYM 0.976089793 1.202508549 1.117296081   0.925933688   0.735666737 0.831056485
40 33XC TA 02 GA 17XYM 0.436863924 0.585463502 0.574954692   0.610948873   0.666208609 0.815763458
41 33XC TA 01 GT 17XYM 0.358540913 0.199420367 0.171928441   0.306032944   0.238596739 0.20933619
42 33XC TA 02 GT 17XYM 0.421734126 0.416752938 0.419222704   0.511196505   0.53562992 0.583772289
43 33XC TA 03 GT 17XYM 0.674439052 0.470690892 0.460230012   0.289828323   0.282870109 0.366099033
44 33XC TC 01 CA 17XYM 0.680970861 0.533626269 0.441328594   0.484071607   0.453595725 0.550206728
45 33XC TC 01 CT 17XYM 0.960828714 1.002441505 0.907118195   0.846010446   0.726945015 0.84218504
46 33XC TC 01 TT 17XYM 0.713736012 0.81469639 0.768405145   0.493713896   0.464952676 0.547478082
47 33XC TC 02 TT 17XYM 0.760495627 0.8616995 0.891704523   0.513129917   0.57459051 0.596000312
48 33XC TC 03 TT 17XYM 0.654911516 0.730929306 0.649783497   0.491883854   0.494950007 0.513156286
49 33XC TG 01 AA 17XYM 0.685874112 0.454111078 0.641131935   0.542046   0.553651 0.404132
50 33XC TG 02 AA 17XYM 0.669118039 0.561612064 0.907664021   0.444775   
     
0.408136 0.373513
     








   RIIs of 33XC markers of the growth rate selected  RIIs of 33XC markers of the growth rate selected 
  progeny of the first genetic cross  progeny of the second genetic cross 
            
  Marker name  the 1st passage  the 2nd passage  the 3rd passage    the 1st passage  the 2nd passage the 3rd passage 
51 33XC TG 01 AT 17XYM 0.591653836 0.506506762 0.344320436   0.331760998   0.355838001 0.373880712
52 33XC TG 02 AT 17XYM 0.63166513 0.51986367 0.725296011   0.268760091   0.302913066 0.331906224
53 33XC TG 03 AT 17XYM 0.485798266 0.399323358 0.541330756   0.347491607   0.295881106 0.431063759
54 33XC TG 04 AT 17XYM 0.527004623 0.34820648 0.377933845   0.378662387   0.452880304 0.549306948
55 33XC TG 01 TT 17XYM 0.819234085 0.859539844 0.414300743   0.564123   0.54378 0.491351
56 33XC TG 01 CT 17XYM 0.586227145 0.507273011 0.81017762   0.736612   0.751917 0.673346
57 33XC TT 01 AA 17XYM 0.563348351 0.491815623 0.579242134   0.351914391   0.315871372 0.282664566
58 33XC TT 01 AG 17XYM 0.511289866 0.552028936 0.391839378   0.222722504   0.227237049 0.288440415
59 33XC TT 01 TA 17XYM 0.214785423 0.161139868 0.132651745   0.512461161   0.452612863 0.557048214
60 33XC TT 01 TT 17XYM 0.869822485 0.978295668 0.691790606   0.36452747   0.571731789 0.854574176
61 33XC TT 01 CT 17XYM 0.429276171 0.274341351 0.243654387   0.364521069   0.259444869 0.330266288
62 33XC TT 02 CT 17XYM 0.308559822 0.296694631 0.284861888   0.43576148   0.282326367 0.42276297
63 33XC CA 01 TC 17XYM 0.977630137 0.777167539 0.855887798   0.497339   0.474408 0.614526
64 33XC CA 01 TT 17XYM 0.414696529 0.635296601 0.567245204   0.282153182   0.298756055 0.326381723
65 33XC CA 02 TT 17XYM 0.640007723 0.724708839 0.58215214   0.503554504   0.538016186 0.525078377
66 33XC CA 03 TT 17XYM 0.724975072 0.663664212 0.697496118   0.533501734   0.509871123 0.413045069
67 33XC CA 04 TT 17XYM 0.684872629 0.721237408 0.521557113   0.461171697   0.435497005 0.488767443
68 33XC CA 05 TT 17XYM 0.007194894 0.001036464 0.003879107   0.044666553 0.061155652 0.033252342 
69 33XC CT 01 AT 17XYM 0.64195752 0.72011289 0.488115518   0.33442408   0.332133026 0.297841584
70 33XC CT 02 AT 17XYM 0.742926087 0.583617045 0.31890988   0.157731504   0.140800281 0.144455462
71 33XC CT 01 TA 17XYM 0.922438267 0.939232556 0.79066993   0.226447409   0.255040734 0.354416245
72 33XC CT 02 TA 17XYM 1.257104291 1.111488934 0.850330653   0.197733268   0.173613423 0.219760564
73 33XC CT 04 TA 17XYM 0.544284526 0.568478098 0.543150293   0.272574545   0.236101429 0.209635744
74 33XC CT 05 TA 17XYM 0.541747859 0.470357893 0.4772943   0.780058129   0.60619238 0.638794
75 33XC CT 01 TG 17XYM 0.381809991 0.431386053 0.3496277   0.440011122   
     
0.376686572 0.34858395
     
  
                (to be continued) 
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   RIIs of 33XC markers of the growth rate selected  
 
RIIs of 33XC markers of the growth rate selected 
  progeny of the first genetic cross  progeny of the second genetic cross 
           
  Marker name  the 1st passage  the 2nd passage  the 3rd passage   the 1st passage  the 2nd passage the 3rd passage 
76 33XC GA 01 AG 17XYM 0.232035828 0.290831949 0.343484412   0.568077355   0.525749915 0.512142338
77 33XC GA 02 AG 17XYM 0.66160615 0.637108623 0.714080897   0.558265184   0.511953395 0.609408875
78 33XC GA 03 AG 17XYM 0.245351161 0.350743801 0.334255937   0.2510511   0.205620774 0.311716516
79 33XC GA 01 TA 17XYM 0.432497472 0.344513369 0.34807883   0.415847   0.46497 0.465391
80 33XC GA 02 TA 17XYM 0.897929072 0.873430788 0.851980676   0.473479   0.494354 0.354886
81 33XC GA 03 TA 17XYM 1.0036122 0.869887591 1.136237076   0.760736034   0.740487945 0.692729985
82 33XC GA 01 TC 17XYM 0.632956807 0.678211569 0.592453033   0.47515   0.484336 0.487382
83 33XC GA 02 TC 17XYM 0.883258123 0.647600054 0.687287846   0.845098   0.823981 0.709666
84 33XC GA 01 TG 17XYM 1.177861787 0.661085636 0.886876412   0.570736   0.630009 0.522531
85 33XC GA 01 TT 17XYM 0.444776812 0.275508635 0.23807108   0.64959   0.645708 0.559742
86 33XC GT 01 AA 17XYM 0.526296127 0.422376426 0.408521001   0.534201343   0.470671995 0.452420757
87 33XC GT 02 AA 17XYM 0.545202618 0.496093424 0.422675807   0.537907433   0.54446494 0.533399465
88 33XC GT 03 AA 17XYM 0.474281496 0.596854797 0.59790204   0.564506465   0.515492789 0.34037125
89 33XC GT 01 AT 17XYM 0.760191778 0.80747966 0.743010406   0.577980139   0.687380476 0.66002888
90 33XC GT 02 AT 17XYM 0.719658154 0.701329705 0.717319775   0.56901366   0.572127793 0.569013275
91 33XC GT 01 TT 17XYM 0.54641755 0.598514784 0.666044366   0.676150208   0.666263665 0.749077598
92 33XC GT 02 TT 17XYM 0.070570447 0.037635575 0.027217906   0.314625621 0.314496936 0.209739016 
93 33XC GT 03 TT 17XYM 0.631882933 0.654663983 0.757957817   0.576390342   0.59649233 0.59545653
94 33XC GT 01 TG 17XYM 0.767947567 0.689259706 775089587   0.648131146   0.570187875 0.53399253
95 33XC GT 02 TG 17XYM 0.912000272 0.809782679 0.937755203   0.779790082   0.872338031 0.726466632
96 33XC GT 03 TG 17XYM 0.950253795 0.808049223 0.904729419   0.9207224   0.977335018 0.88046966
97 33XC AT 01 TG 17XYM 0.73924 0.533192 0.62309   0.307233979   0.234622668 0.243095278
98 33XC AT 01 CA 17XYM 0.747788 0.60341 0.557197   0.497588884   0.519522817 0.423208543
99 33XC AT 02 CA 17XYM 0.103179 0.826477 1.084847   0.473910828   0.440412306 0.440178708
100 33XC TC 01 AG 17XYM 0.789757463 687793033 0.856961312   0.673807792   
     
0.592723943 0.751854236
     




   RIIs of 33XC markers of the growth rate selected  RIIs of 33XC markers of the growth rate selected 
  progeny of the first genetic cross  progeny of the second genetic cross 
                  
  Marker name  the 1st passage  the 2nd passage  the 3rd passage    the 1st passage  the 2nd passage the 3rd passage 
101 33XC CA 01 TA 17XYM 0.954482586 0.838665847 0.720757353   0.446397599   0.595229585 0.529580045
102 33XC CA 02 TA 17XYM 0.719232177 0.752935087 0.71083489   0.68053972   0.745157176 0.558885599
103 33XC CA 03 TA 17XYM 0.505416466 0.394182484 0.630102041   0.459670311   0.405538227 0.386237017
104 33XC CA 04 TA 17XYM 0.977630137 0.77167539 0.855887798   0.806818421   0.68971622 0.548187081
105 33XC CA 05 TA 17XYM 0.25533402 0.01041729 0.02965208   0.198091153 0.207230116 0.164140052 
106 33XC CA 01 CA 17XYM 0.514112082 0.321950775 0.342092757   0.397485   0.370914 0.356542
107 33XC AC 03 TA 17XYM 0.439498787 0.31785305 0.308933858   0.345971746   0.269218164 0.260620725
108 33XC TT 01 GT 17XYM 0.373811153 0.459256158 0.393995728   0.521933037   
         
0.50152333 0.589858372
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